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ABSTRACT 
 
 The histopathological diagnosis of cutaneous melanocytic lesions may be 
difficult to assess. Frequently encountered diagnostic problems include: 1) 
Dysplastic nevus or melanoma in situ?; 2) Melanoma in situ or superficial spreading 
melanoma?; 3) Lentigo maligna or lentigo maligna melanoma?; 4) Compound 
nevocellular nevus or nevoid melanoma?; and 5) Spitz nevus or spitzoid melanoma? 
Moreover, less frequently encountered diagnostic challenges are discussed: 1) 
Deep penetrating nevus or nodular melanoma?; and 2) Cellular blue nevus or 
melanoma metastasis? In this contribution, these problems are discussed after a 
systematic approach involving a concise histopathological description of the classic 
lesions considered in the differential diagnoses, a presentation of the deviating 
histopathological features that give rise to the diagnostic problems, and finally 
diagnostic recommendations on the classification of the problematic lesions. We 
also briefly discuss the contribution of additional immunohistochemistry and 
molecular pathology in aiding to establish a correct diagnosis. 
 
INTRODUCTION 
 
 The histopathological diagnosis of cutaneous melanocytic lesions may be very 
difficult to assess for various reasons.1-9 Often the decision between a benign and 
malignant melanocytic lesion is at stake, which naturally has far reaching 
consequences for the treatment of the patient. In addition, the precise classification 
of the melanocytic lesion may be problematic due to the complexity of its 
architecture or an unusual context. Further, the melanocytic differentiation of a given 
benign or malignant tumor may be doubtful, making substantiation of the diagnosis 
necessary. Consistent histopathological diagnosis of such melanocytic lesions relies 
on specific expertise and experience of a (dermato)-pathologist. As a consequence, 
the pathologist is often consulted with melanocytic lesions in which either a 
diagnosis has to be made, the diagnosis has to be confirmed with more certainty, 
the possibility of melanoma has to be excluded, or the diagnosis has to be refined by 
subtyping.4 
 In The Netherlands, a national panel of expert pathologists, coordinated by 
Professor W. J. Mooi, The Netherlands Cancer Institute, Amsterdam, and one of the 
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authors (DJR) operates from 1987 under the auspices of the Dutch Melanoma 
Working Group. Individual panel members handle consultant cases and discuss 
those showing a discrepancy with the submitting pathologist during the panel 
sessions that take place 5 times per year. In addition, cases with unusual features 
are presented. By doing so, the panel discusses about 300 cases per year. The total 
number of diagnostically problematic melanocytic lesions that are submitted for 
consultation in The Netherlands is estimated 600 per year, reported on earlier.4 In 
this contribution we focus on frequently occurring diagnostic problems in melanoma 
pathology, discuss discriminating histopathological features in the differential 
diagnosis, and provide practical diagnostic recommendations. 
 
 The following diagnostic problems are elucidated: 
1.  Dysplastic nevus or melanoma in situ? 
2.  Melanoma in situ or superficial spreading melanoma? 
3.  Lentigo maligna or lentigo maligna melanoma? 
4.  Compound nevocellular nevus or nevoid melanoma? 
5.  Spitz nevus or spitzoid melanoma? 
 Less frequently encountered problems to be discussed are: 
1.  Deep penetrating nevus or nodular melanoma? 
2.  Cellular blue nevus or melanoma metastasis? 
 
 These diagnostic problems will be discussed separately using a systematic 
approach. First, a concise histopathological description is given of the classic lesions 
that are considered in the differential diagnosis. Second, the microscopical features 
are presented that deviate from the classic description and thereby may give rise to 
diagnostic problems, followed by considerations raised during the process of 
reaching a diagnosis. Finally, recommendations on the diagnostic classification are 
provided. 
 
DYSPLASTIC NEVUS OR MELANOMA IN SITU? 
 
 Histopathology of the classic lesions. A classic dysplastic nevus is 
characterized by: 1) a ground pattern of irregular rete ridges, 2) a nested and
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lentiginous melanocytic junctional proliferation with architectural and cytological 
atypia, 3) a limited intradermal component with small nevus cells that contain finely 
granular melanin, and 4) a distinct stromal reaction. Signs of architectural atypia 
include marked junctional activity (ie, continuous along at least three rete ridges) 
and varying size and shape of the junctional nests. Bridging of nests between 
adjacent rete ridges may be present. Signs of cytological atypia include dust-like 
melanin and large melanocytic nuclei (ie, equal to or larger than those of adjacent 
keratinocytes). The stromal reaction consists of focal lymphocytic infiltrates, 
accumulation of melanophages, increase of small blood vessels, and lamellar 
fibroplasia. Ascension of atypical melanocytes in the epidermis may occur 
sporadically only. 
 A classic melanoma in situ shows a pagetoid proliferation of markedly atypical 
melanocytes throughout the epidermis. In addition, continuous junctional activity as 
nests and single atypical melanocytic cells is observed. Atypical melanocytic cells in 
the dermis are not found. The papillary dermis contains a dense band-like 
lymphocytic infiltrate admixed with melanophages. The degree of cytological and 
architectural atypia within a melanoma in situ may vary. In the periphery of the lesion 
features of a dysplastic nevus may be encountered. 
 Diagnostic problems. Histopathological features that cause diagnostic 
problems in a lesion with otherwise clear-cut characteristics of a dysplastic nevus 
are: 1) pagetoid growth (Figure 1-1A), 2) the presence of mitotic figures, 3) 
preponderance of spindled or epithelioid junctional melanocytic cells, 4) architectural 
and/or cytological atypia of the dermal component, and 5) marked fibrosis and 
scarring exceeding the usual stromal reaction. To our opinion, pagetoid growth 
should only sporadically be found in a dysplastic nevus, ie, only a few melanocytic 
cells and only at one or two different areas of the lesion. In addition, the degree of 
atypia of the intraepidermal melanocytes in a dysplastic nevus should not be severe 
like in melanoma in situ. Furthermore, mitotic figures in our experience are highly 
unusual in a dysplastic nevus. This may indicate melanoma in situ and further 
sections are needed to substantiate the diagnosis. In case of an epithelioid and/or 
spindle cell melanocytic proliferation with mitotic figures a diagnosis of junctional 
Spitz nevus (Figure 1-1B) should be considered. When the nests are remarkable 
large and the melanocytes are spindled and heavily pigmented a diagnosis of 
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Figure 1-1. A: Dysplastic nevus or melanoma in situ? Note a sporadic area of pagetoid 
growth (P) in a further characteristic dysplastic nevus (H&E x100). B: Dysplastic nevus or 
Spitz nevus? Note that the rete ridge pattern of the epidermis (E) is suggestive for a 
dysplastic nevus, but the intradermal component has the appearance of a Spitz nevus (H&E 
x100). C: Melanoma in situ or superficial spreading melanoma? Note the scarring fibrosis (F) 
in the papillary dermis obscuring the presence of invasive melanoma cells (H&E x50). D: 
Melanoma in situ or superficial spreading melanoma? Note the presence of a few melanoma 
cells (arrows) amidst a dense lymphocytic infiltrate in the papillary dermis indicating an 
invasive component (H&E x100) 
 
 
pigmented spindle cell tumor of Reed can be made. The dermal features mentioned 
above are discussed in the next paragraph, as they imply a differential diagnosis 
with superficial spreading melanoma. 
 Diagnostic recommendations. In order to avoid overdiagnosis of dysplastic 
nevi, we classify a lesion as dysplastic nevus with moderate atypia if three out of 
four signs of atypia mentioned in Table 1-1 are found, and as dysplastic nevus with 
marked atypia if all four signs are demonstrated. Slight atypia is insufficient for the 
diagnosis dysplastic nevus. This approach is based on earlier studies of our group10 
and has been incorporated into the Dutch Consensus Text on Diagnosis and 
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Table 1-1. Diagnostic features of common nevocellular naevus, dysplastic nevus, 
melanoma in situ and superficial spreading melanoma 
 
Diagnosis Morphological features 
Common nevocellular nevus • No or less than three of the features mentioned 
below for dysplastic nevus 
 
Dysplastic nevus • Three or more of the following features: 
• marked junctional proliferation 
• irregular nests 
• large nuclei 
• lymphohistiocytic infiltrate 
 
Melanoma in situ • Pagetoid growth 
• Continuous junctional proliferation 
 
Superficial spreading 
melanoma 
• Pagetoid growth 
• Continuous junctional proliferation 
• Invasion of markedly atypical melanocytes into the 
dermis 
Adapted from de Wit et al.10 
 
Treatment of Melanoma.11 In the hand of an expert pathologist the grading of the 
degree of atypia in dysplastic nevi is consistent, as was shown by an inter-observer 
study conducted by the EORTC Melanoma Group.10 
 In case the ground pattern of a dysplastic nevus exists and pagetoid growth is 
found more than sporadically, we call the lesion a melanoma in situ that has arisen 
in a dysplastic nevus. The diagnosis melanoma in situ can be made only if one is 
convinced that the dermal component is not malignant. Otherwise the lesion should 
be considered as superficial spreading melanoma, as will be discussed in the 
following paragraph. If no dermal nevoid component is present and the epidermis 
shows pagetoid growth a diagnosis of melanoma in situ is imminent. To exclude 
microinvasive (Clark level II) superficial spreading melanoma additional sections, 
and when still in doubt, additional immunohistochemistry using antibodies 
recognizing melanocytic differentiation antigens such as S-100 or Melan-A (MART1) 
should be performed.12 We prefer Melan-A for this application as it is much more 
specific than S-100 and has a good sensitivity. In contrast, other melanocytic 
differentiation markers such as gp100 (HMB45) and tyrosinase have a tendency to 
underestimation of invasive melanoma cells. 
Chapter 1 
14 
MELANOMA IN SITU OR SUPERFICIAL SPREADING MELANOMA? 
 
 Histopathology of the classic lesions. The histopathological features of a 
classic melanoma in situ were given in the previous paragraph. A classic superficial 
spreading melanoma is characterised by an extensive and highly irregular junctional 
proliferation of severely atypical melanocytes in irregular groups and single cells, 
with evident pagetoid spread similar to melanoma in situ. In addition, invasion of 
severely atypical melanocytes in the dermis is seen in small groups, nests, or 
micronodules. The extent of invasion is indicated using the levels of Clark.13 Limited 
invasion into the papillary dermis is called as level II, extensive invasion limited to 
the papillary dermis as level III, invasion into the reticular dermis as level IV, and 
invasion into the subcutaneous fat as level V. The type of invasion can be defined in 
terms of its growth pattern, ie, horizontal or vertical growth phase. Horizontal growth 
phase melanoma includes both melanoma in situ (Clark level I) and microinvasive 
melanoma (Clark level II), in which only single melanoma cells and small nests enter 
the papillary dermis; no mitotic figures should be present here. In contrast, vertical 
growth phase melanoma shows nests larger than those in the overlying epidermis 
and micronodules representing tumorigenicity and metastatic potential. 
Characteristically, a dense band-like lymphocytic infiltrate is present adjacent to the 
horizontal growth phase melanoma or the horizontal component of an otherwise 
vertical growth phase melanoma. The vertical growth phase may contain an 
intratumoral lymphocytic infiltrate in a varying degree: nonbrisk or brisk.14 
 Diagnostic problems. As indicated in the previous paragraph a lesion with a 
ground pattern of a dysplastic nevus may show architectural and/or cytological 
atypia in the dermal component that exceed that of the classic dysplastic nevus. 
Architectural atypia in the dermal component is reflected by high cellularity, compact 
growth pattern, and lack of maturation. Increased cellular atypia is present when 
dust-like melanin and/or nuclear hyperchromasia are found. If such intradermal 
melanocytic cells present a morphological appearance similar to that of melanoma it 
follows that a diagnosis of superficial spreading melanoma should be made. A lesion 
with the appearance of melanoma in situ, but with a marked fibrosis in the dermis 
resembling scarring following inflammatory regression (Figure 1-1C), should be 
considered as superficial spreading melanoma of which the dermal component has 
regressed. Another histopathological feature that complicates the differential 
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diagnosis between melanoma in situ and superficial spreading melanoma is the 
presence of a very dense lymphocytic infiltrate in the papillary dermis obscuring 
microinvasion (Figure 1-1D). As elucidated earlier, additional immunohistochemistry 
may demonstrate the invasive melanoma cells convincingly. It goes beyond saying 
that this differential diagnosis can be addressed properly in an excision biopsy only, 
as the entire lesion has to be scrutinized. 
 Diagnostic recommendations. A diagnosis of melanoma in situ is made per 
exclusionem, only after careful examination for microinvasion in the dermis. A 
diagnosis of melanoma in situ that has arisen in a dysplastic nevus is made only 
after careful examination of the dermal component, verifying its nature as nevus. In 
case of inflammatory regression in the papillary dermis and/or accompanying 
scarring with an appearance of melanoma in situ in the overlying epidermis we 
consider the lesion as superficial spreading melanoma with regression and estimate 
its tumor thickness by measuring the depth of the area with regression. 
 
LENTIGO MALIGNA OR LENTIGO MALIGNA MELANOMA? 
 
 Histopathology of the classic lesions. A classic lentigo maligna is 
characterized by a basal proliferation of markedly atypical dendritic melanocytes in 
an atrophic epidermis with extension into epithelium of hair follicles and sweat 
ducts.2,3,15 A few nests of atypical spindled melanocytes may be present. The dermis 
shows elastosis, teleangiectasia, and foci of lymphocytic infiltrate, all compatible with 
actinic damage. Lentigo malignant melanoma in addition shows an invasive 
component, either in nests, compact areas or as single spindle cells that diffusely 
infiltrate the reticular dermis.2,3,15 The degree of cellular atypia is less than observed 
in superficial spreading or nodular melanoma. Infiltration of spindled melanoma cells 
may be found along nerve fascicles including those at some distance of the main 
tumor mass, which has implications for the assessment of the excision margins. 
Scattered foci of dense lymphocytic infiltrates may already suggest a diagnosis of 
lentigo maligna melanoma at low power magnification.  
 Diagnostic problems. Histopathological features that complicate a diagnosis of 
lentigo maligna are pagetoid growth and marked junctional nest formation. An 
extensive pagetoid growth would favor a diagnosis of superficial spreading 
melanoma in situ, especially when the atypical melanocytes lack the dendritic 
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morphology. Marked junctional nest formation may give rise to confusion with a 
dysplastic nevus or with an intraepithelial spindle cell nevus. However, the irregular 
rete ridge configuration of a dysplastic nevus is lacking. In addition, a spindle cell 
aspect of the atypical melanocytes is unusual for dysplastic nevi. Intraepithelial 
spindle cell nevus is accompanied by a hyperplastic and not an atrophic epidermis 
and the atypical melanocytes lack hyperchromasia. Furthermore, the combination of 
a spindle cell nevus with marked actinic changes in the adjacent skin is uncommon. 
Another important aspect of marked spindle cell nested morphology is the fact that it 
may herald dermal invasion, making careful examination to demonstrate or exclude 
invasion warranted. As the degree of atypia of the invasive component in lentigo 
malignant may be limited, it may be missed entirely or be confused with a dermal 
spindle cell nevus or even scar tissue following a previous incision biopsy. 
 Diagnostic recommendations. A diagnosis of lentigo maligna should be made 
only if invasive growth has been excluded adequately by additional sections and/or 
immunohistochemistry (Figure 1-2A). This is especially relevant if the lesion shows a 
striking degree of nest formation. Lentigo maligna melanoma should be microstaged 
with great care using additional immunohistochemistry in order to be able to 
demonstrate deep extension and/or perineural invasion (Figure 1-2B). The surgical 
margins should also be scrutinized. 
 
COMPOUND NEVOCELLULAR NEVUS OR NEVOID MELANOMA? 
 
 Histopathology of classic lesions. A compound nevocellular nevus displays a 
symmetrical architecture, regular and rounded junctional nests, and a cellular 
monotonous nevus cell population in the papillary and upper reticular dermis with 
evident downward maturation.2,3,15 Mitotic figures are rare, especially in the dermal 
component. No evident nuclear atypia is found; nucleoli are inconspicuous. 
Extension around hair follicles, arrector pili muscles and sweat glands is 
encountered in congenital nevocellular nevi. Lymphocytic infiltrate is absent. 
A nevoid melanoma shows a partly asymmetrical architecture, locally irregular 
junctional nests, pagetoid growth and mitotic figures, also in deeper parts of the 
dermal component.2,3,15 The latter is more compact and cellular than in the 
nevocellular nevus, showing less tendency to maturation. The tumor cells are 
relatively  small   with   little   cytoplasm   giving   them  a  nevocellular   appearance.  
Current diagnostic problems in melanoma pathology 
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Figure 1-2. A: Lentigo maligna or lentigo maligna melanoma? Note that 
immunohistochemical staining for MART1 shows few invasive melanoma cells (arrow), which 
is compatible with the diagnosis of early lentigo maligna melanoma (H counterstaining x100). 
B: Depth of invasion in lentigo maligna melanoma? Note the presence of S-100 positive 
melanoma cells in the deep dermis surrounding a nerve tributary (N) (H counterstaining 
x200). C: Nevocellular nevus or nevoid melanoma? Note the somewhat asymmetric 
architecture that should arouse suspicion for melanoma (HE x25). D: Nevocellular nevus or 
nevoid melanoma? Note the compact growth pattern and a lack of maturation suggestive of 
melanoma (HE x100). 
 
 
However, a clear but subtle cellular atypia is present including nuclear 
pleomorphism and hyperchromasia; a nucleolus is often clearly visible. Lymphocytic 
infiltrate is absent. 
Diagnostic problems. A case of nevoid melanoma can easily be overlooked in 
a busy pathology practice, especially when the quality of the paraffin sections and/or 
the histological staining results are not adequate. It is only at intermediate and high 
power magnification that suspicion for melanoma arises based on the presence of 
ascension in the epidermis, mitotic figures and/or cytonuclear atypia. 
 Diagnostic recommendations. As a routine procedure in our laboratory from 
each nevocellular lesion smaller than two centimeters four transverse slices are 
A B
N
C D
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taken including the lesion and both extensions of the excision. From larger lesions 
one transverse slice per centimeter is embedded. Subsequently from each block two 
different levels on two slides are prepared. With this approach, we prevent sampling 
error and enable adequate microscopical examination. If an otherwise unremarkable 
nevocellular nevus contains mitotic figures the lesion is thoroughly assessed for 
nuclear atypia and incomplete maturation, which if present would indicate nevoid 
melanoma. Sporadic mitotic figures may occur in a common nevocellular nevus. 
Increased numbers of mitoses without evidence for cytological or architectural atypia 
may be encountered in nevocellular nevi excised from young children and pregnant 
women. Next to lack of maturation another architectural feature of nevoid melanoma 
is its asymmetry at low power (Figure 1-2C). As a matter of fact this asymmetry and 
the increased cellularity of the dermal component (Figure 1-2D) should arouse the 
suspicion of the pathologist. This will create alertness and action to further careful 
microscopic examination in order to substantiate or exclude the diagnosis of nevoid 
melanoma. In terms of diagnostic categories we discern common nevocellular 
nevus, common nevocellular nevus with increased mitotic activity, lesion suspect for 
nevoid melanoma, and nevoid melanoma. The latter two diagnostic categories are 
treated as melanoma. 
 
SPITZ NEVUS OR SPITZOID MELANOMA? 
 
 Histopathology of classic lesions. A classic Spitz nevus has a dome shaped 
symmetrical configuration in its upper part and a wedge shaped contour in its lower 
part.2,3,15 The lesion consists of well demarcated nests of spindle and/or epithelioid 
cells that contain no or little melanin and have a uniform appearance. The nests 
have a vertical orientation to the overlying epidermis that displays acanthosis with 
elongated rete ridges. The nuclei show slight pleomorphism, a clearly visible 
nucleolus and no hyperchromasia. Occasional mitotic figures may be found in the 
junctional and upper dermal component. The dermal component displays evident 
maturation by which the spindle and epithelioid cells become smaller, lose their 
nested architecture, and have a more dispersed distribution. 
Spitzoid melanoma has several features in common with Spitz nevus, ie, a 
predominance of spindle and/or epithelioid cells, arrangement in nests and even 
some tendency to mature. However, its configuration is asymmetrical, a shoulder 
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junctional component being present, or a compact dermal nodule that distorts the 
wedge shaped contour. The junctional nests are highly irregular and in addition 
solitary cells and small groups of spindle and epithelioid cells ascend into the 
epidermis. The epidermis is not acanthotic but attenuated and may show ulceration. 
The dermal component is compact and cellular with incomplete maturation. 
Occasionally, deeply situated groups of pigmented spindle or epithelioid cells occur. 
Mitotic figures, of which some are atypical, are found throughout the lesion. An 
inflammatory infiltrate of lymphocytes and plasma cells surrounds the nests of the 
lesion. 
 Diagnostic problems. Because a histological spectrum exists of a classic Spitz 
nevus to spitzoid melanoma, which is accompanied with an increasing architectural 
and cytological atypia, the diagnosis of these lesions is notoriously difficult.16 
Alarming features are lack of symmetry, loss of nesting pattern, attenuation of the 
epidermis, ulceration, pagetoid growth, mitotic figures in the deeper dermal 
component with compact cellular growth pattern, lack of maturation, and lymphocytic 
infiltrate (Figure 1-3A). In addition, nuclear polymorphism and hyperchromasia are 
worrisome. 
 Diagnostic recommendations. We discern the following diagnostic categories: 
Spitz nevus (junctional or compound), atypical Spitz nevus, Spitz tumor suspect for 
melanoma, and spitzoid melanoma. Both ends of the morphological spectrum, ie, 
Spitz nevus and spitzoid melanoma were discussed earlier. Although it is difficult to 
completely rule out the possibilty of melanoma in a case of atypical Spitz nevus and 
some authors have proposed to use the term "Spitz tumor of uncertain malignant 
potential" (STUMP) we make a diagnosis of atypical Spitz nevus if increased cellular 
and/or architectural atypia are present, but no deep mitotic figures are accepted.16,17 
If deep mitotic figures are present (Figure 1-3B) but no overt aspect of melanoma we 
call the lesion Spitz tumor suspected of melanoma, which will be treated as a 
melanoma. In children below the age of 15 years we only make a diagnosis of 
spitzoid melanoma if the tumor shows evident signs of architectural and cytological 
atypia. In such lesions ulceration is often found. Follow up data of large series of 
cases should be awaited in order to validate the diagnostic classification of Spitz 
nevi and spitzoid melanomas. Molecular cytogenetic analysis of Spitz nevi has 
shown clear difference to melanoma.18 Based on a recent molecular study using 
loss of heteroygosity analysis on Spitz nevi, atypical Spitz nevi, Spitz tumors suspect 
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for melanoma, and spitzoid melanoma we found increasing genetic abnormalities 
with increase of histopathological atypia.19 Although the set of markers used was not 
yet able to distinguish between the various categories, these results may suggest 
that a more extended and refined set will be able to do so, creating a powerful 
additional tool to the diagnostic pathologist. For practical reasons, one could favor 
DNA in situ hybridisation as an adjunct to the conventional histopathological 
approach as it combines morphology and molecular hybridisation in one slide, and 
earlier studies on Spitz nevi and related lesions have shown promising results.20 
However, interpretation of the hybridization result is difficult and time consuming. 
Unfortunately, other additional techniques such as immunohistohistochemistry, DNA 
cytophotometry, and nuclear morphometry have shown disappointing results 
regarding a contribution to the differential diagnosis. 
 
DEEP PENETRATING NEVUS OR NODULAR MELANOMA? 
 
 Histopathology of the classic lesions. A classic deep penetrating nevus is a 
symmetrical wedge-shaped (with the broad part lying up) or dumbbell-shaped lesion 
localised within the reticular dermis or even infiltrating the subcutaneous fat tissue. It 
is built of closely packed vertically oriented fascicles of spindle cells with variable 
melanin content. Nests and fascicles follow cutaneous adnexes, nerves, and blood 
vessels.21 These fascicles are surrounded by melanophages, and often by a mild 
lymphocytic infiltration. Besides this fasciculated component, in the deep portion of 
the lesion, there are individual melanocytes admixed with dermal collagen and 
elastin fibers in a laminated fashion. The spindle cells show low-grade nuclear 
atypia. In the deep portion there may be melanocytic multinuclear giant cells that 
show more nuclear atypia. 
 The majority of deep penetrating nevi also have junctional nests of the type seen 
in common acquired nevus, separated from the dermal component by a grenz zone 
of spared papillary dermis. About ten percent of the lesions show mitotic activity, 
which should be limited to two per section and preferably not be located in the 
deeper part of the lesion. 
 A classical nodular melanoma consists solely of the vertical growth phase, 
without concomitant radial/horizontal growth phase component. A junctional 
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component may be lacking. Marked cytonuclear atypia is seen throughout the 
lesion, as are mitotic figures. No or incomplete maturation is present.  
 Diagnostic problems. A deep penetrating nevus can mistakenly be diagnosed 
as a vertical growth phase melanoma, including neurotropic melanoma. The deep 
extension into the reticular dermis or subcutaneous fat should not be interpreted as 
invasion in the context of melanoma. In contrast to deep penetrating nevus, 
melanoma invades in an irregular, asymmetrical fashion. Moreover, in case of 
melanoma, the front may be broad and pushing, whereas in deep penetrating nevus 
the front is narrow. Also a confusing characteristic is the absence of melanocytic 
maturation in the deep portion of the lesion. 
 Another feature that may lead to the erroneous diagnosis of melanoma is the 
mild cytonuclear atypia combined with the presence of scattered giant atypical cells 
that may occur in deep penetrating nevus. However, malignant nuclear features as 
seen in melanoma with marked pleomorphism, coarse chromatin, and prominent 
nucleoli are lacking in deep penetrating nevus. Other discriminating features in favor 
of deep penetrating nevus are the sparse mitotic activity, the absence of atypical 
mitotic figures, the absence of mitoses in the deep portion of the lesion, and the 
absence of epidermal involvement with atypical melanocytic hyperplasia or pagetoid 
spread. 
 Diagnostic recommendations. At low power examination the overall 
architecture of the lesion will give an important diagnostic clue. A symmetrical 
wedge or dumbbell-shape certainly points to deep penetrating nevus, as do the 
somewhat organoid and nested arrangement of naevus cells. In order to exclude 
nodular melanoma the lesion should be carefully examined at high power 
magnification to assess mitotic figures and overt nuclear atypia. 
 
CELLULAR BLUE NEVUS OR MELANOMA METASTASIS? 
 
 Histopathology of the classic lesions. A classic cellular blue nevus has no 
epidermal involvement and consists of dermally and frequently also subcutaneously 
located islands and bundles of light staining cuboidal to spindle-shaped cells, 
alternating with elongated sheets of fibrosis in which pigmented dendritic dermal 
melanocytes and melanophages are located, as seen in the common blue nevus.22 
There may be foci of nuclear enlargement and hyperchromasia. However, the 
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chromatin remains undiscernibly, and only few mitoses occur. Areas of cystic 
degeneration may occur. Maturation is lacking in the deep parts of the lesion. 
 A melanoma metastasis often presents as a nodule within the dermis or 
subcutaneous fat, and usually consists of a nodule of malignant appearing 
epithelioid and/or spindle cells, usually without epidermal component. Melanin 
pigmentation is variable and may be absent. Central coagulative necrosis may 
occur. A striking inflammatory host response with stromal reaction is uncommon in 
metastatic melanoma lesions. Intravascular tumor deposits may be encountered in 
the vicinity of the melanoma metastasis. 
 Diagnostic problems. The highly cellular expansive micronodules may 
erroneously lead to the diagnosis of melanoma. However, because a junctional 
component is lacking, a diagnosis of primary nodular melanoma is not likely. On the 
other hand, some melanoma metastases are epidermotropic and therefore may 
present like a primary lesion. However, in case of melanoma metastasis the 
epidermal and dermal tumor cells are similar, whereas in primary melanoma these 
cell populations are obviously different. The coexistence of typical blue nevus areas 
with the cellular nodules strongly speaks against a diagnosis of melanoma 
metastasis. Moreover, in a blue nevus the nuclear pleomorphism and 
hyperchromasia as seen in melanoma are lacking. It should also be recognized that 
perineural extension and cystic degeneration are still compatible with cellular blue 
nevus. 
 Besides the cellular blue nevus, there is the atypical cellular blue nevus in which 
atypical features as variable cytoplasmic pigmentation, an infiltrative margin, 
asymmetry, hypercellularity with sheet-like growth pattern, nuclear pleomorphism, 
hyperchromasia, prominent nucleoli, mitotic figures (Figure 1-3C) or necrosis may 
occur in the background of a further typical cellular blue nevus.23 The cellular blue 
nevus, with or without atypia, may be difficult to discriminate from a malignant blue 
nevus, an extremely rare form of melanoma restricted to the dermis that originates 
from and sometimes coexists with a cellular blue nevus, or arises de novo.7,24 The 
diagnosis of a malignant blue nevus does not depend on a single feature. The 
diagnosis should be made when pigmented spindle cells show marked nuclear 
atypia with coarse chromatin, numerous (atypical) mitoses and necrosis or 
ulceration (Figure 1-3D). The biphasic elements from cellular blue nevus are lacking 
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Figure 1-3. A: Spitz nevus or spitzoid melanoma? Note a lack of maturation and the 
presence of a dense lymphocytic infiltrate (I), favoring melanoma (HE x100). B: Spitz nevus 
or spitzoid melanoma? Note the high number of MIB-1 positive melanocytic cells as 
demonstrated by immunohistochemistry, suggesting melanoma (H counterstaining x50). C: 
Cellular blue nevus or malignant blue nevus? Note the marked nuclear atypia and the 
presence of mitotic figures (arrows) compatible with malignancy (HE x200). D: Cellular blue 
nevus or malignant blue nevus? Note the ulceration (arrow) suggestive of malignancy (HE 
x50). 
 
 
in a malignant blue nevus, but however may be present in the adjacent preexisting 
cellular blue nevus. A further reason to suspect malignancy is a diameter of the 
lesion of greater than 2 cm. 
 
 Diagnostic recommendations. As in other melanocytic lesions the overall 
architecture and the cytonuclear characteristics provide important features for the 
differential diagnosis. Alarming features for either melanoma metastasis or 
malignant blue nevus are frequently occurring mitotic figures, nuclear 
hyperchromasia, and necrosis. Further clinical information should reveal whether the 
patient previously underwent excision of a primary melanoma. In case of melanoma 
metastasis tumor cell emboli may be found in lymph and/or blood vessels adjacent 
to the lesion. 
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CONCLUDING REMARKS 
 
 The diagnosis of cutaneous melanocytic lesions requires special expertise and 
experience of the pathologist. In order to provide an adequate diagnosis, individual 
experts and expert panels operate that are consulted on a regular basis. These 
panels should be stimulated to use standardized forms using a well-defined 
histopathological classification in order to stimulate a consistent reporting. Further, 
the follow-up data of the patients should be properly documented. Along these lines, 
the case material is well accessible to various evaluative studies that are the basis 
for further development of knowledge and insight into the clinicopathological 
characteristics of cutaneous melanocytic lesions. Such case material would be 
ideally suited for performing additional molecular studies that may enable the 
pathologist to improve the assessment of the diagnosis and prognosis in case of 
melanocytic lesions that are difficult to classify using the conventional approach. 
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Outline of the thesis 
 
 
 
Melanocytic cutaneous proliferations can be classified by clinical inspection followed 
by histopathological examination. The histopathologist also provides further 
information on the status of the excision margins and the thickness of the lesion that 
enables the clinician to choose an adequate treatment. A number of melanocytic 
lesions are difficult to classify by a general histopathologist and are sent for 
consultation to an expert histopathologist. In the Netherlands a subset of these 
lesions are examined by the Pathology Panel of the Dutch Melanoma Working 
Party, but even a panel of experts cannot always arrive at a certain diagnosis. 
Therefore, reliable additional techniques could be valuable to support the diagnosis 
in melanocytic lesions. The aims of this thesis are: a) to gain a better insight into the 
various genetic alterations in subtypes of melanocytic lesions, and b) to demonstrate 
these genetic alterations as target for the diagnosis of lesions that are difficult to 
classify. 
 
 More specifically, in this thesis an attempt will be made to answer the following 
questions: 
1. Which problems are encountered in the histopathological diagnosis of 
(cutaneous) melanocytic lesions?  
2. Which techniques are most suitable to detect genetic alterations in these 
melanocytic lesions? 
3. Do subtypes of melanocytic lesions have specific genetic alterations? 
4. What is the best approach to analyze these genetic alterations in a diagnostic 
setting? 
 
  Frequently encountered diagnostic problems were discussed in Chapter 1, 
followed by recommendations on the classification of the problematic lesions. 
Nonetheless, for a substantial number of lesions an unequivocal diagnosis cannot 
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be given. This urges us to develop additional diagnostic methods, concentrating on 
those lesions that prove most frequently difficult to classify.  
 
 A review of the available molecular techniques to detect genetic alterations in 
melanocytic lesions is described in Chapter 2. Alterations already found with each 
of these techniques are described and the advantages and the particular 
disadvantages of a molecular technique including discriminatory diagnostic power, 
applicability on formalin-fixed, paraffin-embedded material, required time and 
personnel and financial aspects. Techniques that might be useful in a routine 
diagnostic setting but that have to our knowledge not (yet) been applied to the 
diagnosis of melanocytic lesions are discussed. As sensitivity of molecular 
techniques is hampered by the presence of contaminating normal cells or normal 
DNA in a sample laser microdissection was used. A mounting solution required for 
an accurate identification of tumour and normal cells that improves the 
morphological quality of tissue sections is described in the Supplement. 
  
Sinonasal melanomas possess several clinical characteristics that separate 
them from uveal and cutaneous melanomas. So far, the genetic alterations in this 
subtype of melanocytic lesions were unknown. In Chapter 3 the use of comparative 
genomic hybridization to provide an overview of chromosomal gains and losses is 
described. Despite its usefulness in a research setting as illustrated in this chapter, 
CGH was not suitable in a diagnostic setting to detect genetic alterations because it 
was too time consuming and required relatively large amounts of good quality DNA. 
Alternatively, we evaluated ploidy analysis and in situ hybridisation, which could be 
performed on formalin-fixed paraffin-embedded tissue. Unfortunately, these 
applications were hampered by insufficient discriminatory power and technical 
difficulties.  
  
 In Chapter 4 we described a study on the possible implementation of allelic 
imbalance (AI) in the diagnosis of benign, atypical, borderline, and malignant Spitz 
tumours. A large series of routinely embedded lesions could be tested and the use 
of this method as an adjunct to the histological diagnosis was critically evaluated. 
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 All previously tested methods had major disadvantages for use in a routine 
diagnostic setting. Fortunately, in 2002 a new technique, called Multiplex Ligation-
dependent Probe Amplification (MLPA) came to our attention. Not only can this 
method be performed on DNA isolated from formalin-fixed paraffin-embedded 
tissue, but it also enabled analysis of up to 45 probes in one experiment. As 
described in Chapter 5, we performed a pilot study to detect chromosomal gains 
and losses in melanocytic lesions by using MLPA. To evaluate the specificity and 
sensitivity MLPA results of a subset of lesions were compared with their 
corresponding CGH data. Furthermore, special attention was given to the 
application of MLPA in a diagnostic setting.  
 
  So far, we had limited ourselves to the analysis of chromosomal gains and 
losses because only a few mutations in melanomas had been described at that time 
and these mutations were only present in less than 30 percent of melanomas. BRAF 
was the first mutated gene present in the majority of melanomas. Soon after the 
publication the BRAF mutation was also described in most benign common nevi with 
the notable exception of Spitz nevi and blue nevi. In Chapter 6 we described 
additional value of BRAF, NRAS, and HRAS gene mutations in the differential 
diagnosis of Spitz nevus and spitzoid melanoma. Routinely processed lesions were 
used as starting material, including a subset of lesions that were difficult to classify. 
 
 Finally, in Chapter 7 a summary of the data described in this thesis is given and 
future perspectives are discussed. 
 

 Chapter 2 
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ABSTRACT 
 
 The precise diagnosis of cutaneous melanocytic lesions is of great importance 
when deciding on the necessary, possibly mutilating, surgical strategy, on further 
staging procedures, and follow-up. Although cutaneous melanocytic lesions usually 
can be diagnosed on histological features, an increasing number of these lesions 
are difficult to classify for various reasons. Therefore, additional diagnostic 
information is needed. So far, there are no special techniques available that 
consistently discriminate between benign and malignant melanocytic lesions and 
can be applied in a routine diagnostic setting. Melanocytic lesions are thought to 
arise from changes in cell cycle regulation due to alterations in the genetic material 
whether hereditary, somatic, or a combination of both. Genetic alterations in 
melanocytic lesions can occur as (partial) chromosomal losses, gains, translocations 
or mutations. Discrete differences between uveal and cutaneous melanomas have 
been described. Also, an increasing number of studies report differences in genetic 
alterations between subtypes of cutaneous melanocytic lesions and therefore, 
molecular genetic techniques hold the promise of diagnostic potential. We will give a 
short description of techniques that are used to detect subtype specific DNA 
alterations, and review results obtained with these methods emphasising those 
lesions that most often cause diagnostic problems. 
 
INTRODUCTION 
 
 The diagnosis of melanocytic lesions is based on clinical inspection and 
histological examination. So far, no adjunct diagnostic method is available that 
provides consistent supportive information. Therefore, further exploration of the 
potential contribution of additional techniques is needed. The biological behaviour of 
melanocytic lesions is related to the proteins that are expressed. Additional 
immunohistochemical staining is therefore the most obvious technique to use in a 
diagnostic setting. Unfortunately, to date no antibodies are available that 
substantially discriminate between benign and malignant melanocytic lesions.25 One 
biological level preceding the proteins is RNA: different types of RNA are 
transported from the nucleus of the cells into the cytoplasm to direct the assembly of 
aminoacids into proteins. Although RNA profiling with array technology or RNA in 
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situ hybridisation on formalin-fixed paraffin-embedded lesions promise to reveal 
more information on the behaviour of tumours in the near future, these techniques 
are not yet available for a routine diagnostic setting. RNA is transcribed from DNA 
that is located in the nucleus and from mitochondrial DNA. In this review we will give 
a short description of the techniques used that aim: 1) to investigate the total amount 
of DNA in a nucleus, 2) to detect gains and deletions at the size of complete 
chromosomes to single genes, and 3) for sequence analysis of the DNA at a 
nucleotide level. We will summarize the alterations found in benign and malignant 
melanocytic lesions with emphasis on those lesions that most often cause diagnostic 
problems. 
 
PLOIDY ANALYSIS 
 
 For ploidy analysis the total DNA content in a nucleus is measured. This can be 
performed using either flow cytometry, whereby the nuclear suspension can be 
measured, or by image analysis of nuclei on object slides. For the image analysis 
method cytospin slides or tissue sections are stained for nuclear DNA according to 
the Feulgen procedure. Next, video images of the nuclei are digitally processed and 
the density correlated with those of diploid reference cells (DNA content of 2c). 
Polyploid cells are defined as those exceeding 3 times the diploid DNA content. The 
aneuploid cell population is defined on a DNA distribution histogram as an apparent 
peak differing more than 10% from the nearest euploid peak.26 As an example, a 
DNA histogram of a sinonasal melanoma is shown in Figure 2-1. Because paraffin-
embedded tissue can be used, this technique could be a valuable complement to 
routine histology in equivocal cases. 
 Vogt et al reported that the large nuclei in Spitz naevi are euploid, in contrast to 
those in melanomas and concluded that it would therefore be possible using DNA 
cytometry to discriminate between both lesions with high accuracy.27 As shown in 
Table 2-1, studies on the DNA content of melanocytic lesions for diagnostic 
purposes have produced conflicting results. Although there is an association 
between aneuploidy and diagnosis of melanoma there is clearly a very large 
variation in the frequency of aneuploidy detected. Moreover, unfortunately there is 
an overlap with premalignant lesions that are difficult to classify such as dysplastic 
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Figure 2-1. Representative DNA distribution histograms of sinonasal melanomas. DNA-index 
(a DNA index of 1 represents a DNA content of 2c) and percentage of the number of cells 
measured at the given DNA content. A: represents a diploid DNA pattern, B and C represent 
DNA distributions classified as (near-) tertraploid. D: represents a case classified as near 
triploid with an aneuploid cell fraction.  
 
 
 
naevi, in which DNA aneuploidy was reported in up to 34% of the lesions 
studied.28,29 Therefore, DNA diploidy does not exclude melanoma and conversely 
aneuploidy does not exclude naevus. As a result, ploidy analysis alone has limited 
diagnostic value.29 Some researchers have therefore opted for a multiparameter 
approach using various cytometric features e.g. 2c deviation index, 5c exceeding 
rate, karyometry (nuclear area, standard deviation of nuclear area reflecting nuclear 
atypia, nuclear perimeter and nuclear length) and maturation parameters (comparing 
cells from superficial and deep zones). These authors reported a better diagnostic 
ability in separating naevi from melanomas.30,31 So far, these results have not been 
confirmed nor falsified by others. 
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Table 2-1. Summary of ploidy studies comparing ploidy in melanocytic lesions 
Me-
thod 
Se Sp Number 
of 
lesions 
analyzed 
Remarks Refe-
rences 
IC: 
DNA 
index 
100 90 55 CN 
16 SN 
8 DN 
61 MM 
 
DNA ploidy by using DNA index 
(correlation with diploid reference cells) 
and 2c deviation index (considers the 
variation of the measured DNA values 
from the normal diploid G0/G1 peak of 
the cell cycle). 
 
29 
IC 97 - 60 CN 
30 MM 
DNA ploidy based on integrated optical 
density. 
28 
 
IC 94 - 28 SN 
34 MM 
Large nuclei in Spitz naevi are diploid in 
contrast to malignant melanoma. No 
false positives. 
27 
IC 92 98 27 CN 
20 DN 
10 SN 
24 MM 
 
Combines DNA microdensitometry, DNA 
karyometry, maturation parameters, 
thereby measuring different zones of the 
lesion. 
30 
IC: 
aneu-
ploidy 
86 83 55 CN 
16 SN 
8 DN 
61 MM 
 
DNA ploidy based on integrated optical 
density. 
29 
IC 74 - 30 DN 
30 MM 
 
Nuclear shape and mean nuclear area. 28 
FC - - 34 CN 
53 MM 
Aneuploid: 
CN 3% 
MM 25% 
 
64 
FC - - 20 CN 
20 SN 
20 MM 
DNA index:  
SN: 1,09 (1,01-1,29) 
MM: 1,82 (1,34-2,50) 
CN: 1,09(1,02-1,16) 
 
26 
FC & 
IC 
- - 43 MM 
15 DN 
11 SN 
16 CN 
 
Aneuploid: 
MM 42% 
 
Diploid: 
DN 100% 
SN 91% 
CN 94% 
65 
IC - - 187 CN 
61 DN 
118 MM 
Aneuploid: 
DN 44%  
MIS 88%  
MM 96% 
Diploid: 
CN 97% 
DN 66% 
66 
 
Se: Sensitivity, Sp: specificity, IC: image cytometry, FC: flow cytometry, CN: common naevi, 
SN: Spitz naevi, DN: dysplastic naevi, MM: malignant melanoma, MIS: melanoma in situ. 
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KARYOTYPING, SPECTRAL KARYOTYPING (SKY), AND COMBINED BINARY RATIO 
LABELLING (COBRA) 
 
In 1969 the chromosome banding technique was developed that allowed 
recognition of individual chromosomes. For chromosome preparation a cell line or a 
short-term culture of tumour cells is required. Dividing cells are arrested in 
metaphase by addition of colcemid and the metaphase chromosomes Giemsa 
stained. Recognition of individual chromosomes is based on the identification of their 
banding pattern. Also chromosomal rearrangements, gains and losses can be 
detected although some tumours harbour such complex karyotypes that not all 
chromosomal parts can be classified; these unidentifiable parts are called marker 
chromosomes. 
In 1996 spectral karyotyping (SKY) was introduced and three years later 
combined binary ratio labelling (COBRA) was first described.32,33 Both techniques 
give all chromosomes a unique fluorescent colour by hybridising metaphase 
chromosomes with a mix of chromosome specific probes each labelled with a 
different combination of fluorochromes. Using SKY or COBRA structural 
chromosomal changes can be detected that cannot be classified with conventional 
chromosome banding, for example the identification of marker chromosomes. An 
example of a marker chromosome of the melanoma cell line Mel57 that could be 
identified by SKY is shown in Figure 2-2.  
 
 
 
 
Figure 2-2. Representative karyotype and SKY experiment showing chromosome 7 from 
melanoma cell line mel57 (formerly known as 1F6-m). A: Giemsa stained chromosomes of 
chromosome 7. Both 7q arms appear normal but both 7p arms are abnormal; the exact origin 
cannot be defined on the Giemsa banding pattern. B: SKY experiment showing three 
chromosomes 7 in SKY-colours (original SKY colors: b=brown, o=orange, y=yellow), inverse 
Dapi staining (Dapi) and artificial colours (Artif.), revealing the origin of the chromosome 7p as 
translocations of parts of chromosome 3 and an 18q arm. Furthermore a marker chromosome 
was identified as isochromosome 7p. 
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Table 2-2. Summary of genetic alterations in melanocytic lesions as detected by 
karyotyping.  
Lesion n= Gains % Losses % 
Translocations/break 
points % 
Melanoma* 551 8q 30 10 40 6q1 26 
  6p21-25 25 Y 40 der(12)t(12;20)(q15;q1) 25 
  1q10-44 20 22 30 der(19)t(10;19)(q23;q13) 25 
  7 20 3 25 der(12)t(12;19)(q13;q13) 25 
  20 15 6q12-27 25 1p1 24 
    8p10-23 20 11q2 20 
    11q22-25 20 1q1 19 
    13p11-13 20   
    16 20   
    X 20   
    1p21-36 15   
    9p22-24 15   
    11p15 15   
    11q13 15   
    12q24 15   
    13q34 15   
    14p10-13 15   
    15 15   
Dysplastic 
naevus 
42 
  
9 < 
15 
t(9;10)(p24;q24) < 
15 
Congenital 
naevus 
6 no alterations     
Common 
naevus 
30 no alterations     
 
*Melanoma not otherwise specified, also including uveal melanomas and melanoma 
metastases.68-74 Only alterations that were present in at least 15% of the investigated 
melanoma are presented. 
 
 
With conventional karyotyping we found that the short arms of both chromosomes 7 
were replaced by some other chromosome part: one by the long arm of 
chromosome 18, of the other unfortunately the replacement could not be identified. 
SKY proved superior and revealed that it was composed of a zebra pattern of parts 
of chromosome 7 and chromosome 3. Additionally, SKY confirmed that the short 
arms of chromosome 7 were present as an iso-chromosome. 
 By analyzing large numbers of karyotypes it has been shown that two distinct 
karyotypic pattern can be identified in uveal and cutaneous melanoma: one pattern 
including -1p, -3 and +8q, and the other pattern showing a gain of 6p often in 
combination with a loss of 6q (related with isochromosome 6p in 60% of the 
cases).34  
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 Because these techniques require short-term cultures there are only a handful of 
publications on benign melanocytic lesions in contrast to the large number of 
reported melanoma karyotypes. However, the limited number of naevi that were 
examined by karyotyping already revealed only a few chromosomal alterations in 
these lesions, in contrast to most melanomas. An overview of the alterations that 
were revealed by karyotyping and SKY is given in Table 2-2. Karyotyping as well as 
SKY is not suited for diagnostic purposes because short-term cultures can only be 
made from a small percentage of solid malignant tumours and from only an even 
smaller fraction of benign tumours. Furthermore, selection of non-representative 
tumour cell clones and culture artefacts may occur. Nonetheless, these techniques 
have revealed a number of common alterations that can be used as targets for other 
less laborious techniques such as in situ hybridization and allelic imbalance 
analysis, as described below. 
 
COMPARATIVE GENOMIC HYBRIDIZATION (CGH) AND ARRAY CGH 
 
 Comparative genomic hybridization (CGH) was first described in 1992. It is 
based on the comparison of genomic tumour and normal DNA each labelled with 
different fluorochromes and subsequently hybridized on normal metaphase 
chromosomes. During this co-hybridization, tumour and reference DNA compete for 
the same target on the metaphase chromosomes. The relative amount of tumour 
and reference DNA bound to a given chromosomal region is dependent on the 
relative abundance of these sequences in both DNA samples. Therefore, intensity 
difference in the fluorescent hybridization pattern of tumour and normal DNA can be 
interpreted as copy number differences between both genomes. CGH provides 
information on the avarage copy numbers of chromosome loci in the tumour cells 
with a resolution of 10-20 Mb.35 
 Array CGH is based on the same technique as conventional CGH but instead of 
using metaphase spreads, an array of very small spots of genomic DNA, 
representing different genes or chromosomal locations, is used as the target for 
hybridization of the differentially labelled DNA. Therefore, array CGH does not 
require karyotyping. The resolution of array-CGH depends on the genomic size and 
spacing of the targets and can be as small as 50 kb using a 32K full genome 
coverage array analysing 99% of the sequenced human genome.36  
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Figure 2-3. An overview of the frequency of chromosomal imbalances in different cutaneous 
melanocytic lesions as reported in publications with at least 5 lesions per subtype.40,99-101 The 
chromosome arms are indicated on the x-axis. In this figure no distinction is made between 
complete of partial imbalances of the chromosome arms. n= number of analysed tumours. 
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 So far, using CGH we and others have provided different genetic profiles in 
several subtypes of melanocytic lesions.18,37 In the majority of the melanomas one or 
more gains or losses are seen whereas none of the investigated benign melanocytic 
lesions such as blue naevi or congenital naevi had such alterations. However, Spitz 
naevi did show a gain of 11p without other alterations in a substantial part of the 
investigated lesions.18,38 A summary of the CGH results is given in Figure 2-3. For 
diagnostic application it is a distinct advantage that (array) CGH can be performed 
on paraffin embedded tissue and that a large amount of targets can be analyzed 
simultaneously without prior knowledge of the expected alterations. Limitations of 
(array) CGH are the inability to detect structural alterations such as reduplications, 
translocations or mutations that do not produce changes in DNA copy number. More 
importantly, it is a laborious technique that requires relatively large amounts of good 
quality DNA (0.5-1 µg) and highly specialized personnel and equipment limiting its 
applicability to highly qualified molecular core-labs only. DNA microdissected from 
archival tissue is not optimal and some lesions are too small to obtain sufficient 
amounts of DNA. Therefore, (array) CGH is mainly used in a research setting to 
reveal genetic differences between lesions. For diagnostic purposes other 
techniques are favoured for practical and financial reasons. 
 
(FLUORESCENT) IN SITU HYBRIDIZATION (F)ISH 
 
 (Fluorescent) In situ Hybridization (F)ISH has been used in the study of tumours 
since the 1980's to visualise copy number changes as well as translocations. A 
small DNA fragment of known origin (probe) is (fluorescently) labelled and 
hybridised to metaphase chromosomes, nuclear suspensions or interphase nuclei in 
tissue slides. The number of spots per nucleus is indicative of the copynumber of the 
chromosome locus analyzed. Sequences of whole genomes, centromeres, 
telomeres or specific regions on genes can be used as probes. (F)ISH can be 
applied on paraffin embedded tissue slides and therefore provides a link between 
cytogenetics, histology and if necessary immohistochemistry (Figure 2-4). In 
melanomas for example, cells with chromosomal aberrations that are present in the 
primary tumour can be detected in the deep margin of a cutaneous melanoma or in 
adjacent normal appearing skin.39,40 Numerical aberrations detected by (F)ISH of the 
chromosome investigated are much more extensive in melanomas than in normal  
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Figure 2-4. Combined immohistochemical staining for S-100 with ISH for centromere probe 8. 
S-100 revealed a few positive cells (darker cells, indicated with an arrowheads). The positive 
cells show an average of 7 dots, whereas the S-100 negative epithelial cells show one or two 
spots. 
 
 
tissue or benign tumours.41-43 Several authors have described the association of the 
accumulation of chromosomal gains and losses with tumour progression and higher 
metastatic potential.44-47 Bastian et al detected a gain of chromosome 11p15.5 in a 
subset of Spitz naevi, an alteration that is only very rarely seen in melanomas.38 A 
overview of the literature comparing numerical alterations detected with (F)ISH in 
naevi and melanomas is shown in Table 2-3. Multicolor FISH has been used to 
analyse chromosome breakage in cell cultures; so far, this has not been used on 
paraffin embedded tissue.48 
 Disadvantages of the use of (F)ISH on tissue sections is the presence of 
incomplete nuclei in a section causing artificial loss of chromosome parts which 
makes the technique difficult to evaluate: about 100-200 nuclei need to be analyzed 
for a reliable copy number of the probe used.41 Furthermore, only a limited number 
of locations can be tested in one experiment even with the application of two- or 
three-colour FISH. Because the representative area of a naevus is frequently small, 
there are insufficient numbers of nuclei for a reliable evaluation.49 
 
Diagnostic application of molecular methods 
41 
Table 2-3. Summary of (F)ISH studies comparing genetic alterations in benign and 
malignant melanocytic lesions 
Method 
probes 
Number of lesions 
analysed 
Results 
Remarks Refe-
rences 
Cen 1 Mean number of nuclei with 
> 2 ISH spots (mean per 
HPF): 
15 SN   9 lesions 0-0.5 
             6 lesions 0.5-1 
20 MM  3 lesions 0.5-1 
             5 lesions 1-2 
            12 lesions >2 
 
60% of 5 misdiagnosed melanomas 
could be correctly identified. 
20 
Cen 17 Mean signals per nucleus: 
4 SN: 1.3 (1-2) 
4 DN: 1.5 (1-4) 
8 MM: 2.1 (1-6) 
 
 42 
Cen 1, 
6, 7, 9, 
17 ,18 
Mean signals per nucleus 
(cen 9): 
42 SN: 1.56 +/- 0.17 
25 MM  2.02-2.70 (+/- 0.09-
0.94) 
Due to limited naevus area 
investigated only 20/42 SN could be 
evaluated. The signal indices of 
chromosome 9 of all the 
melanomas exceeded those of the 
Spitz naevi. As a trend, but below 
significance this was also valid for 
the other chromosomes evaluated. 
 
49,67 
Cen 1 Mean log (> 2 spots per 
nucleus): 
21 CN: 1.9 
22 DN: 2 
21 MIS: 2 
21 MM: 3.2- 3.9 
Increased copy number in a 
staggered pattern between 
melanoma in situ and the 
intraepidermal component of 
invasive melanoma rather than a 
smooth progression between the 
two groups. 
 
41 
 
Cen: centromere probe, CN: common naevi, SN Spitz naevi, DN dysplastic naevi, MM: 
malignant melanoma, MIS: melanoma in situ. 
 
 
To overcome this problem (F)ISH can be performed on whole nuclei, nuclear 
suspensions or touch preparations. It however remains difficult to obtain sufficient 
nuclei from small melanocytic lesions and retaining the link with the histological 
information is impossible. Although most of these reports describe promising results, 
to our knowledge (F)ISH is not yet (routinely) implemented as diagnostic assay in 
difficult to classify lesions. 
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LOSS OF HETEROZYGOSITY (LOH) - ALLELIC IMBALANCE (AI) ANALYSIS - 
MICROSATALLITE INSTABILITY 
 
 With loss of heterozygosity (LOH) analysis, also known as allelic imbalance 
analysis (AI), polymorphic microsatellite markers are used to detect an allelic 
imbalance(s) in a tumour cell population. In the genome 90% of the DNA exists of 
non-coding segments arranged in repetitive units. Approximately 30% of these 
sequences are arranged as short tandem repeats of 1 to 4 nucleotides, the so-called 
microsatellites. These repeats are spread throughout the genome and vary in length, 
thereby often demonstrating a difference in length between the maternal- and 
paternal alleles. Normal cells harbour one maternal and one paternal allele whereas 
in tumour cells one allele can be lost or gained which results in an imbalance.   
Using PCR with (fluorescent) primers encoding for adjacent DNA sequences a 
repeat can be amplified. After electrophoresis and visualisation of the PCR products 
the relative amount of each microsatellite present in tissue can be analysed. Only 
those markers that show a distinct difference in size for both alleles are informative 
and can be used for analysis. Because DNA fragments of different sizes amplify with 
different efficiency, the ratio of alleles was calculated for each normal and tumour 
sample and subsequently the tumour ratio is divided by the normal ratio (i.e. 
T1:T2/N1:N2). The mean ratio of the results of the experiment performed in 
duplicate is calculated. Mean ratios larger than 1.0 were converted (1/x) to obtain 
values of 1.0 or below. Ratios under 0.70 were considered to be indicative of allelic 
imbalance. Although LOH sometimes is interpreted as a loss of one allele it might 
also be caused by a gain of the other allele. As this distinction cannot be made the 
term allelic imbalance analysis (AI) is preferable over LOH.  
 Previous studies that explored the use of AI analysis for diagnostic purposes 
have demonstrated marked genetic differences between naevi and melanomas 
(Table 2-4). Besides detection of specific allelic imbalance for diagnostic purposes, 
allelic imbalance in the short arm of chromosome 6 might also play a role in the 
escape of melanoma from immunosurveillance or the response in a vaccination 
trial.50,51  
The finding of additional bands in tumour DNA compared to normal DNA reveals 
micosatellite instability. Microsatellite instability (MSI) does occur in melanomas but 
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Table 2-4. Summary of genetic alterations in melanocytic lesions as detected by 
allelic imbalance analysis  
Location  Marker CN SN DN MM  
  N     AI% N     AI% N    AI% N     AI% 
 
 
 
1p36 D1S1612, 1S228 15 27     19 22 77 
1p36 D1S407 3 0     16 40 79 
1p34 LMYC 3 0     16 40  
1p33-32 D1S207   16 0   12 33 19 
1p33-32 D1S209   16 13   14 14  
3p D3S1293 28 0 9 0   28 0 75 
3p21.2-21.1 D3S1289   16 13   11 18 19 
3pter-24.2 D3S1293   20 11   11 9  
5q21 D5S592 3 0     16 25 79 
6p22-23.3 D6S1038 D6S310 15 29     19 48 77 
6q D6S262, D6S305 28 0 14 0   28 0 75 
6q21-22 D6S262   17 14   13 23 19 
6q21-23.3 D6S287   15 13   13 46  
8q11.2-11.2 D8S260   12 0   10 30 19 
8p22-24 LPL-GZ NEFL 15 7     19 30 77 
8q11.2-12 D8S285   16 13   10 10 19 
9p D9S168    28 4 19 0   35 46 75 
 D9S171 28 4 20 5   26 19  
 D9S165  28 4 12 0   26 19  
9p13-12 D9S970   14 17   15 67 19 
9p21 D9S171   15 20   12 67  
9p21 D9S157, D9S942 D9S259 6 50   
1
4 64 44 40 
80 
9p21 D9S251 3 0     16 60 79 
9p21 D9S254 3 0     16 60  
9p21 D9S165, D9S104 D9S171, IFNA 13 0   9 78   
78 
9q D9S197 24 0 15 0   26 19 75 
9q D9S176 24 0 15 0   26 19  
10q D10S185 22 0 17 0   29 31 75 
10q23 D10S2491, D10S185 15 25     19 48 
77 
10q23 MXI1 3 0     16 40 79 
10q23 D10S520 3 0     16 40  
10q23-24 D10S1285   17 0   9 33 19 
11q23 D11S29, D11S528 15 10     19 21 77 
11q23 D11S925   14 0   12 25 19 
17p D17S796 21 0 17 0   32 16 75 
17p13 D17S1163 3 0     16 40 79 
17p13 P53.I1 3 0     16 40  
17p13 TP53 13 0   7 43   78 
18q D18S70 32 0 10 0   23 20 75 
Xq HUMARA 11 9     12 33 76 
 
N: number of lesions investigated, AI%: percentage of lesions with allelic imbalance, CN: 
common naevi, SN: Spitz naevi, DN: dysplastic naevi, MM: malignant melanomas.  
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does not seem to play an important role in the malignant progression of this 
tumour.52 Some authors suggested that MSI occurs in late stages of melanoma 
progression whereas others reported MSI already in common naevi.53,54 This striking 
difference might be explained by the fact that MSI analysis is prone to technical 
artefacts which may to some extent preclude its usefulness for diagnostic purposes, 
whereas others have propagated its use in the classification of melanocytic 
lesions.55  
 A major obstacle for a more general application of AI analysis in routine 
diagnostic practice of melanocytic lesions is the necessity for DNA from non-tumour 
cells from the same patient. Such normal DNA is only found in limited or insufficient 
amounts in the peri-lesional tissue. In addition, only limited number of chromosomal 
locations can be analysed in one experiment and LOH analysis is prone to PCR 
artefacts, especially if limited amounts of DNA are used. In conclusion, in our 
opinion LOH has no direct diagnostic application, especially considering there are 
other techniques such as ISH and MLPA that are either more reliable or can analyse 
more loci, respectively.19 
 
MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION (MLPA) 
 
 Multiplex Ligation-dependent Probe Amplification (MLPA) is a method that was 
first published in 2002 and is based on the annealing of up to 45 probes each 
consisting of two oligonucleotides that hybridize adjacently on a specific 
chromosome region.56 Besides a target specific sequence, both oligonucleotides 
also contain a universal PCR primer whereas one oligonucleotide additionally 
contains a so-called stuffer sequence which has a probe specific length. After 
ligation of the hybridized adjacent oligonucleotides the probe is amplified using the 
universal PCR primers. As each probe has a unique length due to the stuffer 
sequence, electrophoresis can be used to separate and quantify the amount of PCR 
product that is indicative for the DNA copy number.  
 We have performed MLPA analysis on a series of 29 naevi and melanomas with 
a commercially available kit and compared the results with the CGH results of the 
same tumours. Melanomas harboured several gains and losses, whereas naevi 
demonstrated only a few gains and losses.57 Interestingly, several investigated Spitz 
naevi showed a gain of 11p, an alteration that appears to be specific for Spitz 
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naevi.38 We showed that MLPA is a sensitive technique but false positive results 
may occur. The applicability of MLPA in routine diagnostics needs to be confirmed 
but this method seems to be a good alternative for AI analysis and ISH because no 
normal patient DNA is needed and up to 45 probes can be tested in a single 
experiment. 
 
MUTATION ANALYSIS 
 
 Single base pair substitutions, insertions or deletions can result in alteration of 
the transcribed RNA and subsequent alteration of the encoded protein and can be 
detected by mutation analysis. Mutations that alter the protein due to amino acid 
substitution must be discriminated from mutations that result in the same amino acid 
(silent mutations). This can be detected by PCR amplification of the chromosome 
locus where the mutation is located. The nucleotide sequence in this amplified DNA 
fragment is analyzed after a sequence reaction by electrophosesis. 
 A major advantage of this technique is that it is sensitive and only needs a 
limited amount of tumour DNA. Although the knowledge of genetic alterations in 
melanocytic lesions is steadily growing, up until 2001 the mutated genes reported 
only occurred relatively infrequently in sporadic melanoma (Table 2-5). Therefore, 
the genetic changes were not useful for diagnostic purposes. However, since the 
recent discovery of BRAF mutations in melanocytic lesions there have been rapid 
advances in the understanding of genetic changes that may underlie the 
development of benign and malignant melanocytic lesions.58 The various 
publications exploring BRAF mutations in benign and malignant melanocytic lesions 
reveal that they may be limited to certain subtypes.59-62 The alteration in BRAF in 
combination with for example HRAS mutation and amplification analysis may offer 
diagnostic opportunities, such as in the discrimination between Spitz naevus and 
spitzoid melanoma. Based on our previous observations in Spitz naevi and spitzoid 
melanomas, the presence of HRAS mutations would favour the diagnosis of Spitz 
nevus and the presence of either BRAF or NRAS mutation would strongly support 
the diagnosis of spitzoid melanoma (Chapter 6). For those lesions that do not have a 
mutation of any of these three genes, mutation analysis in other genes as PTEN, 
CDKN2A and TP53 may increase the sensitivity of mutation analysis. With respect 
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Table 2-5. Overview of mutations in sporadic benign and malignant cutaneous 
melanocytic lesions 
Gene Name Location Function Frequency Ref 
 
BRAF   
 
v-raf murine 
sarcoma viral 
oncogene 
homolog B1 
 
7q34 
 
O 
 
CN 21-87.5% 
SN 0% 
MM 29-75 % 
 
59,60,6
2,81-86 
NRAS Neuroblastoma 
RAS viral 
oncogene 
homolog 
1p13.2 O CN 11-18.2% 
DN 52-60% 
MM 10-56% 
   SSM 0% 
   NM 31% 
 
 
82,83,8
6-91 
K-RAS Kirsten Rat 
Sarcoma viral 
oncogene 
homolog 
12p12.1 O CN 0-50% 
MM 0%-25% 
83,87,8
8,92,93 
HRAS Harvey Rat 
Sarcoma viral 
oncogene 
homolog 
11p15.5 O SN with copy 
number increase 
of 11p 67% 
SN without copy 
number increase 
5% 
38,83,8
8 
 
PTEN Phosphatase and 
tensin homolog 
10q23.3 TSG MM 13% 94 
CDKN2A cyclin-dependent 
kinase inhibitor 
2A 
9p21 TSG MM 4% 
(mainly AI studies 
and hereditary 
melanomas) 
95,96 
TP53 tumor protein 53 17p13.1 TSG  97 
TTC4 Tetratricopetide 
repeat domain 4 
1p31.3 PP CN 0% 
DN 0% 
MM 19% 
98 
 
CN: common naevi, SN: Spitz naevi, DN: dysplastic naevi, MM: malignant melanomas, SSM: 
superficial spreading melanomas, NM: nodular melanomas. O: oncogene, TSG: tumor 
supressor gene, PP: mediates protein-protein or protein-membrane interaction. 
 
to spitzoid lesions in children different results have been published: Gill et al did not 
detect any BRAF, NRAS, and HRAS hotspot mutations in 9 spitzoid melanomas and 
in 10 Spitz naevi obtained from children younger than 1 years. In our study only one 
patient younger than 11 years was included and in contrast to Gill et al this spitzoid 
melanoma harboured a BRAF mutation.63 As there are some variations in mutation 
frequency, additional studies on a larger number of cases are needed to definitively 
establish the diagnostic potential in pediatric melanocytic lesions. 
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CONCLUSION 
 
 The discovery of genetic alterations in various human melanocytic lesions is 
continuously expanding. Results from ploidy analysis, karyotyping, (F)ISH, AI and 
mutation analysis reveal that there are large differences in DNA alterations in 
subgroups of benign and malignant melanocytic lesions. These genetic variations 
contribute to a better understanding of the development of melanocytic lesions and 
are a target for use as an additional diagnostic tool. At this moment however 
histological examination is still the golden standard. In the near future we expect that 
information on the genetic profile of melanocytic tumours will be used to provide 
more certainty about the diagnosis. It will be important to perform multi-centre 
studies with long-term follow-up to establish the diagnostic value of additional 
molecular tools in pathology practice and to subsequently implement them properly 
into pathology practice. 
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ABSTRACT 
 
 Sinonasal mucosal melanomas are the most frequent type of mucosal 
melanoma and arise from melanocytes located in the nasal cavity and the paranasal 
sinuses. The melanoma types, cutaneous melanoma, uveal melanoma, and 
mucosal melanoma, differ in etiology, geographical distribution, and clinical 
behavior. Genetic alterations have been previously studied in cutaneous and uveal 
melanomas, but to the best of our knowledge, not in mucosal melanomas. 
Comparative genomic hybridization (CGH) was performed on 14 routinely processed 
sinonasal mucosal melanomas. Furthermore, ploidy analysis was performed on 11 
tumors to provide complementary data on the DNA index. The CGH profiles of 
sinonasal mucosal melanomas show remarkable consistent alterations: 
chromosome arm 1q is gained in all tumors and gains of 6p and 8q are present in 93 
and 57%, respectively. Comparison of CGH data with both the common variants of 
cutaneous melanoma and uveal melanoma revealed that sinonasal mucosal 
melanomas harbor a distinct pattern of chromosomal abnormalities. Ploidy analysis 
also showed that diploid tumors exhibit gains of 1q and alterations of chromosome 6 
(3 of 3 cases tested), whereas clear-copy gains and high-copy gains were only seen 
in triploid and tetraploid tumors (6 of 8 cases tested). This indicates that alteration of 
chromosomes 1 and 6 may precede polyploidization and formation of clear-copy 
gains and high-copy gains. 
 
INTRODUCTION 
 
 Melanomas can be subdivided according to site of origin in cutaneous 
melanoma, uveal melanoma, and mucosal melanoma. Mucosal melanoma in the 
sinonasal cavity is the second most common form of non-cutaneous melanoma, 
after uveal melanoma.102 Several differences between the types of melanomas exist, 
regarding: (1) etiology: mucosal and uveal melanoma are not associated with UV 
exposure in contrast to cutaneous melanoma103; (2) geographical distribution: 
mucosal melanoma is less frequent in Europe and the United States compared to 
cutaneous and uveal melanoma, whereas the incidence of mucosal melanoma is  
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much higher in Uganda and Japan104; (3) age of onset: compared to cutaneous and 
uveal melanoma, the age of onset of mucosal melanoma is approximately 15 years 
later104; (4) clinical behavior: mucosal melanomas are reported to be more 
aggressive, and tumor thickness or disease free margins do not have prognostic 
value for occurrence of local recurrences or metastases105; (5) therapeutic options: 
surgical removal is the primary treatment for both cutaneous and mucosal 
melanoma. However, local recurrences or irresectable tumors are very frequent in 
mucosal melanoma compared to cutaneous melanoma. Although there is no clear 
indication that radiotherapy is useful in cutaneous melanoma, it is successful in the 
treatment of uveal melanoma and can also contribute to a longer disease-free 
survival in mucosal melanoma patients.105-107 
 The occurrence of various types of melanoma and their different features as 
mentioned above might be related to genetic differences; with multivariate analyses 
of genomic imbalances, cutaneous and uveal melanomas were shown to harbor 
different chromosomal copy number changes.34 The most frequently detected 
imbalances in cutaneous melanomas are loss of 9p (63%) and loss of 10 (41%), 
whereas loss of 3 (50%) and gain of 8q (50%) are most frequently detected in uveal 
melanoma.101,108 Furthermore, acral melanoma, a subtype of cutaneous melanoma 
that develops on subungual skin or palms of hand and foot, showed frequent 
amplifications involving 11q13, 22q11-13, and 5p15, and gains of 1q (67%), 6p 
(67%), and 8q (53%).40 With regard to mucosal melanomas, only one oral mucosal 
melanoma cell line has been karyotyped, showing chromosomal imbalances unique 
to this cell line.109 To the best of our knowledge, no data on chromosomal 
aberrations have so far been described for sinonasal mucosal melanoma or mucosal 
human melanoma in general. Therefore, we examined chromosomal imbalances in 
a series of mucosal melanoma with comparative genomic hybridization (CGH) and 
ploidy analyses. Because mucosal melanomas arise most frequently in the 
sinonasal cavity, the CGH experiments were focused on this tumor location.  We 
show that sinonasal mucosal melanomas harbor a pattern of chromosomal 
alterations that is distinct from the common variants of cutaneous melanoma, that is, 
superficial spreading melanoma, nodular melanoma, and from uveal melanoma. 
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MATERIALS AND METHODS 
 
Case Selection 
 Paraffin embedded tissues of 14 sinonasal mucosal melanoma cases who 
underwent surgery between 1986 and 2000 were retrieved from the archives of the 
Department of Pathology, Radboud University Medical Center Nijmegen, Nijmegen, 
The Netherlands. No or insufficient DNA could be obtained from decalcificatied 
tissue for histotechnical reasons, and therefore such tumors were excluded from the 
current study. A pathologist (DJR) reviewed the corresponding slides to confirm the 
diagnosis. Clinical findings and histopathological data are summarized in Table 3-1. 
The mean age of the patients was 71.3 years at presentation (range 52-86 years), 
and the female to male ratio was 1.3:1. The thickness of tumor in resection 
specimen varied from 3 mm to 35 mm (mean 15.1 mm). Histologically, most tumors 
consisted of epithelioid cells. Only five tumors were of a mixed spindle and 
epithelioid cell type, and pure spindle cell tumors were not seen. Eight tumors 
contained melanin pigment and all tumors were immunohistochemically positive for 
vimentin and at least one melanoma-associated antigen (Table 3-1). The patients 
did not have a history of cutaneous or uveal melanoma except for patient 1 who had 
had a Clark II cutaneous melanoma 20 years preceding the diagnosis of the 
sinonasal mucosal melanoma. After surgical removal of the primary tumor, all 
patients (exept patient 9) received radiotherapy. 
 
DNA Isolation 
 Five to ten 50 mm paraffin-embedded tissue sections from representative tumor 
areas were used for DNA isolation. Areas with more than 80% tumor cells were 
selected based on parallel 4 mm H&E stained sections. After incubation in 1M 
sodium thiocyanate at 80°C for 1 hr, the tissue was washed twice with distilled 
water. Protein digestion was performed in cell lysis solution (Gentra, Minneapolis, 
MN) supplemented with 0.5 mg/ml proteinase K (Roche Diagnostics GmbH, 
Mannheim, Germany) at 37°C for five days, and fresh Proteinase K (0.5 mg/ml) was 
added every 24 hr. Subsequently, genomic DNA was isolated using the Puregene 
DNA Isolation Kit (Gentra), and RNA was removed with RNase-A (20 mg/ml) for 1 
hr. PCR Purification spin columns (Qiagen GmbH, Hilden, Germany) were used for  
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Table 3-1. Relevant clinical, histological, and immunohistochemical data of 
sinonasal mucosal melanomas 
    Thick
nessc
Cell 
typed
Immunohistochemical 
staininge 
 
Case  Sexa Ageb Location   S-
100
 
HMB-
45 
Tyr Mel 
1 F 74 Nasal cavity 6 Ep - - - + 
2 M 61 Nasal cavity 30 Mx ++ - - - 
3 F 52 Maxillary sinus 15 Ep + + + + 
4 M 72 Nasal cavity 15 Ep ++ - - + 
5 F 80 Nasal cavity 5 Mx + + Ne + 
6 M 86 Nasal cavity 3 Mx ++ + + ++ 
7 F 65 Nasal cavity 12 Mx ++ + + ++ 
8 F 82 Nasal cavity 28 Mx - ++ ++ ++ 
9 M 71 Nasal cavity 20 Ep + + ++ ++ 
10 F 76 Nasal cavity 17 Ep ++ + ++ ++ 
11 M 76 Nasal cavity 15 Ep + - + ++ 
12 F 57 Nasal cavity 7 Ep ++ + Ne Ne 
13 M 64 Nasal cavity 3 Ep ++ + + + 
14 F 82 Maxillary sinus 35 Ep - ++ Ne Ne 
 
a F, female; M, male, b Age at surgery (in years), c Tumor thickness of the resected tumor 
sample (in mm), d Ep, epithelioid cells; Me, Mixed epithelioid and spindle cells, eHMB-45, anti-
human melanosome; Tyr, tyrosinase; Mel, Melan-A; -,negative immunohistochemical staining; 
+, weak positive immunohistochemical staining; ++, strong positive immunohistochemical 
staining; Ne, not evaluable. 
 
 
final DNA Purification, and the DNA was eluted with 50 ml water (pH 8.0). 
The DNA concentration was measured on a UV spectrophotometer (GeneQuant, 
Amersham Pharmacia Biotech Europe GmbH, Freiburg, Germany). 
 
DNA Labeling 
 The molecular weight of the DNA was checked on ethidium bromide-stained 
agarose gel. Tumor DNA with a bulk fragment size larger than 1 kb was labeled with 
biotin-16-dUTP nick translation mix (Roche Diagnostics GmbH); otherwise, the 
tumor DNA was labeled with ULYSIS dGreen nucleic acid labeling kit (Kreatech, 
Amsterdam, The Netherlands). Two tumors with an intermediate bulk fragment size 
between 1 and 2 kb were labeled with both ULS and nick-translation. Reference 
DNA was isolated from normal paraffin-embedded tissue as described above and 
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labeled with digoxigenin-11-dUTP nick-translation mix (Roche Diagnostics GmbH), 
as the DNA fragment length was larger than 1 kb. 
 
CGH 
 CGH was performed as described by Jeuken et al.110 Briefly, 350-400 ng labeled 
tumor DNA, 350-400 ng labeled reference DNA, a 100-fold excess of Cot-1 DNA, 
and a 50-fold excess of herring sperm DNA were ethanol precipitated and dissolved 
in hybridization buffer (62.5% formamide, 10% dextran sulphate, 2xSSC-tween, pH 
7.0). This mixture was applied on normal metaphase chromosome spreads, 
denatured for 3 min at 74°C, and hybridized at 37°C for 3 days on an OmniSlide 
thermal cycler (Thermo Hybaid, Thermo Life Sciences, Breda, The Netherlands). 
After hybridization, the slides were washed twice in 0.4 SSC-Tween at 68°C for 1 
min in a wash module (Thermo Hybaid). Detection, image acquisition, and analysis 
were performed as described elsewhere.110 Detection thresholds for loss and gains 
of chromosomal regions were set at 0.85 and 1.15, respectively. These values were 
based on comparisons of normal DNA samples in which ratio profiles were never 
outside 0.9 and 1.1. As copy number gains vary from 1.15 to the software-based 
limit of 2, the degree of gain was subdivided into three categories. CGH profiles 
between 1.15 and 1.3 were classified as “normal gains”, representing a copy 
number increase of 1.5 or 2 times the average copy number. Aberrations with an 
arbitrarily chosen ratio of 1.3 were called “clear-copy number changes”, and 
aberrations with a ratio of at least 1.45 were called “high-copy gains”. Clear-copy 
gains and high-copy gains hence represent higher copy numbers. Because CGH 
only detects relative copy number changes, it is technically not possible to give a 
more specific copy number. Centromere regions and the Y chromosome were not 
included in the evaluation. All CGH experiments were performed in duplicate. 
 
DNA Ploidy Analysis 
 Nuclei extraction was performed from three to four 50 mm sections from 
representative tumor areas as described by Oud et al.111 Cytocentrifugation 
preparations of the nuclei suspension were stained with the Schiff-Feulgen stain, 
and the DNA content of 200 stained intact nuclei was then measured using the CAS 
100 System (Cell Analysis, Lombard, IL).112 Twenty lymphocytes were used as 
internal controls (DNA index 1). Histograms of DNA contents and DNA indices of the 
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highest peak were calculated, and tumors were classified according to the following 
definitions: (near-)diploid (DNA index 0.8-1.2), (near-)triploid (DNA index 1.3-1.7), or 
(near-)tetraploid (DNA index 1.8-2.2). 
 
Statistics 
 For statistical analysis, we used published CGH data of 48 cutaneous melanoma 
not otherwise specified,101,108 15 superficial spreading cutaneous melanoma,40 15 
acral melanoma,40 12 melanoma metastases,101 46 uveal melanoma,113,114 and 104 
nasopharyngeal carcinoma.115-118 The statistical significance of the differences in 
CGH results between the melanoma subtypes was determined with the Fisher’s 
exact test. Because we compared results obtained from different laboratories and 
relatively small numbers of specimens, the P values were considered significant 
when they were equal or less than 0.01. The X and Y chromosomes were not 
evaluated to avoid false-positive results due to sex-mismatch and variation between 
the numbers of males and females in each of the studied groups. The statistical 
analyses were not adjusted for multiple comparisons as they are considered 
descriptive, with the aim to generate hypotheses that can be tested in further 
studies.  
 
RESULTS 
 
 CGH was successfully performed on 14 sinonasal mucosal melanomas. The 
relevant clinical, histopathological, and immunohistochemical data of these tumors 
are summarized in Table 3-1. The duplicate experiments showed similar ratio 
profiles, including two cases where tumor DNA was labeled with both ULS and nick-
translation. Chromosomal imbalances were detected in all sinonasal mucosal 
melanomas. They occurred with an average frequency of 10 aberrations per case. 
CGH results are depicted in Figure 3-1. Overall, there were slightly more 
chromosome arms with losses compared to gains (85 vs 64). All 14 tumors showed 
a gain of the long arm of chromosome 1 (1q). The short arm of chromosome 6 (6p) 
was gained in all tumors except for tumor 1 (93%). The CGH results for each 
individual sinonasal mucosal melanoma, the number of altered chromosome arms, 
and the results of the DNA-ploidy analysis are given in Table 3-2. 
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Table 3-2. CGH Gains and losses in sinonasal mucosal melanomas and ploidy 
analysis results 
Case CGH losses CGH gainsa Nob DNA 
ploidyc 
DNA-
index 
 
1 6q, 13q 1q 3 Di 0.8 
2 6q, 9p, 17p 1q, 6p 5 Di 1 
3 6q, 9p, X 1q, 6p 6 Di 1.2 
4 9p, 15qcen-q21 1q, 6p, 7 6 Tri 1.7 
5 9, X 1q, 6p, 12q 7 Tri 1.7 
6 1p31-pter, 4q, 8p21-pter, 
10, 11, 16q, 17p, 19q 
1q, 6q13-pter, 8p12-
qter 
13 Tri 1.7 
7 1p, 3p21-q21, 6q, 8p, 9p, 
10,11q21-qter, 12q21-
qter, 13q, 15q 
1q, 6p, 8q, 11q14-21,  
12p11.2, 12q21, Xp 
17 Tet 1.9 
8 15qcen-q21, X 1q, 5, 5p13, 6p, 7p, 7q, 
8p, 8q, 17q22, 18  
13 Tet 1.9 
9 3, 4p, 9, 10pter-q24, 
11pter-q13, 12q23-24, 
13q, 14q, 15q, 16, 
17pter-q12, X 
1q, 6p, 8q, 11q14-qter, 
21q 
21 
 
Tet 1.9 
10 6q, 10, 11, 14q, X 1q, 6p, 7, 8, 13q22-qter, 
17q22 
16 Tet 1.9 
11 14q21-qter 1q, 6p, 8q 4 Tet 2.1 
12 10q, 13q 1q, 6p, 17q, 19q 6 Ne Ne 
13 3q, 8p, 10, 15qcen-q21, 
17p 
1q, 6p, 8q 9 Ne Ne 
14 1p, 6q, 9p, 11, 13q, 14q, 
X 
1q, 4, 6p, 7q, 8q 15 Ne Ne 
 
aBold type, clear-copy gains; bold type underlined, high-copy gains. bNumber of chromosome 
arms with imbalances. cDi, (Near-)diploid; Tri, (Near-)triploid; Tet, (Near-)tetraploid; Ne, not 
evaluable. 
 
 
Ploidy analysis showed that also diploid tumors exhibited gains of 1q and alterations 
of chromosome 6 (3 of 3 cases tested), whereas clear-copy gains and high-copy 
gains (located on 5p13, 8q, 12p11.2, and 17q22) were only seen in triploid and 
tetraploid tumors (6 of 8 cases tested). In Figure 3-2, the distribution of 
chromosomal imbalances in the present series of sinonasal melanomas is compared 
to those inother previously described melanoma types. Only chromosome arms with 
statistically different frequency of gains and losses in one or more melanoma 
subtypes are displayed. 
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Figure 3-1. Summary of all the chromosomal imbalances detected by CGH analyses of 14 
primary sinonasal mucosal melanomas. Lines to the right of the chromosome ideograms 
represent gains, lines to the left represent losses. Thick lines indicate clear-copy gains and 
thick lines highlighted by arrows indicate high-copy gains. 
 
 
DISCUSSION 
 
 In this study, we analyzed the chromosomal imbalances of 14 sinonasal 
mucosal melanomas by CGH and ploidy analyses. To our knowledge, no genetic 
data of sinonasal mucosal melanomas have been described previously. Before 
discussing the CGH pattern in sinonasal mucosal melanomas and comparing the 
frequency of specific chromosome arm aberrations with those in other melanoma 
types, attention will be given to technical aspects of CGH analysis of formalin fixed 
tissues. Although CGH on paraffin-embedded tissue results in less bright CGH 
signals compared to CGH on snap-frozen tissue because of the decreased DNA 
quality, we performed reliable CGH experiments as shown by identical duplicate 
experiments. Decalcified tissue did not appear to be suitable for DNA extraction, as 
previously reported,119 and these samples were therefore excluded from this study. 
Due to variation in fixation times between tissues, DNA fragment length varied 
among the 14 different tumor samples. To obtain optimal CGH results, ULS labeling 
was used for DNA samples with a bulk fragment length below 1 kb, whereas nick-
translation was used for the DNA samples with large fragment lengths. Two tumors 
with an intermediate bulk fragment size between 1 and 2 kb were labeled with both 
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ULS and nick-translation, and these CGH experiments resulted in similar profiles, 
ensuring compatibility of both labeling techniques. In a number of cases, we 
detected a reproducible deviation from the normal profile that did not exceed the 
0.85 or 1.15 thresholds, suggesting that these aberrations were present in a minority 
of the cells (data not shown). 
 The CGH results of the sinonasal mucosal melanomas revealed two remarkable 
observations. First, chromosome arm 1q was gained in all tumors, and all tumors 
harbored a gain of 6p, a loss of 6q, or both (Table 3-2). The frequency of alterations 
of chromosome 1 and 6 combined with the fact that these aberrations are already 
present in tumors that are still diploid indicated that these alterations occur earlier in 
the tumor progression and may result in a growth advantage by a gain of oncogenes 
or loss of tumor suppressor genes. Furthermore, regions with high copy number 
gains (5p13, 12p11.2, and 17q22) and regions of frequent losses, such as 9p, 10q, 
13q, and 15q11-21, may harbor genes important in tumor progression. The second 
interesting observation is that gains of 1q, 6p, and 8q in sinonasal mucosal 
melanoma occurred frequently in combination with a loss of copy number or a 
normal copy number of the opposite chromosome arm, suggesting isochromosome 
formation. The latter alteration can occur in tumors with two normal copies and an 
isochromosome of the gained arm with loss of the other arm or a combination of a 
normal copy, an isochromosome, and a copy of the normal arm with loss of the 
gained chromosome. Isochromosomes are mostly described as secondary changes 
and are found in 36% of melanomas, with i(8q) being most frequent followed by i(1q) 
and i(6q).120 In uveal melanoma, isochromosome formation is described to be 
associated with loss of chromosome 3.34,114,121 However, because loss of 
chromosome 3 is only seen in 21% of the sinonasal mucosal melanomas, alterations 
on other chromosomes or alterations too small to be detected by CGH precede the 
isochromosome formation in sinonasal mucosal melanoma. It is also possible that 
this pattern of imbalance is caused by more complex chromosomal aberrations. 
 Several authors have reported an association between tumor thickness or a 
poor prognosis and increase in the number of chromosomal alteration, the number 
of amplifications, formation of isochromosomes, loss of chromosome 3, and gain of 
7 and 8q.101,108,122,123 Therefore, we analyzed the correlation between tumor features 
and chromosomal alterations in our sinonasal melanomas. No association was 
detected between chromosomal alterations and age of the patient or recurrence 
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Figure 3-2. Literature review of the most frequent chromosomal gains and losses detected by 
CGH in A: Cutaneous melanoma (not otherwise specified) (n=48).101,101,108 B: Superficial 
spreading cutaneous melanoma (n=15).40 C: Acral melanoma (n=15).40 D: Uveal melanoma 
(n=46),113,114,114 E: Melanoma metastases (n=12).101 F: Nasopharyngeal carcinoma 
(n=104),115,116,116,117,117,118,118 (all outlined bars). These results are compared to the results of 
the present study in sinonasal mucosal melanoma (solid gray bars). Statistical significant 
difference are indicated with * and **; * P = 0.01 - 0.001; ** P < 0.001 
 
 
pattern, probably because sinonasal mucosal melanomas are asymptomatic for a 
long time and patients are usually diagnosed at a late stage of the disease. 
 Because genetic differences between different melanoma types have been 
reported previously, we compared our CGH results with other melanoma types 
previously reported. Comparing the CGH results, sinonasal melanoma harbor a 
more consistent CGH pattern than other melanoma types and subtypes. Alterations 
of 1q and 6p were seen in almost all examined sinonasal melanomas, whereas in 
other melanoma types the most frequent alterations are only seen in 40-70% of the 
tumors. It is not likely that admixture with normal cells as previously described for 
thin melanomas and the stage of the disease process cause these differences, 
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because the CGH results of melanoma metastases from cutaneous melanomas and 
the CGH results of cutaneous melanoma show a similar pattern, although the latter 
tumors contain more non-neoplastic cells and are of a lower stage (Figure 3-2).101,108 
Another explanation for the observed difference may be that cutaneous and uveal 
melanomas were studied as single groups, although in fact may consist of several 
subtypes. A highly statistical significant qualitative difference between acral 
melanoma and superficial spreading melanoma in amplification frequencies was 
found by Bastian et al.40 Also, for uveal melanomas chromosome 3 may be a 
specific marker for ciliary tumors, because uveal melanomas without ciliary 
involvement do not show alterations of chromosome 3.124 However, CGH analyses 
of 11 uveal melanomas have not confirmed these results.113 
 Chromosomal imbalances detected by CGH in sinonasal melanomas were also 
compared with non-melanocytic tumors that arise in mucosa in the head and neck 
region. Comparison with published CGH results from nasopharyngeal carcinomas 
shows that these tumors harbor alterations frequently seen in head and neck 
carcinomas, such as a loss of 3p and gain of chromosome 12.115-118 Differences in 
distribution of chromosomal imbalances between sinonasal melanoma and 
nasopharyngeal carcinoma (Figure 3-2F) suggest that chromosomal alterations are 
mainly determined by the cell type and less by location or carcinogen exposure. 
Although sinonasal and uveal melanomas both arise from non-dermal melanocytes 
and independent of UV-exposure, the CGH patterns of these two melanoma types 
displayed the largest differences (Figure 3-2D). Sinonasal mucosal melanomas were 
most similar to acral melanomas, a subtype of the cutaneous melanomas (Figure 3-
2C). Both tumor types most frequently show gains of chromosome arms 1q and 6p. 
However, amplifications were only detected in five of the 14 sinonasal mucosal 
melanomas (36%), whereas amplifications have been described in all investigated 
acral melanomas.40 Interestingly, similarities between immunohistochemically 
staining patterns in mucosal melanomas and acral melanomas have also been 
described, whereas mucosal melanoma lesions display an antigenic profile that is 
different from nodular cutaneous and uveal melanoma lesions.125  
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ABSTRACT 
 
 To test the diagnostic usefulness of allelic imbalance (AI) analysis based on 
routinely paraffin-embedded tissue, we investigated a series of 55 benign Spitz 
naevi, Spitz tumours with uncertain malignant potential, and spitzoid melanomas. 
Laser microdissection was used to ensure representative sampling of lesional cells 
and to investigate AI in separate tumour areas of four melanomas. AI was found in 
2/12 (17%) typical Spitz naevi, 3/9 (33%) atypical Spitz tumours, 12/17 (65%) 
atypical Spitz tumours suspect for melanoma, and 15/17 (88%) spitzoid melanomas. 
Additional immunohistochemical staining for Ki-67 using the MIB-1 antibody 
revealed positive deeply situated lesional cells in 0/6 (0%) Spitz naevi, 1/8 (13%) 
atypical Spitz tumours, 5/14 (35%) atypical Spitz tumours suspect for melanoma, 
and 7/14 (50%) spitzoid melanomas, respectively. Two of the melanomas examined 
for AI in separate tumour areas showed intratumoural genetic heterogeneity. In view 
of the finding of AI and deeply situated Ki-67 positive cells not only in melanomas 
but also in Spitz tumours with uncertain malignant potential, these approaches 
appear to have no direct diagnostic applicability for the distinction between benign 
and malignant Spitz tumours. Further molecular studies may provide additional 
information whether genetic differences can be found between Spitz tumours and 
spitzoid melanomas or, alternatively, whether there is a true spectrum of tumour 
progression. 
 
INTRODUCTION 
 
 The histological differential diagnosis of Spitz naevus versus melanoma 
resembling Spitz naevus, often referred to colloquially as spitzoid melanoma, is 
notoriously difficult.2,15,17 In a recent series, about a quarter of Spitzoid lesions 
submitted for consultation to a panel of experts could not be diagnosed with 
certainty by general pathologists.4 Even more alarmingly, some of the lesions 
diagnosed as Spitz naevus by a majority of expert pathologists later gave rise to 
metastasis.126 Thus, there remains an obvious need for further diagnostically 
applicable parameters. Several workers have explored the possible contribution of 
ploidy analysis,127 morphometry,128 and immunohistochemistry129 but so far, none of 
these techniques has gained acceptance in routine practice, because of insufficient 
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discriminatory power or because they have not yet been tested on large enough 
series of cases. Genetic studies have been performed, using in situ hybridisation20 
and Loss of Heterozygozity (LOH), better referred to as Allelic Imbalance (AI) 
analysis.75,130,131,132 Most of these latter studies have revealed significant genetic 
differences between typical Spitz naevi and melanomas with usual histological 
appearance, that is without a close resemblance to Spitz naevus: melanomas were 
found to contain a wide variety of deletions and amplifications of loci on various 
chromosome arms, which were not identified in Spitz naevi.108 This suggests that 
Spitz naevus and melanoma are unrelated disease entities. However, the practical 
diagnostic applicability of this difference between Spitz naevi and melanomas needs 
to be tested on lesions that are difficult to classify histologically, namely atypical 
Spitz tumours of uncertain malignant potential, and the results should be compared 
to those of typical Spitz naevi and unequivocal spitzoid melanomas. Since the most 
promising genetic differences reported so far concerned AI we chose AI analysis of 
microsatellite repeats and limited ourselves to paraffin-embedded tissues,75 which is 
the material available in a routine diagnostic setting, and employed laser 
microdissection in order to enhance sensitivity of AI detection. The AI results were 
compared to the presence of Ki-67 positive lesional cells, because a correlation 
between both findings has been reported and Ki-67 is described as an additional 
diagnostic marker in melanocytic lesions.129,133 
 
MATERIALS AND METHODS  
 
Case selection 
 Paraffin blocks of typical Spitz naevi, atypical Spitz tumours, atypical Spitz 
tumours suspicius for melanoma, and primary sporadic cutaneous spitzoid 
melanomas were retrieved from the archives of the Departments of Pathology of the 
Radboud University Medical Centre, Nijmegen, The Netherlands Cancer Institute 
(Amsterdam) and the Rijnstate Hospital (Arnhem) The Netherlands. All lesions had 
been previously classified histologically by the Dutch melanoma panel, which 
includes two of the authors (DJR, WJM), using established criteria.2,15,17 A lesion 
was diagnosed as atypical Spitz tumour when all of the three following features were 
present: (1) irregular junctional activity with absence of well-defined nests at the  
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Table 4-1. Clinical and histological data 
 
Spitz 
naevus 
(n=12) 
 
Atypical spitz 
tumour 
(n=9) 
 
 Suspect
 
Spitzoid 
melanoma 
(n=17) 
 
Primary 
Spitzoid 
melanoma 
(n=17) 
 
Thickness (mm) 
 (range) 
 
1.05 
(0.30-2.50)
2.49 
(0.70-4.10) 
3.20 
(0.75-6.0) 
4.02 
(0.22-10.00) 
% Tumour cells 
 (range) 
 
68 
(60-70) 
71 
(60-≥80) 
74 
(60-≥80) 
76 
(60-≥80) 
Mean age 
(years) 
 
21.8 
(7-39) 
24.2 
(0-56) 
45 
(10-82) 
55 
(17-86) 
Cell type 
  Spindle 
  Epithelioid 
  Small  
  Mixed 
 
 
8 
2 
1 
1 
 
1 
3 
1 
4 
 
6 
8 
2 
1 
 
1 
11 
1 
4 
Gender 
  Male 
  Female 
 
6 
6 
4 
5 
9 
8 
11 
6 
Follow-up 
  Recurrence 
  Metastasis 
  Unknown 
0 
0 
2 
1 
0 
5 
5 
1 
11 
0 
10 
1 
 
dermoepidermal junction, asymmetry, or both, (2) nuclear pleomorphism exceeding 
that generally seen in Spitz naevi, (3) compact growth pattern of the dermal 
component. An atypical Spitz tumour was considered suspicious for melanoma 
when, in addition, loss of maturation and occasional deep mitotic figures were found, 
but these findings were considered to be insufficient for a confident diagnosis of 
melanoma. In lesions derived from patients below 15 years of age, lesions were only 
classified as atypical Spitz when atypia was severe.15 The thickness of the tumours, 
the nuclear pleomorphism, and the type of the tumour cells (ie, spindle, epithelioid, 
small cells or mixed cell population) were recorded. The relevant clinical and 
histological data are presented in Table 4-1. The percentage of normal cells in the 
tumour cell isolates was estimated and isolates that contained over 40% of non-
lesional cells were excluded from further analysis. 
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Laser microdissection and DNA isolation 
 Five to ten 20 µm paraplast embedded tissue sections per tumour were mounted 
on object slides and were haematoxylin and eosin stained. For the laser 
microdissection procedure the tissue sections were mounted in a mounting medium 
to provide optimal histological precision. The mounting solution was prepared of 
Pinpoint solution (Zymo Research, Orange, CA, USA), distilled water and blue ink. 
After application on the complete tissue area, the solution subsequently dried into a 
thin film. A pulsed Nitrogen laser (Leica Mikrosysteme Vertrieb GmbH, Bensheim, 
Germany) was used to separate tumour cells from neighbouring normal cells. 
Microdissected tumour and normal tissues embedded in the Pinpoint film were lifted 
with a sterile needle and transferred separately to two microfuge tubes. After 1 hr 
incubation at 80°C in 1M sodium thiocyanate the tissue was washed twice with 
distilled water. Genomic DNA was isolated using the Puregene DNA Isolation Kit 
(Gentra, Minneapolis, USA). The DNA was dissolved in 50 µl distilled water. 
 
Allelic Imbalance analysis 
 A polymerase chain reaction (PCR) amplifying a 210 bp part of the FSH receptor 
gene (chromosome 2q21-16) was used to check the DNA quality and quantity. 
When there was no or little PCR product, representing less than 25 ng normal or 
tumour template DNA that could be amplified in each PCR, no further analysis was 
performed because little DNA or very fragmented DNA can cause PCR artefacts 
resulting in false positive AI test outcome.134 DNA samples with very strong control 
products were diluted to prevent overamplification. Highly polymorphic CA repeat 
markers located on chromosome arms with frequent genetic alterations in 
melanoma (1p (D1S207; D1S209), 3p (D3S1293; D3S1289), 6q (D6S287; D6S262), 
8q (D8S260; D8S285), 9p (D9S970; D9S171), 10q (D10S185), and 11q (D11S925)) 
were selected from the Genome DataBase (http://www.gdb.org).70,75,108 On most 
chromosome arms two markers were chosen to reduce the effect of non-informative 
markers. Primers with a maximum expected PCR product length of 215 bp were 
purchased from Life Technologies (Rockville, Maryland, USA). The forward primer of 
each primer pair was fluorescently labelled at the 5’ end. The duplex PCR was 
performed in a total volume of 15 µl and contained 2.5 µl template DNA, buffer IV 
(Integro, Dieren, The Netherlands), 200 µM of each deoxynucleotide triphosphate, 
1-3 mM MgCl2, 1-3 pmol of each forward primer and 30 µg bovine serum albumin 
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(BSA, Sigma-Aldrich Chemie B.V, Zwijndrecht, The Netherlands). A modified 
hotstart was used to prevent primer dimerisation and mispriming; after an initial 
denaturation at 92°C for 3 min 1-3 pmol of the reverse primer and the 0.25 units of 
thermostable DNA polymerase (Integro, Dieren, The Netherlands) were added. This 
was followed by 35 cycles of denaturation at 92°C for 30 s, annealing at the 
appropriate temperature (55-59°C) for 45 s and extension at 72°C for 45 s with a 
final extension of 30 min at 72°C. DNA amplification was performed in a PTC 200 
thermal cycler (MJ Research, Inc, Waltham, Massachusetts, USA). Aliquots of 1 µl 
of the diluted PCR product (1:2 to 1:100) were combined with 0.5 µl of a TAMRA-
labelled commercial size standard (Genescan 350-TAMRA, Applied Biosystems) 
and 1.5 µl formamide. Samples were denatured and electophoresed in a 6% 
denaturing polyacrylamide gel in a DNA sequencer (Applied Biosystems, Foster 
City, California, USA; model 373) and analysed using the Genescan software 
(Applied Biosystems, Foster City, California, USA; model 373). All experiments were 
performed in duplicate. After visually checking the signal noise ratio and the pattern 
of the peaks, peak heights and sizes (in base pairs) were imported into Excel 97 for 
further calculations. Because DNA fragments of different sizes amplify with different 
efficacy, the ratio of alleles was calculated for each normal and tumour sample and 
subsequently the tumour ratio was divided by the normal ratio (i.e. T1:T2/N1:N2). 
The mean ratio of the two experiments was calculated and ratios larger than 1.0 
were converted (1/x) to obtain values of 1.0 or below. Because the ratios of 99% of 
the repeated normal DNA analyses were larger than 0.75, ratios under 0.70 were 
considered to be indicative of allelic imbalance. To avoid false positive or false 
negative results due to PCR artefacts, experiments with a variation larger than 0.20 
were considered inconclusive.  
 
Immunohistochemistry 
 Four µm paraffin sections were deparaffinized and rehydrated, followed by 
microwave antigen retrieval in citrate buffer (10 mM, pH 6.0) two times for 5 minutes. 
The MIB-1 antibody (Dako, Glostrup, Denmark) was used in a 1:100 dilution for 60 
minutes. Immunohistochemical staining with the avidin-biotin complex-peroxidase 
method was performed using the MARK 5 histochemical staining system (Diagnostic 
Products Corporation, Breda, The Netherlands). Cases with at least 5% 
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immunoreactivity of melanocytic cells in the deep dermal zones of the lesion were 
regarded as positive.  
 
Statistical Analysis 
 The fractional allelic loss (FAL) was calculated by dividing the number of 
markers with AI by the total number of informative loci for each tumour. The Mann-
Whitney U-test was used to examine the correlation between histopathological 
diagnosis and FAL. A p value under 0.05 was considered significant.  
 
RESULTS 
 
DNA and AI quality 
 In over half of the lesions, up to ten 20 µm sections provided insufficient normal 
DNA, tumour DNA, or both. In five cases it was impossible to obtain the required 
minimum of 60% tumour cells, due to a large number of infiltrating lymphocytes or 
stromal cells. Finally, all lesions with more than three inconclusive markers were 
excluded. Because of these strict requirements, only 55 lesions were analysed for 
AI. 
 
AI and Ki-67 expression in melanocytic lesions 
 First, AI analysis was used to compare typical Spitz naevi and primary spitzoid 
melanomas. Results are shown in Figure 4-1. AI was observed in two of 12 Spitz 
naevi (mean FAL: 2.8), but in 15 of 17 primary melanomas (mean FAL: 28.2). Three 
of nine atypical Spitz tumours and 12 of 17 atypical Spitz tumours that were suspect 
of melanoma showed allelic imbalance (mean FAL: 12.0 and 20.2, respectively). 
The AI frequency for each individual marker is shown in Table 4-2. The difference in 
FAL between the typical Spitz naevi and the primary melanomas was statistically 
significant (p=0.01), but there was no difference between the FAL in atypical Spitz 
tumours and Spitzoid tumours suspicious for melanoma (p=0.51). 
 The AI ratio distribution of the markers ranged from 0.07-1.00. AI most 
commonly involved markers on chromosomes 9 and 1. These markers showed also 
a high percentage of complete loss in contrast to those on chromosome 6, which 
also showed a high percentage of losses but only a few complete AI (Figure 4-2). 
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Figure 4-1. AI results of the Spitz tumour lesions. The cases are represented in rows and the 
markers in columns. AI is observed in 2 of 12 typical Spitz naevi, 3 of 9 atypical Spitz 
tumours, 12 of 17 atypical Spitz tumours suspicious of melanoma, and 15 of 17 primary 
spitzoid melanomas. 
 
Table 4-2. AI results for each microsatellite marker 
  
Spitz 
naevus 
Atypical 
spitz 
tumour 
Suspect
 
spitzoid 
melanoma 
Primary 
spitzoid 
melanoma 
Marker* 
 
Location 
 
AI/ 
inf. 
 
AI% AI/ inf. AI% 
AI/ 
inf. AI% 
AI/ 
inf. AI% 
D1S207 1p33-32 0/10  0/6  5/16 31.3 4/12 33.3 
D1S209 1p33-32 0/8  1/8 12.5 6/13 45 2/14 14.3 
D3S1289 3p21.2-21.1 0/8  1/8 12.5 1/15 6.7 2/11 18.2 
D3S1293 3pter-3p24.2 0/11  1/9 11.1 1/14 7.1 1/11 9.1 
D6S262 6q21-22 0/10  1/7 14.3 3/11 27.3 3/13 23.1 
D6S287 6q21-23.3 1/10 10 1/5 20 3/10 30 6/13 46.2 
D8S260 8q11.2-11.2 0/6  0/6  0/14  3/10 30 
D8S285 8q11.2-12 1/8 12.5 0/8  0/11  1/10 10 
D9S171 9p21 1/10 10 2/5 40 5/15 33.3 8/12 66.7 
D9S970 9p13-12 0/8  1/6 16.7 2/10 20 10/15 66.7 
D10S185 10q23-24 0/9  0/8  4/13 30.8 3/9 33.3 
D11S925 11q23 0/7  0/7  3/12 25 3/12 25 
 
AI/inf.: Number of cases with Allelic Imbalance / total informative cases, AI%: percentage of 
informative cases with allelic imbalance. *Data retrieved from The Genome DataBase: 
http://www.gdb.org. 
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Figure 4-2. Frequency of allelic imbalance for each microsatellite marker in the total set of 
spitzoid lesions. Dark gray: ratio’s <0.3, light gray: ratio’s 0.3-0.7 
 
 
Comparison of the informative markers located on the same chromosome showed 
concordant AI results in 93% of the analyses. To investigate genetic heterogeneity in 
the melanomas tested, two to five different tumour areas of four large tumours 
(cases 47, 49, 53, and 54) were isolated and analysed separately. Two of these 
tumours revealed different AI patterns in different areas. These tumours displayed 
also different morphologies in the dissected areas. A representative sample of a 
dissected tumour and corresponding AI results are shown in Figure 4-3. There was 
not a clear relationship between Breslow thickness and presence of AI, as four of 
the five melanomas and tumours suspect for melanoma below 1.5 mm thickness, 
and 19 of the 29 thicker lesions, showed AI. AI was more frequent in thinner atypical 
Spitz naevi of young patients (below 15 years of age) (4/5) compared to thick 
atypical Spitz tumours of older patients (0/4). Frequencies of AI in thin and thick 
lesions according to diagnostic group are summarised in Table 4-3. The follow-up 
data revealed no metastases in the Spitz naevus and atypical Spitz tumour patients, 
whereas one patient with an atypical Spitz tumour suspicious for melanoma and 10 
primary spitzoid melanoma patients developed metastases. All but one of these 
metastasising lesions showed AI. 
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Figure 4-3. A: Primary spitzoid melanoma (case 47); tumour areas ‘1’ and ‘2’ are analysed 
separately. B: Shown are the electropherogram results for tumour part one (1), part two (2), 
and normal DNA (N). Marker D3S1293 has no allelic imbalance. C: Marker D1S207 has a 
relative loss of the small allele in both parts of the tumour. D: Marker D6S262 has a relative 
loss of the small allele in part 1 and a relative loss of the other marker in part 2.  
 
 
Table 4-3. AI frequency in thin and thick lesions 
Spitz naevus 
Atypical  
Spitz tumour 
Suspect
 
spitzoid 
melanoma 
Primary spitzoid 
melanoma 
Thickness 
(mm) 
AI/ 
inf. AI% 
AI/ 
inf. AI% 
AI/ 
inf. AI% 
AI/ 
inf. AI% 
<1.5 1/9 11% 2/3 66% 3/3 100% 1/2 50% 
1.5-3.5 1/3 33% 1/2 50% 5/8 63% 5/5 100% 
>3.5 0/0 0% 0/4 0% 4/6 67% 9/10 90% 
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 Immunohistochemical staining for Ki-67 using the MIB-1 antibody on 42 lesions 
of the four different categories studied revealed positive deeply situated lesional 
cells in 0/6 (0%) Spitz naevi, 1/8 (13%) atypical Spitz tumours, 5/14 (35%) atypical 
Spitz tumours suspicious for melanoma and 7/14 (50%) spitzoid melanomas, 
tumours suspect for melanoma and 3/14 melanomas. Less than 1% deeply situated 
Ki-67 positive cells were commonly found in Spitz naevi (4/6) but only sporadically 
seen in atypical Spitz tumours (2/7), atypical Spitz tumours suspicious for melanoma 
(1/14), and spitzoid melanomas (1/14). There was no correlation between FAL and 
the Ki-67 results. 
 
Unusual cases 
 Two lesions originally diagnosed as typical Spitz naevus showed AI. Case 1, a 
Spitz naevus with AI on chromosome 6 and a region of 9p, was removed from the 
forearm of a 10-year-old boy. The lesion was dome shaped and symmetric (Figure 
4-4A), with a thickness of 2.5 mm, and was composed of uniform spindle cells 
sometimes arranged perpendicular to the epidermis. The cells contained nuclei with 
prominent nucleoli, some cells were multinucleated, and there were a few deep 
mitotic figures (Figure 4-4B). At first evaluation, these features were felt to be 
insufficient for a diagnosis of an atypical Spitz tumour. However, on revision of the 
case, we felt that the presence of marked cytological and architectural atypia in 
combination with occasional deep mitotic activity should have led to a diagnosis of 
atypical Spitz tumour. The lesion was removed totally with a margin less than 1 mm. 
During the follow-up period of 67 months, no recurrence or metastasis became 
evident.  
 The other typical Spitz naevus (case 5) with an allelic imbalance on 
chromosome 8 was removed from the knee of a 9-year-old boy. This symmetric 0.7 
mm thick lesion showed prominent vertically oriented junctional nests surrounded by 
clefts (Figure 4-4C). The lesion consisted of pigmented spindle cells with atypical 
nuclei. There were a few infiltrating lymphocytes and several melanophages were 
noted (Figure 4-4D). At first evaluation, these findings were felt insufficient for the 
diagnosis of atypical Spitz tumour. However, again at review, the lesional cytological 
and architectural atypia were considered to be marked, consistent with a diagnosis 
of atypical Spitz tumour. The lesion was completely removed and no recurrence or 
metastases occurred during a follow-up period of 36 months.  
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Figure 4-4. Photomicrographs of unusual cases A en B: case 1, originally underevaluated 
Spitz naevus with a sporadic mitosis (arrowhead); C and D: case 5, similar Spitz naevus as 
case 1; E and F: case 44, unequivocal primary spitzoid melanoma. 
 
 
 The two primary melanomas not showing AI with our markers were removed 
from an ear lobe of an 86-year-old woman and from the back of a 57-year-old man. 
The first lesion (case 41) with a Breslow thickness of at least 8 mm, showed 
frequent mitoses and, strikingly, areas of necrosis. A brisk lymphocytic infiltrate was 
apparent. Liver metastases became evident 7 months later.  
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 The second patient (case 44) with a melanoma without AI presented with a very 
dark lesion on the back. Histologically, a 0.4 mm thick asymmetric lesion with 
irregular pigmentation was observed (Figure 4-4E). Nuclei were very atypical and 
the cells contained dusty melanin pigment and few mitotic figures (Figure 4-4F). A 
scattered lymphocytic infiltrate was present. The lesion was removed with a wide 
margin; during the follow-up period of 36 months, no recurrence or metastasis was 
observed.  
 Of the atypical Spitz tumours suspicious for melanoma, one tumour (case 23) 
showed metastasis. This was a lesion removed from the foot of a 64-year-old male 
with a Breslow thickness of 1.8 mm. The lesion was asymmetric and consisted of 
moderately atypical epithelioid cells that did not show maturation towards the base 
of the lesion. A few mitotic figures were seen. The lesion was completely removed 
with a margin of at least 15 mm. AI analysis showed two allelic imbalances. 
 
DISCUSSION 
 
 We investigated a series of benign, malignant and diagnostically equivocal Spitz 
tumours by AI analysis in order to test the possible diagnostic contribution of this 
molecular approach. AI was found only occasionally in typical Spitz naevi (17%) but 
frequently in primary spitzoid melanomas (88%). In atypical Spitz tumours and 
atypical Spitz tumours suspicious for melanoma, the percentages of AI amounted to 
33% and 65%, respectively. These results are paralleled by a similar increase in 
prevalence of deeply lesional Ki-67 positive cells. Before discussing the potential 
diagnostic and pathobiological implications, attention will be given to technical 
aspects of AI analysis in order to substantiate the validity of the molecular findings. 
 AI analysis uses microsatellite markers to detect allelic imbalance in a tumour 
cell population compared to a normal cell population of the same patient. The 
technique is prone to PCR artefacts, especially when using routinely processed 
paraffin-embedded tissue. This can result in false negative and false positive results. 
An important cause of false negative AI results is contamination by normal cells. 
Therefore, we minimised the proportion of contaminating normal cells by laser 
microdissection, which allows obtaining individual melanocytic cell nests. This 
probably explains why we detected AI so frequently in primary melanomas with a 
thickness of less than 1.5 mm, which contrasts with the findings reported in an 
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earlier study where microdissection was not employed.135 Intratumoural 
heterogeneity can also cause false negative AI results. Others and we have showed 
that intratumoural genetic heterogeneity is frequent in melanomas.136 The high 
percentage of incomplete AI ratios provides indirect evidence of this phenomenon. 
Theoretically, in absence of non-neoplastic cells, a complete deletion would result in 
an AI ratio of 0. When part of the tumour does not contain the deletion, the ratio 
increases accordingly. A limitation of AI analysis is the fact that low copy number 
gains cannot be detected reliably. To identify those, morphological techniques such 
as fluorescence in situ hybridisation (FISH) on tissue sections, directly visualising 
copy number, would be more appropriate. The risk for false positive AI was reduced 
to a minimum by strict control of DNA quality and quantity. This lead to exclusion of 
over half of the lesions originally selected for the study. Fixation with unbuffered 
formalin or extended duration of fixation, probably accounted for poor DNA quality in 
about 10% of the cases. In the remaining 40% of the non-analysable lesions, the 
amount of normal tissue was insufficient for DNA isolation. In several of these 
paraffin blocks ten 20 µm sections did not provide a sufficient amount of normal 
DNA, for which 3000-6000 cells are needed per PCR.137 This problem mainly 
occurred in Spitz naevi, which are generally excised with narrow margins and thus 
often contain very little normal skin. It is reassuring for the consistency of the data 
that 93% of the informative AI analyses of different markers on the same 
chromosome arm resulted in identical findings. The remaining 7% are probably due 
to loss of a chromosomal region rather than a complete arm.  
 Previous studies that explored the use of AI analysis for diagnostic purposes 
have demonstrated important genetic differences between typical Spitz naevi and 
unequivocal melanomas.75 Although these findings are promising, they do not prove 
the diagnostic efficacy of this approach in problem cases. In order to test this, we 
have compared typical Spitz naevi, atypical Spitz tumours, atypical Spitz tumours 
suspicious for melanoma, and unequivocal spitzoid melanomas using AI analysis. 
We confirmed the marked differences between the unequivocal benign and 
malignant lesions, but the picture was unclear with respect to equivocal categories. 
A further impediment to the use of this technique is the low yield of DNA from the 
paraffin embedded lesions. This leads us to conclude that AI analysis as performed 
in this study is not suitable in a routine diagnostic setting. The molecular changes as 
illustrated by AI analysis and comparative genomic hybridisation (CGH) may still be 
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diagnostically valuable, provided an optimal set of markers is found and their 
analysis in routinely processed tissue would be possible in a limited number of 
sections. Based on positive results by De Wit et al, using centromere probes for 
chromosome 1 and Wettengel et al, using a probe on chromosome 9, in situ 
hybridisation may still be the best choice to obtain additional diagnostic information 
at this time.20,49 Great advantages of that technique are the preservation of the 
morphology, allowing optimal correlation with conventional histopathological 
characteristics, and the limited number of tissue sections needed. 
 The finding of occasional AI in typical Spitz naevi is in line with earlier findings in 
these and other benign lesions.138 In contrast to Healy, AI in the Spitz naevi of our 
series was not restricted to chromosome 9, but was also detected on chromosomes 
3 and 8.75 However we note that the two cases originally classified as typical Spitz 
naevi after review were considered as atypical Spitz tumours. The initial diagnosis 
may have been biased by the young age of the patients. In the two primary 
melanomas where we could not demonstrate AI, the brisk lymphocytic infiltrate 
noted during revision could explain the lack of detectable AI. Quite possibly, the 
number of melanomas without detectable AI could be further reduced by the 
investigation of more markers. As in most cases the isolated amount of DNA was 
just sufficient for the AI analyses with the current markers, a larger number of 
markers would have required more lesional and normal DNA; this effort, however, 
could also have expanded the number of AI detected in Spitz naevi. 
The frequency of AI (33%) in atypical Spitz tumours was considerable. This 
increased to 65% in atypical Spitz tumours suspicious for melanoma, and 88% in 
unequivocal primary spitzoid melanomas. For these findings different explanations 
are possible. For example, a Spitz naevus might progress, via intermediate lesions 
to fully fledged spitzoid melanoma.126,139 In keeping with this, a few genetic 
aberrations detected in Spitz naevi, such as deletion of chromosome 9 and 
amplification of chromosome 7, are also common aberrations in melanoma. Only the 
gain of 11p has been detected more frequently in Spitz naevi.18 Nonetheless, this 
latter finding, and the fact that Spitzoid precursor lesions in the neighbourhood of 
spitzoid melanoma have only rarely been described, may alternatively indicate that 
Spitz naevus and melanoma develop through different pathways.140 Secondly, the 
cases with molecular changes based on AI analysis, but with a benign morphology, 
may represent incipient melanomas that would have progressed to overt melanomas 
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if not surgically removed. Further molecular studies may show additional genetic 
differences, or may reveal a true spectrum of tumor progression between Spitz nevi 
and Spitzoid melanomas. 
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ABSTRACT 
 
Molecular analysis on formalin-fixed paraffin-embedded tissue is of increasing 
importance in diagnostic histopathology and tumor research. Multiplex ligation-
dependent probe amplification (MLPA) is a technique that can be used for detection 
of copy number alterations of up to 45 different DNA sequences in one experiment. 
It can be performed on partially degraded DNA, which makes this technique very 
suitable for analysis of formalin-fixed lesions. We tested the reliability of MLPA by 
analyzing DNA isolated from formalin-fixed melanomas that were previously 
characterized by comparative genomic hybridization (CGH), and additionally the 
application of MLPA was tested by analyzing 29 routinely processed melanocytic 
lesions. MLPA appears to be a reliable and efficient method to evaluate DNA copy 
number changes as 86% of the loci tested revealed concordant CGH results. 
Discordance mainly involved alterations that were detected by MLPA and not by 
CGH probably due to a combination of lower resolution of CGH and occasionally 
false positive MLPA results. For application of MLPA in a diagnostic setting, different 
probes on a specific region of interest should be used to prevent false positive 
MLPA results. In a research setting as well as in a diagnostic setting, MLPA is a fast 
technique to screen large numbers of formalin-fixed lesions for DNA gains and 
losses. 
 
INTRODUCTION 
 
 With the increasing knowledge on genetic alterations associated with various 
lesions, there is also an increasing need for a method that identify these alterations 
in a diagnostic setting to support the histological diagnosis. Most benign melanocytic 
lesions have a normal karyotype whereas the majority of malignant melanomas 
harbor several gains and losses. Application of this knowledge for diagnostic 
purposes has been hampered by the fact that these lesions harbor a large variety of 
genetic alterations; therefore, many loci should be investigated. Furthermore, these 
lesions are notoriously difficult to investigate with molecular techniques due to 
limited amounts of DNA of moderate quality that can be obtained from these lesions. 
Different methods for screening of routinely processed material for copy number 
changes are available, but unfortunately most of them have technical limitations. An  
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Table 6-1. Advantages and limitations of common molecular techniques used to 
detect chromosomal imbalances. 
Technique Karyotyping/ 
SKY 
CGH array-
CGH 
(F)ISH LOH (AI) MLPA 
Starting 
material 
needed 
Metaphases 
of tumor cells 
500 ng 
DNA 
1 µg 
DNA 
Isolated 
nuclei or 
tissue 
sections 
50 ng 
DNA* 
 
50 ng 
DNA 
Sensitivity 10-20 Mb 10-20 Mb 100-200 
bp** 
100-500 bp 10-100 
bp 
1-40 
bp 
Number of loci 
investigated 
per experiment
whole 
genome 
whole 
genome 
up to 
35000 
loci 
1 to 3 loci 1 to 5 
loci 
up to 45 
loci 
No prior 
knowledge 
needed 
+ + + - - +/- 
Applicable on 
formalin fixed 
tissue 
- + + + + + 
Routine 
diagnostic 
setting 
+/- +/- +/- + +/- + 
Fast - - - + +/- +/- 
Discrimination 
between gains 
and losses 
+ + + + - + 
 
SKY: spectral karyotyping, CGH: comparative genomic hybridization, (F)ISH: (fluorescent) in 
situ hybridization, LOH: loss of heterozygosity, AI: allelic imbalance, MLPA: multiplex ligation 
dependent probe amplification. * Also normal DNA needed obtained from the patient. **The 
resolution of array experiments depends on the genomic size and spacing of the targets. The 
average resolution of array CGH using a 3.5K set of BACs and PACs evenly spaced 
troughout the genome is approximately 0.8 Mb whereas this is about 50 bp for a 32K set.  
 
 
overview of these methods and their characteristics is given in Table 6-1. 
Multiplex ligation-dependent probe amplification (MLPA) fills the gap between 
techniques that provide information on many loci but are time consuming and 
require relative large amounts of DNA and techniques that are fast and need small 
amounts of DNA but only provide information on specific loci.56 The principles of 
MLPA are shown in Figure 6-1. Briefly, MLPA is based on the annealing of up to 45 
probes that each consists of two oligonucleotides that hybridize adjacently on a 
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Figure 6-1. Overview of multiple ligation-depended probe amplification. A: With MLPA up to 
45 target specific probes are used in one reaction. Each probe consists of two different 
oligonucleotides, both containing a target specific sequence (**) and a universal PCR-primer 
sequence (*), and additionally one oligonucleotide also contains a so-called stuffer sequence 
(***). Target-specific sequences (**) are complementary to sequences of genes of interest. 
Stuffer sequences (***) are nonhybridizing oligonucleotides of the probe with varying length 
and sequence. PCR-primers sequences (*) are identical for all probes. The two 
oligonucleotides of each probe are hybridized adjacent on denatured whole genomic DNA. B: 
In a ligation reaction, the two adjacent hybridized oligonucleotides of each probe are joined. 
C: To be able to detect the amount of ligated probes, PCR amplification is performed with a 
fluorescent-labeled universal primer. Only ligated probes contain both PCR primer sequences 
and will thus be amplified exponentially in the PCR amplification reaction, and as all probes 
contain the same PCR primer pair they will be amplified with the same efficacy. D: As each 
probe had a unique length (due to variation in stuffer sequence length) capillary 
electrophoresis can be used to identify and quantify the amplification products (represented 
by peak height and peak area) that reflect the relative copy number of target sequences in the 
analyzed DNA sample. A fragment of a peak pattern is shown. For tumor and normal DNA 
samples, relative peak values are calculated by dividing peak value (height or area) by peak 
values of all 40 to 45 probes of the tumor sample. To calculate the probe ratio for each tumor, 
the relative peak value is divided by the mean of the normal relative peak values. For 
chromosomes X and Y, only the mean values of the sex-matched normal samples are used. 
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specific chromosome region. Besides a target specific sequence, both 
oligonucleotides also contain a universal PCR primer whereas one oligonucleotide 
also contains a stuffer sequence of a unique length for each probe. After ligation of 
the hybridized adjacent oligonucleotides, the probe is amplified using the universal 
PCR primers. As each probe has unique length due to the stuffer sequence, 
electrophoresis is used to separate and quantify the amount of PCR product that is 
indicative for the DNA copy number. 
 Besides detection of relative DNA copy numbers in tumors as well as in germ 
line abnormalities, MLPA can also be used for mutation analysis or to detect mRNA 
expression level changes.149-156 So far, published MLPA results were obtained with 
DNA isolated from fresh or frozen samples, but, in a routine diagnostic setting, most 
samples are formalin fixed, which compromised DNA quality and quantity. Since 
MLPA seems to have several advantages over already established methods, we 
examined the possibilities and limitations of MLPA analysis for the detection of DNA 
copy number changes in DNA isolated from formalin-fixed paraffin-embedded tissue. 
We performed MLPA analysis on formalin-fixed melanomas that were genetically 
characterized by CGH and evaluated the influence of DNA degradation and the 
amount of DNA used for analysis on the reliability of MLPA. Furthermore, nevi, 
primary melanomas, and melanoma metastases were examined to confirm the 
usefulness of MLPA in a routine diagnostic setting.  
 
MATERIAL AND METHODS 
 
Case selection and DNA isolation  
 Two common nevi, two blue nevi, one Spitz nevus, nine congenital nevi, three 
primary cutaneous melanomas, five mucosal melanomas, and five melanoma 
metastases were randomly selected from the Department of Pathology, Radboud 
University Medical Center Nijmegen, The Netherlands. Normal tissue was obtained 
from six male and six female patients of whom the spleen was removed after 
traumatic injury without medical history of malignancy. All samples were formalin-
fixed paraffin-embedded tissues. Five to ten, 10 µm thick tissue sections were 
mounted on glass slides. In melanomas and nevi areas with more than 80% tumor 
cells were selected based on parallel 4 µm thick H&E stained sections. For thin 
lesions or tumors with marked infiltration of nonneoplastic cells, laser 
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microdissection was used as described previously.146 The selected areas were 
deparaffinized and collected in microfuge tubes after which they were incubated in 
125 µl P-buffer (50 mM Tris-HCl pH 8.2, 100 mM NaCl, 1 mM EDTA, 0.5% Tween-
20, 0.5% NP40, 20 mM DTT) for 15 minutes at 90°C. Protein digestion was 
performed by adding proteinase K (Roche Diagnostics GBMH, Mannheim, 
Germany) (final concentration of 0.5 mg/ml) and incubation at 55°C for 24 hrs 
followed by incubation at 37°C for 48 hrs with addition of 5 µl fresh Proteinase K (20 
mg/ml) every 24 hrs. Subsequently, genomic DNA was isolated using DNeasy 
Tissue kit (Qiagen GBMH, Hilden, Germany). DNA was eluted with 50 to 100 µl TE 
buffer (10 mM Tris pH 8.5, 1mM EDTA pH 8.0) and the DNA concentration was 
measured on a UV spectrophotometer (GeneQuant, Amersham Pharmacia Biotech 
Europe GBMH, Freiburg, Germany). For samples used for CGH and for the DNA 
degradation experiment, the DNA fragment length was determined by gel 
electrophoresis.  
 
MLPA procedure 
 The SALSA human chromosomal aberration kit 1 (P005) was used (MRC 
Holland, Amsterdam, The Netherlands) containing 41 probe pairs coding for unique 
human single copy DNA sequences that were designed and prepared as described 
by Schouten et al (description can be found at http://www.mlpa.com).56 For each 
MLPA reaction, 50-100 ng DNA was dissolved in 5 µl TE-buffer (10 mM Tris pH 8.2, 
1 mM EDTA pH 8.0). DNA was denatured for 5 min at 98°C and subsequently 
cooled down to 25°C. After addition of 1.5 µl probe mix and 1.5 µl buffer (1.5 KCl, 
300 mM Tris-HCl pH 8.5, 1 mM EDTA) the sample was denaturized (1 min at 95°C) 
and the probes were allowed to hybridize for 16 hrs at 60°C. Ligation was performed 
for 15 minutes at 54°C after addition of 32 µl Ligase-65 mix (2.6 mM MgCl2, 5 mM 
Tris-HCl pH 8.5, 0.013% non-ionic detergents, 0.2 mM NAD) containing one U 
Ligase-65 enzyme. The ligase was heat inactivated at 98°C for 5 min. PCR was 
performed in a volume of 50 µl containing 10 µl of the ligation reaction mixture, 2 µl 
SALSA PCR-primers and 2 µl SALSA enzyme dilution buffer. PCR was performed in 
a PTC 200 thermal cycler (MJ Research, Inc, Waltham, MA), by 33 cycles of 
denaturation at 95°C for 20 sec, annealing at 60°C for 30 sec and extension at 72°C 
for 1 min with a final extension of 20 min at 72°C. Aliquots of 2 µl of the PCR 
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reaction were combined with 0.5 µl ROX-labeled internal size standard (ROX-500 
Genescan, ABI 401734) and 7.5 µl deionised formamid. Samples were denatured 
and separated by electrophoresis on an ABI 3700 capillary sequencer (Applied 
Biosystems) and analyzed using the Genescan software (version 3.6) (Applied 
Biosystems). Peak identification by the Genescan software was checked visually. 
Values corresponding to peak size in bp, peak heights, and peak areas were 
imported into SPSS 10.0 for further data processing as described below. All 
experiments were performed in duplicate. Normal male and female DNA obtained 
from identically treated tissues and a negative control (without DNA) were included 
in each experiment. 
 
Data processing 
 To calculate the probe ratio, peak values are commonly imported in Excel files. 
Calculation of MLPA data in Microsoft Excel is relatively time consuming (10 min for 
96 samples according to the MRC-holland website (http://www.mlpa.com)) and 
prone to data handling errors especially when large data sets are used. Therefore, 
values corresponding to peak sizes in bp, peak heights, and peak areas were 
imported into SPSS 10.0, and a syntax was composed for normalization of the probe 
ratios. The probe ratio is calculated by dividing the value of peak area of each probe 
amplification product by the combined value of the peak areas of all 41 probes. This 
resulting 'relative peak area' was then divided by the 'mean relative peak area' of the 
probe within all normal tissue samples (exemplified in Figure 6-1). The result of 
these calculations is the 'normalized peak area'. Similar calculations were performed 
for ‘peak heights’ and compared with the results of the ‘peak area’ calculations. 
Probes located on chromosomes X and Y are calculated by normalization with only 
sex-matched normal samples. If graphical visualization was preferred the results 
were saved as Excel file after calculation in SPSS and imported in Excel for 
graphical visualization. According to the manufacturers instructions, probe ratio 
below 0.8 or above 1.2 were considered to represent DNA losses and gains, 
respectively. In each SALSA probe mix, one control probe and four control 
fragments are included. The four control fragments will generate amplification 
products of 64, 70, 76, and 82 bp if less than 20 ng DNA is used for MLPA. The 
control probe will generate an amplification product of 94 bp only when ligation 
occurs. In a good experiment with sufficient DNA these control peaks should be 
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below 20% of the mean peak ratio, whereas the ligation control peak should be at 
least 80% of the mean peak ratio. 
 
CGH 
 CGH was performed on one primary melanoma, five mucosal melanomas, and 
one melanoma metastases as described by Jeuken et al.110 Briefly, 350-400 ng 
labeled tumor DNA, 350-400 ng labeled reference DNA, a 100-fold excess of Cot-1 
DNA, and a 50-fold excess of herring sperm DNA were pooled and ethanol 
precipitated and dissolved in hybridization buffer (62.5% formamide, 10% dextran 
sulphate, 2xSSC-tween, pH 7.0). This mixture was applied on normal metaphase 
chromosome spreads, denatured for 3 min at 74°C, and hybridized at 37°C for three 
days on an OmniSlide thermal cycler (Thermo Hybaid, Thermo Life Sciences, 
Breda, The Netherlands). After hybridization, the slides were washed twice in 0.4 
SSC-tween at 68°C for 1 min in a wash module (Thermo Hybaid). Detection, image 
acquisition, and analysis were performed as described elsewhere.110 Detection 
thresholds for loss and gains of chromosome regions were set at 0.85 and 1.15 for 
paraffin-embedded tissue. Centromere regions and the Y chromosome were not 
included in the evaluation. All CGH experiments were performed in duplicate; both 
single values of the duplicate experiments were used for comparison with MLPA 
results.  
 
RESULTS  
 
 Analyzing a dilution series of tumor and normal samples containing 20, 50, 100, 
or 150 ng DNA the minimal amount of DNA needed for MLPA was determined. 
Using 20 ng DNA, copy number changes could still be detected but DNA quantity 
control peak values higher than 20% of the mean peak value occurred and the 
number of false positive results increased (Figure 6-2). We obtained reproducible 
MLPA results using at least 50 ng DNA. In all experiments the ligation peak was 
present; only occasionally the relative peak value was below 80% (Figure 6-2). In all 
other experiments, 50-100 ng DNA was used and experiments with DNA control 
peak values above 20% of the mean peak height or DNA ligation control peak value 
below 80% of the mean peak height were repeated. 
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Figure 6-2. Electrophoresis peak patterns. A: Representative example of a good MLPA peak 
profile showing gene-specific probe peaks (from BCL2 till NRAS) preceded by five control 
peaks (indicated by arrows). The input DNA quantity control peaks (control 1 – control 4) are 
sufficiently low, i.e. maximally 20% of the mean peak values (indicated by arrows). B: 
Example of a MLPA peak pattern with an insufficient amount of DNA in the ligation reaction. 
The four DNA input control peaks are significantly higher than 20% of the mean peak values 
(indicated by arrows). C: Example of a MLPA peak pattern from a reaction with a low 
efficiency. The ligation peak is significantly lower than 80% of the mean peak values 
(indicated by arrows). 
 
 
 Besides the effect of the amount of input DNA, we also studied the effect of DNA 
degradation on the reliability of MLPA profiles. For this purpose, we boiled DNA for 
15, 30, and 60 minutes, resulting in various degrees of degradation of a DNA 
sample. DNA degradation was confirmed by gel electrophoresis and maximum DNA 
fragment lengths varying from 10 kb to less than 500 bp were obtained. No 
detrimental effect of DNA degradation on MLPA efficiency was found, and all 
experiments resulted in similar MLPA results without increase of false positive or 
false negative results.  
 The specificity of the MLPA was examined by calculating the ratio for each 
MLPA probe for the normal DNA samples. In experiments with normal DNA, an 
average of three out of 41 probes (7.3%) showed false positive results. A graphical 
representation of a moderate experiment containing 12 normal DNA control samples 
is shown in Figure 6-3A. Most false positive results had probe ratio between 0.6 and 
1.4. Both peak height and peak area were used to calculate probe ratios, we did not 
detect significant differences in the outcome of normalized areas or heights. When 
MLPA ratios were calculated for test samples using normal samples from other 
MLPA experiments instead of reference samples included in the same experiment, 
the number of false positives raised to 20% (8/41). Therefore, normal DNA samples 
were included in each experiment to decrease the number of false positives as also  
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Figure 6-3. Graphical representation of MLPA results. ‘Peak height’ and ‘peak area’ MLPA 
results are shown for each probe in this order, black bars: standard deviation, black dots: 
mean probe ratio. A: MLPA analysis of 12 control samples. Small stripes: probe ratios for 
each individual DNA sample. B: Lesion 6, a Spitz nevus, showing a distinct gain of 11p. C: 
Lesion 26, a melanoma metastasis, harboring many alterations. 
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Tabel 6-2. Comparison of MLPA and CGH results. 
Lesion  19 20 21 22 23 24 29 
Probe  Locations M C M C M C M C M C M C M C 
F3 1p22-21     -     + + 
BCAR3 1p13.2 +    -  -  -  + + 
NRAS 1p13.2    + +  -  -  - * 
IL10 1q31-32 *  + + + + + + + + + +   
IL1A 2q14       - - - - 
TANK 2q24-q31   + +    - -   
PIK3C 3q26.3 - -    - -     
IL13 5q31     +   + + * + 
IL4 5q31.1     +  + + + + + + 
CDKN1 6p21.2 + +  + + + + + + + +   
MYB 6q22    - - - - - - -   
ABCB1 7q21    +    +   
FGFR1 8p11.1-2   -  +   -   + - - 
MYC 8q24.12 +    + + + + + + + + 
PTP4A 8q24.3 +   + * + + + + + +   
RECQL 8q24.3 * *  * + + + + + + + * 
CDKN2 9p21 - -  - - -      
RENT2 10p14-3  *   - - - - - - - - 
CREM 10p12.1-1.1 - -  - - - -  - -   
HRAS 11p15.5 + *   - - - -     
LMO2 11p13   *  *   - -   - - 
EMS1 11q13 +        +  
RELA 11q13 +  +       +  
TNFRS 12p13 + +   - *    - - 
LRMP 12         - * 
BRCA2 13q12.3 - - - -    - - - - 
RB1 13q14 - - -  +     - - 
ABCC4 13q32 - - - -    - -   
CDH1 16q22.1     - - - - - -   
CRK 17p13.3    +   - -  *   
ERBB2 17q21.1      +  - -   
BRCA1 17q21 +          
TIMP2 17q25 + *  + * + *  + +   
CDH2 18q12.1 - -      + - - 
BCL2 18q21.3 - -  - * - - *  + +   
BAX 19q13.3-q13.4 +   + * - -      
STK15 20q13    + +     -  
STCH 21q11   *         
MIF 22q11.23 +      +  +  
PDCD8 Xq25-q26    *  -  -  - -   
UTY Yq11 + * * * - * - *  *  * 
 
M: multiplex ligation dependent probe amplification (MLPA), C: comparative genomic 
hybridization (CGH), +:gain, - : loss, *: not determined, light gray: alterations detected with 
MLPA but not with CGH, dark gray: alterations detected with CGH but not with MLPA. 
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Tabel 6-3. MLPA results of melanocytic lesions. 
  
Common 
nevus 
Blue 
nevus SN 
Congenital 
nevus 
Cutaneous
melanoma
Mucosal 
melanoma 
Melanoma 
metastases 
 Lesion 1 2 3 4 5 6 7 8 9 10 11 12 13 14 1516 17 18 19 2021 22 2324 25 26 27 28 29 
Probe Location             
F3 1p22-21       *    -  - - - * + 
BCAR3 1p13.2         + - - - - - - - + 
NRAS 1p13.2       + + * + +  -  + - - + + - - - 
IL10 1q31-32       -  + * + + + + + - -  +  
IL1A 2q14       +   - - -   - 
TANK 2q24-q31       + -  + -      
PIK3C 3q26.3       - + + * * - - -  +  -   
IL13 5q31       - - - +  + +  -  - * 
IL4 5q31.1       *  -  + + + -  *  + 
CDKN1 6p21.2     +  * + * - + + + + + + - - +   
MYB 6q22       +   - - - - - -   
ABCB1 7q21       * +     -    
FGFR1 8       *    - + -  - - - - - 
MYC 8q24.12        + + + + + + + +  + 
PTP4A 8q24.3   -    - * - + + + + + +      
RECQL 8q24.3       - - -  * + + + -    + 
CDKN2 9p21     *   + - -       
RENT2 10p14-13       * * + *  - - -   - - - 
CREM 11.1         - - - - -  - +  
HRAS 11p15.5      + + * * - + + - -  + - +   
LMO2 11      + +    * * -   +   - 
EMS1 11q13       - -  +  -    + 
RELA 11q13       -  + +  - - + + + 
TNFRS 12p13       + * * + -  + + -  + + + + - 
LRMP 12       * + -    - -  - 
BRCA2 13q12.3       * * + + - - - + +   - 
RB1 13q14       - - - * + - - +  - - -  - 
ABCC4 13q32       -   - - - * - - *  
CDH1 16q22.1       * *    - - - + + - -  
CRK 17p13.3   *    *  -  + -  + +    
ERBB2 17q21.1       -   + - - -    
BRCA1 17q21       *  - +  + +    
TIMP2 17q25       + * +  + + + + + + + +   
CDH2 18q12.1       * + + - -  + + -  - 
BCL2 18q21.3       - *  - - - * + - - + +  
BAX 19q13.3     +  + - + + + -  * - + +  
STK15 20q13   *    - + *  +  +  -   - - 
STCH 21q11      - + + + -  *  - -    
MIF 22q11.23       - - - -  + + + + + + + 
PDCD8 Xq25-q26 + + +   + * * * + + * + -  -  * - - +  -   
UTY Yq11       * * * *   *  *    +   - -  +   +  
 
SN: Spitz nevus, +:gain, -: loss, *: not determined 
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was advised by the manufacturer. To establish the sensitivity of MLPA for the 
analysis of routinely processed formalin-fixed tissue, melanomas, which had 
previously been genetically characterized by CGH, were analyzed. CGH and MLPA 
results of seven tumors were compared (Table 6-2). Of the 287 data points, 29 data 
points could not be analyzed; seven showed inconsistent MLPA duplicates, 21 could 
not be analyzed with CGH (mainly centromer or telomer regions), and one probe 
could not be analyzed by CGH nor by MLPA. Of the remaining 258 data points, in 
85.7% (221/258) of the cases, MLPA results confirmed the chromosomal status as 
previously detected by CGH, and in 2.7% of the cases (7/258), a gain or loss was 
seen with MLPA while deviation of the CGH profile not exceeding the threshold of 
0.85 or 1.15 was seen, suggesting that these aberrations might not be false-positive 
MLPA results. In an additional 8.9% (23/258) of the cases, MLPA detected a gain or 
loss, whereas CGH did not detect an aberration in these regions and in 2.7% (7/258) 
alterations were only detected with CGH and not with MLPA. 
 To test the applicability of MLPA in a diagnostic setting with routinely processed 
tissue, we analysed 29 melanocytic lesions with MLPA (Table 6-3). A graphical 
representation of a Spitz nevus and a melanoma metastasis are shown in Figure 6-
3. 
 
DISCUSSION 
 
 In this study we evaluated the use of MLPA for analysis of DNA copy number 
alterations using formalin-fixed paraffin-embedded tissue. Before actual analysis of 
chromosomal aberrations in routinely processed lesions, we determined the minimal 
amount of DNA needed for reliable MLPA results, the effect of DNA fragmentation 
on MLPA, and the sensitivity and specificity of MLPA. For all experiments the P005 
human chromosomal test kit was used. According to the manufacturer's protocol, 20 
ng DNA is sufficient for MLPA analysis. However, at this amount of input DNA we 
noticed an increase of false-positive gains and losses and as well as an increase of 
the DNA quantity control peaks, indicating that this amount of DNA was insufficient. 
The appearance of high DNA control peaks correlated with an increase of false-
positive results. As our results are in concordance with previous publications using 
DNA isolated from fresh material, the increased minimal amount of DNA might not 
be due to the decreased quality of DNA isolated from formalin-fixed tissue.157 
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Reliable results were obtained with 50 to 100 ng DNA. In contrast to DNA quantity, 
DNA quality is not critical because MLPA only needs small DNA fragments. 
 We have shown that MLPA is a sensitive technique; 97.3% of the alterations 
detected with CGH were also detected with MLPA (Table 6-2). This slight 
discrepancy can either be caused by false-positive CGH results or by false negative 
MLPA results. Others have shown that MLPA is a sensitive technique as there are 
only sporadic false negative results by comparing FISH with MLPA results.149 
Alterations detected with MLPA and not with CGH were detected in 11.6% of the 
probes and can have several causes. Firstly, CGH has a lower resolution (10-20 
Mb); therefore, gains and losses of small chromosomal parts cannot be detected by 
conventional CGH, while they can be detected by MLPA which has a much higher 
resolution (40-bp).158 Also in 2.7% of the cases, gains or losses were seen with 
MLPA while an obvious deviation of the CGH profile not exceeding the threshold of 
0.85 or 1.15 was seen, indicating that MLPA might be more sensitive compared to 
CGH. Secondly, the mean probe value of all probes is considered to represent a 
balanced karyotype. As in some tumors, more than half of the probes show gains or 
losses and several probes even show high-copy gains; the average probe ratio 
might not represent a balanced karyotype. Consequently, other probes might 
mistakenly be interpreted as losses. Finally, it might be caused by false-positive 
MLPA results as also normal samples show gains or losses in 7.3% of the probes 
analyzed. Our results of occasionally false positive gains and losses are in line with 
previously published results of MLPA on DNA obtained from fresh tissue of normal 
samples revealing a standard deviation of 0.13-0.3 dependent on the probe.149,152 In 
some experiments increase of the standard deviation of the longer PCR products 
was seen caused by gradual decrease of peak heights due to PCR and/or capillary 
gel electrophoreses as also can be noticed in Figure 6-2A. However, this gradual 
decrease in peak height could not be due to differences in PCR efficiency, as it did 
not lead to an increase of false-positive gains or false-positive losses for the smaller 
fragments and the larger fragments respectively. 
 To test the applicability of MLPA in a diagnostic setting we examined 
melanocytic lesions, as some of these lesions are difficult to classify by 
histopathology. It is, however, known that benign and malignant lesions differ in 
genomic alterations. Molecular genetic analysis could contribute to the diagnosis but 
introduction of a molecular test is hampered by the small amount of degraded DNA 
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that can be analyzed from these small formalin-fixed lesions. We were able to obtain 
MLPA data from all 29 lesions tested (Table 6-3). In lesions 7, 11, and 15 five or 
more probes were classified as undetermined due to irreproducible duplicates. 
There might be a higher chance for false-positive gains and losses as lesions 11 
and 15 harbored more alterations than we expected based on their histopathological 
classification and previously published literature on genetic aberrations in 
melanocytic lesions.77 Still, there is a clear difference in the number of alterations in 
benign and malignant melanocytic lesions as was expected. Interestingly, in the 
analyzed Spitz nevus (lesion 6), a gain on 11p was detected, which is an alteration 
that is common for this type of lesion (Figure 6-3).159 For specific applications, we 
advice to combine kits with several different probes for each chromosomal region of 
interest as also is used in for example the trisomy kit to minimize the number of false 
positive results.149 
 In summary, we have extensively tested the MLPA technique and found that it is 
relatively easy to perform for the assessment of multiple chromosomal aberrations in 
formalin-fixed paraffin-embedded tissue requiring 50 to 100 ng of DNA per 
experiment. The sensitivity of the MLPA is good. With regard to specificity, false-
positive results may occur occasionally but can be prevented by choosing more than 
one probe per chromosomal location and/or using stricter thresholds for gains and 
losses, which, however, could lead to a decrease of the sensitivity. The fact that 
MLPA is as fast as a conventional PCR-based technique and has no detrimental 
effects of DNA degradation makes it a useful method for the analysis of DNA 
obtained from archival formalin-fixed paraffin-embedded tissue in both research as 
well as diagnostic setting. 
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ABSTRACT 
 
 A definite diagnosis cannot be established on histologic features alone in a 
considerable number of Spitz nevi and spitzoid melanomas. In a vast majority of 
common benign and malignant melanocytic lesions, BRAF and NRAS mutations 
have been described, but these were not detected in Spitz nevi. In contrast, HRAS 
mutations were frequently detected in Spitz nevi, but only rarely in melanomas. To 
date, BRAF mutation analysis has not been reported in atypical Spitz nevi, and there 
are only a few reports of it in spitzoid melanomas. We analysed 96 formalin-fixed, 
paraffin-embedded spitzoid melanocytic lesions for hotspot mutations in BRAF, 
NRAS, and HRAS genes to test the assumption wheter mutation analysis would 
assist a more accurate diagnosis of spitzoid melanocytic lesions, which are 
notoriously difficult to classify. BRAF or NRAS mutations were observed in 31 of 36 
(86%) spitzoid melanomas, and in 6 of 7 (86%) spitzoid melanoma metastases. In 
contrast, none of the 14 Spitz nevi and none of the 16 atypical Spitz nevi had 
mutations in any of these genes. A BRAF or NRAS mutation was found in 8 of 23 
(35%) spitzoid lesions suspected for melanoma. HRAS mutations were detected in 4 
of 14 (29%) Spitz nevi, in 3 of 22 (14%) atypical Spitz nevi, in 1 of 15 (7%) spitzoid 
tumors suspected for melanoma, but in none of the spitzoid melanomas. These 
results strongly indicate that Spitz nevi and spitzoid melanomas are genetically 
unrelated entities. Furthermore, we can conclude that mutation analysis may be 
useful as an additional diagnostic tool to discriminate between benign and malignant 
spitzoid lesions. 
 
INTRODUCTION 
 
 Spindle and epithelioid cell melanocytic lesions are amongst the most 
problematic cases in diagnostic dermatopathology. These lesions are frequently 
submitted for consultations to expert dermatopathologists and are at the top of 
malpractice claims for misdiagnosed lesions in surgical pathology.4,141 Sophie Spitz 
originally described a series of spindle and epithelioid cell melanocytic lesions in 
children and, although they were classified as juvenile melanoma, it was already 
noted that these lesions were frequently benign.142 These lesions are now 
diagnosed as Spitz nevi. In a large number of the spitzoid lesions, a specific 
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diagnosis is difficult to establish based on histological features alone. These lesions 
are often referred to as ‘atypical Spitz nevus’ or ‘spitzoid tumor of uncertain 
malignant potential’.143 Therefore, there is an obvious need to reach an additional 
diagnostic tool for an accurate diagnosis of spitzoid melanocytic lesions. Little is 
known at the molecular level of the development and clinical behavior of spitzoid 
lesions. It is even unclear whether Spitz nevi and spitzoid melanomas are related 
entities with a continuum between both lesions from benign Spitz nevus progressing 
via atypical Spitz nevus to malignant spitzoid melanoma.126 
 Studies using molecular biological techniques such as allelic imbalance analysis 
and comparative genomic hybridization have provided some clues on the genetic 
basis for the development of melanocytic tumors. However, these techniques have 
failed to gain acceptance in routine practice because of technical difficulties and 
insufficient discriminatory power. Mutation analysis seems to be by far the best 
option for use as diagnostic tool when marker genes are known because it can be 
easily achieved using routine formalin-fixed, paraffin-embedded lesional tissue. Until 
recently, NRAS mutations were the most frequently detected mutations in 
melanoma. However, these were present in only 30% of the lesions, thereby limiting 
the discriminatory power.87 Since 2002, BRAF mutations have been detected in 
approximately 50% of melanomas with a large variation (rang, 31-75%) between the 
reported studies.58,61,144 Mutations in the BRAF gene were also detected in the 
majority of common benign melanocytic lesions but were not detected in typical 
Spitz nevi in several studies.59-62,81 Instead, mutations in HRAS gene were observed 
in 9 of 33 (27%) Spitz nevi examined.38 Mutations in BRAF and HRAS genes may, 
therefore, contribute to an accurate diagnosis of Spitz nevi and spitzoid melanoma. 
However, important information on the mutation frequency of these genes in Spitz 
nevi with features that can pose diagnostic problems is still lacking. Furthermore, 
lesions that are marked by lack of maturation, nuclear atypia, or mitoses in deeper 
dermal component, further referred to as atypical Spitz nevi and lesions suspected 
for spitzoid melanoma, should also be investigated to determine the correlationship 
between histological features and mutation frequency. Therefore, we investigated a 
series of 96 Spitzoid lesions comprising 14 Spitz nevi, 16 atypical Spitz nevi, 23 
spitzoid lesions suspected for melanoma, and 43 spitzoid melanomas for hotspot 
mutations in BRAF exon 11 and 15, NRAS exon 2 and 3, HRAS exon 2 and 3. 
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MATERIAL AND METHODS 
 
Cases 
 Paraffin blocks of 101 paraffin blocks of Spitzoid lesions that were sent for 
consultation to an expert dermatopathologist were obtained from various hospitals in 
The Netherlands. Some of the latter lesions were received with incomplete clinical 
information of the patients or with unknown follow-up for reasons of privacy. All 
lesions were removed from Caucasian patients. An expert pathologist (DJR) who 
was unaware of the results of the genetic analysis conducted two separate histologic 
evaluations at a 2 months interval. Besides the diagnosis, tumor thickness and cell 
type (ie, spindle, epithelioid, or mixed cell population with or without a non spitzoid 
component) were determined. A melanocytic lesion was classified as spitzoid when 
it was largely composed of spindle cells, epitheloid cells or a mixture of both. A 
lesions was diagnosed as Spitz nevus when it consisted of these cell types and had 
no features of spitzoid melanoma according to the established criteria.2,145 In 
accordance with these criteria, lesions were classified as atypical Spitz nevus if only 
one of the following criteria was present: diameter larger than 1 cm, prominent 
nuclear atypia, ascending melanocytes in the epidermis, ill defined lateral borders, 
lack of maturation or mitoses in deep parts of the dermal component. Lesions 
meeting two criteria were classified as suspect for spitzoid melanoma. Lesions with 
more characteristics for melanoma were classified as spitzoid melanoma. The 
relevant clinical and histological characteristics of the cases are presented in Table 
5-1.  
 
DNA isolation 
 Paraffin-embedded specimens were cut into 5- to 10-µm thick tissue sections 
and mounted on glass slides. Areas with more than 80% tumor cells were selected 
based on parallel 4-µm thick hematoxylin and eosin-stained sections in nevi and 
melanomas. Laser microdissection as described previously was used for thin lesions 
or tumors with marked infiltration of nonneoplastic cells.146 Two or three tumor areas 
with with morphologically different cell types were isolated separately by laser 
microdissection from six lesions. The selected areas were deparaffinized and 
collected in microfuge tubes after which they were incubated in 125 µl P-buffer (50  
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Table 5-1. Clinical and histological data 
 Spitz 
nevus 
(n=14) 
Atypical 
Spitz 
nevus 
(n=16) 
Suspect 
spitzoid 
melanoma 
(n=23) 
Primary 
spitzoid 
melanoma 
(n=36) 
Spitzoid 
melanoma 
metastasis 
(n=7) 
Predominant cell 
type 
     
   Spindle 10 8 17 7 4 
   Epitheloid 2 1 3 11 1 
   Mixed  2 7 3 18 2 
      Presence of 
other cell type 
 
0/2 1/7 2/3 16/18 0/2 
Average 
thickness (mm) 
(range) 
 
1.6 
(0.3-5.5) 
2.5 
(0.55-
8.75) 
2.4 
(0.3-7.2) 
3.6 
(1.1-7) 
- 
Average age 
(years) 
(range) 
 
27.8 
(10-43) 
19 
(1-49) 
35 
(13-59) 
52 
(10-88) 
40 
(26-66) 
Gender      
   Male 1 8 4 13 2 
   Female 9 8 7 11 2 
   Unknown 
 
4 0 6 12 3 
Tumor site      
   Head and neck 1 2 2 3  
   Arm 0 4 0 6  
   Trunk 2 3 1 8  
   Leg 5 7 5 9  
   Unknown 
 
6 0 9 10  
Follow-up      
   Recurrence 0 0 0 0  
   Metastasis 0 0 2 8  
   No further 
events 
11 13 7 4  
   Unknown 3 3 14   
   Period (range) 7.8 
(6-16) 
6 
(2-9) 
7.6 
(4-10) 
8.2 
(4-12) 
 
 
mM Tris-HCl pH 8.2, 100 mM NaCl, 1 mM EDTA, 0.5% Tween-20, 0.5% NP40, 20 
mM DTT) for 15 minutes at 90°C. Protein digestion was performed by adding 
proteinase K (Roche Diagnostics GBMH, Mannheim, Germany) (final concentration 
of 0.5 mg/ml) and incubation at 55°C for 24 hrs followed followed by incubation at 
37°C for 48 hrs with addition of 5 µl fresh Proteinase K (20 mg/ml) every 24 hrs. 
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Subsequently, DNA was purified using the DNA Clean & Concentration kit (Zymo 
Research, Orange, CA). DNA was eluted with TE buffer (10 mM Tris pH 8.2; 1mM 
EDTA pH 8.0). The DNA concentration was measured on a UV spectrophotometer 
(GeneQuant, Amersham Pharmacia Biotech Europe GmbH, Freiburg, Germany).  
 
PCR and sequence analysis 
 Primer sequences are shown in Table 5-2. Hotspot mutations in NRAS and 
HRAS genes are often reported on exons 1 and 2 in earlier studies. These are the 
first two exons of these genes that are translated, but there is one exon before the 
first translated exon that is transcribed into RNA but not translated into a protein (5’ 
untranslated region). Therefore, the hotspot mutations are located on exon 2 and 3 
and not on exons 1 and 2 as often reported. PCR amplification of specific BRAF 
exon 15 and 11, NRAS exon 2 and 3, and HRAS exon 2 and 3 sequences was 
performed in a total volume of 20 µL PCR mix containing at least 40 ng template 
DNA, buffer IV (Integro, Dieren, The Netherlands), 200 µm of each deoxynucleotide 
triphospate, 3 mM MgCl2, 0.5 pmol of each primer, 30 µg bovine serum albumin 
(BSA, Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands), and 0.25 units of 
thermostable DNA polymerase (Integro). An initial denaturation at 94°C for 5 min 
was followed by 30 cycles of denaturation at 94°C for 45 sec, annealing at 60°C for 
45 sec, and extension at 72°C for 45 sec with a final extension of 5 min at 72°C. 
DNA amplification was performed in a PTC 200 thermal cycler (MJ Research, Inc. 
Waltham, MA). PCR products were purified using the PCR Product Pre-Sequencing 
kit (USB Corporation, Cleveland, OH). One to two microliters of the PCR product 
was used for the sequence reaction, using the Big Dye terminator kit and ABI 
PRISM 3700 DNA analyser (Applied Biosystems, Foster City, CA). Sequencing on 
both strands was performed. 
 
Statistics 
 The two-tailed Fisher exact test was used to examine the correlation between 
histopathological diagnosis and combined mutation frequency of BRAF, NRAS, and 
HRAS genes. A P value of lower than 0.01 was considered significant. Correlation 
between mutation frequency and metastasis, site, age, and presence of  
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Table 5-2. Primer sequences 
Primer Length Accession 
number* 
Primer sequence Ref 
BRAF 
exon 15 
224 bp NC00007 
[gi:51511723] 
Forward: GGCCAAAAATTTAATCAGTGGA 
Reverse: TCATAATGCTTGCTCTGATAGGA 
58 
BRAF 
exon 11 
323 bp NC00007 
[gi:51511723] 
Forward: CGAACAGTGAATATTTCCTTTGAT 
Reverse: TCCCTCTCAGGCATAAGGTAA 
58 
NRAS 
exon 2 
301 bp NC00001 
[gi:51511461] 
Forward: GAACCAAATGGAAGGTCACA 
Reverse: TGGGTAAAGATGATCCGACA 
58 
NRAS 
exon 3  
272 bp NC00001 
[gi:51511461] 
Forward: GGTGAAACCTGTTTGTTGGA 
Reverse: AACCTAAAACCAACTCTTCCCA 
58 
HRAS 
exon 2 
169 bp NC00011 
[gi:51511727] 
Forward: AGGAGACCCTGTAGGAGGA 
Reverse: CGCTAGGCTCACCTCTATAGTG 
38 
HRAS 
exon 3 
160 bp NC00011 
[gi:51511727] 
Forward: CTGCAGGATTCCTACCGGA  
Reverse: ACTTGGTGTTGTTGATGGCA 
38 
 
* NCBI gene bank nucleotide sequence accession number.  
 
 
allelic imbalances as performed earlier on 36 lesions were analyzed by the Fisher 
exact test.19  
 
RESULTS 
 
Histopathological evaluation 
 Fourteen lesions were classified as unequivocal Spitz nevus and 36 were 
diagnosed as unequivocal spitzoid melanoma. In addition, lesions of 7 spitzoid 
melanoma metastases were studied. Sixteen lesions were classified as atypical 
Spitz nevus due to prominent nuclear atypia (5 of 16), several mitoses in deep parts 
of the dermal component (5 of 16), lack of cellular maturation or hypercellular basis 
(5 of 16), or a diameter of more than 1 cm (1 of 16). The other 23 lesions harbored 
two atypical features, most frequently a combination of prominent nuclear atypia (13 
of 23), attenuation of the epidermis (13 of 23), lack of maturation (10 of 23), and 
several mitoses in deep parts of the dermal component (9 of 23) and were, 
therefore, classified as suspected for spitzoid melanoma. Kamino bodies were 
present in 6 of 14 Spitz nevi, 4 of 22 atypical Spitz nevi, and 4 of 23 lesions 
suspected for melanoma. However, also in 3 of 36 spitzoid melanomas, eosinophilic 
globules were seen. Five lesions were excluded because the obtained paraffin 
blocks did not contain a Spitzoid lesion. 
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Table 5-3. Prevalence of the mutations according to lesions subtype in Spitzoid 
melanocytic lesions.  
Lesion 
subtype 
BRAF 
exon 15 
BRAF 
exon 11 
NRAS 
exon 2 
NRAS 
exon 3 
HRAS 
exon 2 
HRAS 
exon 3 
Spitz 
nevus  
(n=14) 
Wt 100% Wt 
Nd 
64% 
46% 
Wt
Nd
93% 
7% 
Wt 100% Wt 
Nd
93% 
7% 
Q61L  
Q61R  
Q61K  
Wt  
Nd  
14%
7% 
7% 
64%
7% 
Atypical 
Spitz 
nevus 
(n=16) 
Wt 100% Wt 
Nd 
81% 
19% 
Wt
Nd
94% 
6% 
Wt 
Nd 
88% 
22% 
Wt 100% 
 
Q61L  
Wt  
Nd  
13%
81%
6% 
Suspected 
for 
melanoma 
(n=23) 
V600E 
Wt 
26% 
74% 
Wt 
Nd 
87% 
13% 
G13D
Wt
Nd
4% 
91% 
4% 
Q61R 
Wt 
Nd 
4% 
91% 
3% 
Wt 
Nd 
96% 
4% 
Q61K  
Wt  
Nd  
4% 
87%
8% 
Spitzoid 
melanoma 
(n=36) 
V600E 
V600K* 
K601E 
Wt 
58% 
3% 
3% 
36% 
Wt 
Nd 
72% 
28% 
Wt
Nd
97% 
3% 
Q61R 
Q61K 
Wt 
Nd 
11% 
8% 
78% 
3% 
Wt 
Nd 
97% 
3% 
Wt  
Nd  
94%
6% 
Melanoma 
metastasis 
(n=7) 
V600E 
Wt 
57% 
43% 
Wt 
Nd 
43% 
57% 
Wt 100% Q61K 
Wt 
29% 
71% 
 
Wt 
Nd 
86% 
14% 
Wt  
Nd  
86%
14%
 
*: Tandem mutation (GTG>AAG), WT: wild type, ND: not determined. 
 
 
Mutations analysis 
 Results of the mutation analysis are summarized in Table 5-3. BRAF exon 15 or 
NRAS exon 3 mutations were detected in 86% of the spitzoid melanomas, whereas 
none of the Spitz nevi harbored a BRAF or a NRAS mutation. Moreover, none of the 
atypical Spitz nevi harbored any of these mutations. In lesions suspected for spitzoid 
melanoma, either a BRAF or NRAS mutation was found in 35% of the cases. The 
difference in mutation frequency of the combined results of BRAF and NRAS 
mutations between (atypical) Spitz nevi and spitzoid melanomas was highly 
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Figure 5-1. A: Frequency of BRAF exon 15 and NRAS exon 2 and 3 mutations in Spitzoid 
lesions. B: Frequency of HRAS exon 3 mutations in Spitzoid lesions. 
 
 
significant (P < 0.001). HRAS mutations were only detected in Spitz nevi (29%), 
atypical Spitz nevi (14%), and in one lesion that was suspected for spitzoid 
melanoma (7%) but not in spitzoid melanomas. The difference in HRAS mutation 
frequency between Spitz nevi and spitzoid melanoma was significant (p=0.009). The 
difference in HRAS mutation frequency between Spitz nevi and atypical Spitz nevi or 
lesions suspect for melanoma were not significant (P=0.65 and P=0.15 
respectively). All BRAF, NRAS, and HRAS mutations appeared to be mutually 
exclusive because mutations were not detected in more than one gene in any of the 
lesions. A graphical representation of BRAF exon 15 and NRAS exon 2 and 3 
mutations and the percentage of HRAS exon 3 mutations are shown in Figure 5-1. 
BRAF exon 11 and HRAS exon 2 mutations were not detected in any of the lesions. 
 The correlation between mutations and allelic imbalance as analysed 
previously19, site, age, cell type, and follow-up was studied. There was no 
relationship between BRAF and NRAS mutation frequency and allelic imbalance. 
There was also no relationship between thickness, age and site, the presence of 
Kamino bodies, the age, and the site. Although BRAF mutations were more 
frequently detected compared with NRAS in patients younger than 60 years and in 
melanomas located on the trunk, the difference was not statistically significant. 
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Special cases 
 Two or three tumor areas with morphological different cell types were isolated 
separately and analyzed for BRAF and NRAS mutations in six lesions. An identical 
mutational status was found in the separately isolated cases in each of the lesions. 
In three lesions, the separate areas all harbored a Q61R NRAS mutation; in two 
lesions they harbored a V600E BRAF mutation; and one lesion was completely wild 
type.  
 A polypoid spitzoid melanoma was obtained from a 10-year-old boy and 
harbored a BRAF mutation (Figure 5-2A). An HRAS mutation was detected in one 
lesion diagnosed as suspected for spitzoid melanoma. This lesion was obtained 
from the arm of a 14-year-old male. This symmetric 3-mm-thick lesion showed 
prominent cytonuclear atypia, lack of maturation, and only a few mitoses in deep 
parts of the dermal component. There were no ascending atypical melanocytes in 
the acantotic hyperkeratotic epidermis (Figure 5-2B). A spitzoid melanoma was 
removed from a 38-year-old female. Five years later a second lesion was removed 
diagnosed as Spitz nevus. The spitzoid melanoma harbored a BRAF exon 15 
mutation, whereas the latter lesion was wild type for BRAF exon 15 and NRAS exon 
2 and 3 (Figures 5-2C and 5-2D). 
 
 
DISCUSSION 
 
 High frequencies of BRAF and NRAS mutations have been reported in 
cutaneous melanomas but rarely in Spitz nevi.59-62 Therefore, it was suggested that 
mutation analysis of BRAF, NRAS, and HRAS genes may contribute to a more 
accurate diagnosis of spitzoid melanocytic lesions that are difficult to classify. In 
contrast, HRAS mutations are common in Spitz nevi, wheras they are seldomly 
found in melanomas.38 However, previous studies have mainly focused on BRAF 
mutation analysis of unequivocal Spitz nevi and cutaneous melanomas that were not 
otherwise specified. Although these findings were promising, more specific 
information on BRAF mutations in atypical Spitz nevi and spitzoid melanoma is 
necessary to confirm or reject the assumption that mutation analysis can contribute 
in the precise diagnosis of spitzoid lesions that are difficult to classify. Therefore, in 
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Figure 5- 2. A: Spitzoid melanomas with polypois growth (inset) with a epitheloid cell type 
obtained from a 10-year-old boy. The lesion harbored a V600E BRAF mutation. B: Lesion 
suspected for spitzoid melanoma with a diameter of more than 1 cm (inset) and mitosis in 
deep parts of the dermal component (arrowhead). This lesion harbored an HRAS mutation. C: 
Spitzoid melanoma showing asymmetry, polypoid growth (inset), and lack of maturation and 
nuclear atypia. The lesion harbored a BRAF muation. D: Spitz nevus of the dame patient as 
in C, arising five years following excision of the melanoma, shows a symmetrical architecture 
(inset) and no evident nuclear atypia. This lesion lacked a BRAF mutation. 
 
 
this study we have analyzed a large series of benign, borderline, and malignant 
spitzoid lesions including unequivocal Spitz nevi, atypical Spitz nevi, lesions 
suspected for spitzoid melanomas, and spitzoid metastases. 
 Our analysis of spitzoid melanomas showed BRAF exon 15, NRAS exon 2, and 
NRAS exon 3 mutations in 86% of the cases, whereas no HRAS exon 2 or 3 
mutations could be detected. In contrast Spitz nevi frequently harbored HRAS 
mutations but completely lacked BRAF and NRAS mutations. This highly significant 
finding in mutation frequency of BRAF, NRAS, and HRAS between Spitz nevi and 
spitzoid melanomas indicates that Spitz nevi are genetically different from spitzoid 
melanomas. For instance, it is very unlikely that a HRAS exon 3 mutation would be 
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present in the precursor Spitz nevus and would be lost in the subsequent 
melanoma. Our findings in Spitz nevi are also in line with previously published 
studies, which reported lack of BRAF mutations in more than one hundred cases.59-
63 Our findings in spitzoid melanoma differ from the results as reported by Gill et al.63 
In their study, they did not detect any BRAF, NRAS, and HRAS hotspot mutations in 
9 spitzoid melanomas and 10 Spitz nevi obtained from children younger than 11 
years.63 Although in our study, only one spitzoid melanoma that had metastasized 
from a 10-year-old boy was included and it did have a V600E BRAF mutation 
(Figure 5-2A). Also two lesions suspect for melanoma in a 13-year-old and a 14-
year-old patient harbored a BRAF and a HRAS mutation respectively (Figure 5-2B). 
Since the diagnostic problems are mostly encountered in spitzoid lesions with 
features of atypia we have studied a considerable number of such cases. Lesions 
that were classified as atypical Spitz nevi harbored a HRAS mutation 14% of the 
cases, which was statistically not different from the frequency found in 29% of the 
cases with unequivocal Spitz nevi. Furthermore, we analyzed lesions suspected for 
spitzoid melanoma, which represents a borderline category between atypical Spitz 
nevi and spitzoid melanomas. In these cases, complete removal or treatment as a 
melanoma is advised because malignancy cannot be ruled out with certainty. In 
cases investigated in this study, 35% harbored a BRAF or a NRAS mutation, 
strongly suggesting that they are indeed melanomas. In one lesion that was 
suspected for spitzoid melanoma, an HRAS mutations was detected. 
Retrospectively, this lesion was also classified as suspected for melanoma because 
the diameter of more than 1 cm and there were frequent mitoses in deeper dermal 
component (Figure 5-2B). Based on our observations in Spitz nevi and spitzoid 
melanomas, presence of HRAS exon 3 mutations would favor the diagnosis of Spitz 
nevus and presence of either a BRAF or NRAS mutation would strongly argue for 
the diagnosis of spitzoid melanoma, which would in turn reduce the number of 
lesions that would be classified as 'unknown malignant potential'. For those lesions 
that do not have a mutation of any of these genes, mutation analysis for other genes 
such as PTEN, CDKN2A, or TP53 mutations that may increase the sensitivity of 
mutation analysis to enable the diagnosis of spitzoid lesions.147,148 Mutation analysis 
may also be useful in patients with more than one lesion as illustrated by the case of 
a patient with a spitzoid melanoma who developed a Spitz nevus five years later 
(Figure 5-2C and 5-2D). The melanoma harbored a BRAF mutation whereas the 
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Spitz nevus harbored no BRAF or NRAS hotspot mutations suggesting that it truly is 
a second primary spitzoid lesion.  
 In summary, mutation analysis is easy to perform on routinely processed tissue 
specimens, and the results of our study showed that there is a marked difference 
between atypical Spitz nevi and spitzoid melanomas. In contrast to other techniques 
such as ploidy analysis, morphometry, and allelic imbalance analysis, which never 
gained acceptance in routine practice because of insufficient discriminatory power 
and technical difficulties, mutation analysis seems to be by far the best option as an 
additional diagnostic tool. As there are some variations in mutation frequency, multi-
center studies and long term follow up are needed to establish the diagnostic value 
of this additional molecular biological approach in pathology practice, especially for 
spitzoid lesions that cannot be classified solely based on histological features. We 
emphasize that the mutation analysis at this moment cannot replace conventional 
histologic examination, which is still the gold standard, but it may provide additional 
important diagnostic information. 
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SUMMARY 
  
 Melanoma is one of the most aggressive types of skin cancer and thick lesions 
(2 mm or more) have a high potential for metastatic spread. In contrast, a 
melanocytic naevus is a frequently occurring skin lesion that can be notoriously 
similar to melanoma, exhibiting however a completely benign behaviour. Obviously, 
a correct diagnosis is needed for an adequate therapy and proper information on the 
prognosis of the patient. So far, the only effective therapy consists of complete 
surgical excision of the primary melanoma with a 1 or 2 cm margin, depending on  
tumour thickness. A subsequently performed sentinel node procedure may provide 
additional prognostic information. Such extra procedures are not needed in case of a 
naevus. As summarized in the outline of this thesis, the aim was to gain a better 
insight into the frequency of the various genetic alterations in benign and malignant 
types of melanocytic lesions and the way in which these alterations may be utilised 
in diagnostic pathology practice. 
  
 A proper clinical differential diagnosis combined with an adequate histological 
examination of the lesion is in the majority of the lesions sufficient to arrive at an 
unequivocal diagnosis. The remaining lesions however may present considerable 
diagnostic problems. In Chapter 1 these lesions are discussed in depth and 
recommendations on their correct classification are given. Making a histological 
differential diagnosis of a melanoma versus a naevus requires good quality paraffin 
sections and histological inspection at low power magnification for symmetry and 
careful search at intermediate and high power magnification for distinguishing 
cytonuclear features such as atypia and (atypical) mitotic figures. Lesions that may 
cause diagnostic problems, such as dysplastic naevus, melanoma in situ and 
microinvasive melanoma, are considered to represent subsequent stages of 
malignant progression and therefore they may show overlapping histopathological 
features. Diagnosis of a melanoma in situ is based on pagetoid proliferation of 
markedly atypical melanocytes throughout the epidermis. An accurate diagnosis of 
melanoma in situ or lentigo maligna can be reached by performing additional 
immunohistochemical staining to exclude an invasive component, thereby 
preventing an incorrect diagnosis. While some malignant lesions, such as nevoid 
melanoma, may show a certain degree of symmetry and maturation as in a naevus, 
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naevi meanwhile may exhibit features that occur in melanomas. In a deep 
penetrating naevus mild cytonuclear atypia and scattered giant atypical cells may 
occur. In Spitz naevi nuclear pleomorphism, a prominent nucleolus and occasionally 
mitotic figure may be found. Especially among spitzoid lesions there is a subgroup in 
which it is difficult to (completely) exclude a diagnosis of melanoma and therefore 
malignant behaviour could be possible. The number of lesions diagnosed as 
'spitzoid tumour of uncertain malignant potential' (STUMP) is increasing, probably 
due to removal in an earlier stage and the threat of lawsuits following diagnostic 
errors. The diagnosis of cutaneous melanocytic lesions requires special expertise 
and experience of the pathologist. To help provide an adequate diagnosis, individual 
experts and expert panels are consulted on a regular basis. These panels should be 
stimulated to use standardized forms using well-defined histopathological 
classifications and terminology in order to reach consistent reporting. Further, the 
follow-up data of the patients should be properly documented. Along these lines, the 
case material should be well accessible for various evaluative studies, which may 
provide a basis to further increase the understanding of the clinicopathological 
characteristics of cutaneous melanocytic lesions. Such case material would be 
ideally suited for performing additional molecular studies, thereby enabling the 
pathologist to improve his assessment of the diagnosis and prognosis in cases of 
melanocytic lesions that prove difficult to classify using the conventional 
morphological approach. As spitzoid lesions are the most difficult to classify 
histopathologically we focused on these lesions in this thesis. 
  
 To find additional diagnostic markers we directed our efforts on routinely 
processed formalin-fixed paraffin-embedded tissue. Detection of DNA alterations 
seems to be very attractive because DNA can be relatively reliably and easily 
isolated from this routinely processed tissue. This in contrast to RNA that is more 
difficult to recover from this material. Regarding the changes at protein level, 
immunohistochemical staining profiles that may discriminate between malignant and 
benign melanocytic lesions are still lacking, despite many years of effort. In Chapter 
2 we critically evaluate the various molecular techniques used to analyse genetic 
alterations on the DNA level in formalin fixed lesions and review the results 
published so far. At the beginning of the exploration of their diagnostic utility, 
karyotyping, ploidy analysis and in situ hybridisation already had shown interesting 
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differences between benign and malignant melanocytic lesions, but they were not 
useful in pathology practice due to insufficient diagnostic power or technical 
difficulties. By the end of the previous decade characteristic patterns of gains and 
losses emerged for different melanocytic subtypes using comparative genomic 
hybridisation (CGH). Although this technique is of great value in a research setting 
to identify chromosomal imbalances, it is unfortunately quite laborious and therefore 
cannot be easily implemented in a routine diagnostic laboratory. Initially, Allelic 
Imbalance (AI) analysis showed some promise as a useful technique to analyse 
these gains and losses; however, only a few loci can be analyzed per experiment 
and gains cannot be distinguished from losses. Recently, a new technique to 
analyse gains and losses called Multiplex Ligation-dependent Probe Amplification 
(MLPA) was marketed; this technique solved the most important drawbacks from AI 
analysis. More recently, mutation of the BRAF gene in melanomas was reported, 
that could have diagnostic implications. Because AI, MLPA, and mutation analysis 
could be used to analyse genetic alterations on the DNA level, their possible value 
for diagnostic purposes was further explored in this thesis. For all techniques 
mentioned above, isolated tumour DNA with more than 70 - 80% tumour cells is 
needed. We therefore used laser microdissection (LMD) to separate tumour cells 
from contaminating normal cells. LMD does not allow the use of a coverslip, 
therefore we developed a mounting method to improve the morphological image of 
the tissue sections (described in the supplement). 
  
 As described in Chapter 2, data was already available on the genetic alterations 
in most subgroups of melanocytic lesions. However, in the subgroup of mucosal 
melanomas they were so far lacking. As these lesions possess several clinical and 
pathological characteristics that are different from cutaneous melanoma, we 
investigated them using CGH, thereby demonstrating that sinonasal melanoma 
harbours a distinct pattern of chromosomal abnormalities compared to uveal 
malanoma and cutaneous melanoma (described in Chapter 3). The CGH results of 
sinonasal mucosal melanoma revealed two remarkable alterations. First, 
chromosome arm 1q was gained in all tumours and secondly all tumours harboured 
a gain of 6p, a loss of 6q or both. Ploidy analysis also showed that diploid tumours 
exhibit gains and losses, whereas clear-copy gains and high-copy gains were only 
seen in triploid and tetraploid tumours. This suggested that alterations of 
Chapter 7 
116 
chromosomes 1 and 6 might precede polyploidization and formation of clear-copy 
gains and high-copy gains. The large differences in distribution of chromosomal 
imbalances between sinonasal melanoma and nasopharyngeal carcinoma suggest 
that chromosomal alterations are mainly determined by the cell type and less by 
location or carcinogen exposure. This is also applicable to the CGH patterns of 
sinonasal melanoma and uveal melanoma, both of which arise from non-dermal 
melanocytes and are therefore independent of UV-exposure. Sinonasal melanomas 
were most similar to acral melanomas, a subtype of cutaneous melanoma that is 
located on the glabrous skin of the extremities.  
  
 Encouraged by the results of the analysis of genetic aberrations as described in 
Chapters 2 and 3, we subsequently explored the utility of molecular techniques that 
have not (yet) been applied in a diagnostic setting for melanocytic lesions. In 
Chapter 4 we tested AI analysis as an adjunct in the diagnosis of spitzoid lesions. 
We confirmed the previously reported marked differences between unequivocal 
Spitz naevi and melanomas; however, the picture was unclear with respect to the 
equivocal lesions. Moreover, we noticed a low yield of DNA isolated from normal 
adjacent tissue, needed for this technique, which limited the number of lesions that 
could be examined for allelic imbalance. This led us to suggest that AI analysis is 
not suitable in a routine diagnostic setting and a better method had to be found for 
this purpose. Furthermore, subsequent molecular studies are needed to 
demonstrate additional genetic differences. In addition, they may reveal whether a 
true biological spectrum between Spitz naevi and spitzoid melanomas exists. 
Therefore, we explored other methods to analyse chromosomal gains and losses in 
formalin-fixed melanocytic lesions, which were derived from diagnostic excisions. 
  
 In Chapter 5, we have critically evaluated the applicability of MLPA in a routine 
diagnostic setting. In contrast to AI analysis, gains and losses can be detected 
separately. More importantly, no normal DNA of the patient is needed, because 
normal reference DNA can be isolated from formalin-fixed normal tissue samples 
obtained from other patients or healthy persons. An additional advantage, compared 
to ISH and AI, is that up to 45 loci can be analysed in one experiment. To validate 
this technique we compared the results with those of CGH on the same cases and 
the sensitivity of MLPA appeared to be good. For application in a diagnostic setting 
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different probes on a chromosome region of interest should be used to prevent false 
positives. We conclude that MLPA using a carefully chosen set of probes is a 
reliable and fast technique to screen large numbers of formalin-fixed lesions for DNA 
gains and losses in a research as well as a diagnostic setting. Currently the 
technique is being further refined, kits directed to specific lesions are being prepared 
and new software for data analysis developed. 
  
 In molecular diagnostics on formalin-fixed tissues the analysis of mutations 
would be the most easy and reliable method. Until recently, the most frequently 
mutated gene was NRAS, which was mutated in only approximately 30% of the 
melanomas. The BRAF gene was the first gene that was found to be mutated in the 
majority of cutaneous melanomas. In pilot experiments we noticed that these 
mutations were also present in most benign and malignant subtypes of melanocytic 
lesions but were notably absent in mucosal melanoma, blue naevi, and most 
importantly, in Spitz naevi. Others have confirmed these results. As spitzoid 
melanomas were not well investigated we determined the frequency of BRAF, 
NRAS, and HRAS gene mutations in (atypical) Spitz naevi, borderline spitzoid 
lesions, and spitzoid melanomas in patients of 10 years and older. The results 
described in Chapter 6 show a striking difference in frequency: no BRAF or NRAS 
mutations were detected in (atypical) Spitz naevi, whereas these genes were very 
frequent mutated in spitzoid melanomas. In borderline lesions a lower percentage 
was detected. In contrast to the AI findings these results suggest that these spitzoid 
lesions might not be part of a biologic spectrum but two separate subtypes. 
  
FUTURE PERSPECTIVES 
  
 It is generally accepted that alterations in one or more genes are the cause of 
melanomas. This results in up- and down- regulation of the corresponding mRNA, 
and subsequent different protein expression. Tumour diagnostics is more than the 
one-dimensional look at genes; RNA analysis and proteomics may reveal lesion 
specific profiles. Because histological examination is the most important diagnostic 
method formalin-fixation is needed to provide good quality paraffin HE sections; 
however it hampers RNA analysis. Therefore, in the near future DNA alterations 
remain the most promising target for techniques to be implemented as additional 
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diagnostic tool. Also, it might be useful to explore other fixation methods that result 
in optimal morphology without destructing RNA or cross-linking proteins instead of 
finding methods to retrieve RNA and undo the cross-linking effect of formalin. 
 As summarized before, studies using molecular biological techniques have 
provided important clues on the genetic basis for the development of melanocytic 
tumours. Also comparison of for example cell lines with a low and high metastatic 
potential revealed important differences in RNA and protein profiles. However, these 
techniques have failed to gain acceptance in routine practice because of the 
technical difficulties and insufficient discriminatory power. BRAF and NRAS mutation 
analysis seems to be by far the best option for use as an additional diagnostic tool in 
the differential diagnosis of spitzoid lesions. In previous studies, we and others have 
found that BRAF and NRAS mutations were frequently detected in spitzoid 
melanoma and common naevi in contrast to Spitz naevi where no BRAF or NRAS 
mutations were detected. Instead, mutations in the HRAS gene were observed in 
approximately 20-30% of the Spitz naevi, whereas these mutations where very 
rarely detected in spitzoid melanomas. Detection of mutations in BRAF, NRAS, and 
HRAS genes may therefore contribute in the discrimination between Spitz naevi and 
spitzoid melanoma. Currently, we are studying the frequency of these mutations in 
tumours removed from patients younger than 15 years, as the diagnosis of spitzoid 
lesions in this group of patients is extremely difficult. In the near future, we are 
planning to implement mutations analysis in a routine diagnostic setting. By doing so 
it may become of use to the pathology panel of the Dutch melanoma working party 
enabeling multi-centre studies. Long-term follow-up of the patients is required to 
establish the diagnostic value of this additional molecular biology tool in pathology 
practice. 
 Because several types of naevi already harbour BRAF gene mutations it is clear 
that additional alterations are needed to accomplish malignant transformation and 
further progression. Therefore, further genetic characterization of subtypes of benign 
and malignant lesions might reveal important diagnostic information, including early 
stages of tumour progression that have not been characterized so far. This is based 
on the fact that we and others have found that primary and metastastic lesions 
harbour almost the same genetic alterations within one patient and also between 
patients. Therefore, these alterations either already occurred early in the 
development of the malignant lesion or the metastasising subclone has overgrown 
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the other primary tumour cells. Independent of which scenario took place genetic 
analysis of differences between primary melanoma and melanoma metastasis 
seems not to substantially contribute to our knowledge of tumour evolution. 
Therefore, alterations in early stages of melanoma development may be a more 
important study object than the more advanced stages of primary melanoma and 
melanoma metastases. 
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Samenvatting en toekomst perspectieven 
 
 
Samenvatting 
 
Het melanoom behoort tot de meest agressieve vormen van huidkanker waarbij met 
name de dikke laesies (2 mm of meer) een grote kans op metastasering (uitzaaiing) 
hebben. Dit in tegenstelling tot de vaak voorkomende naevi (moedervlekken) die 
goedaardig zijn maar macroscopisch en microscopisch erg op melanomen kunnen 
lijken. Een juiste diagnose is nodig om de beste behandeling vast te stellen en om 
informatie over de prognose te kunnen geven aan de patiënt. Tot op heden is de 
enige therapie chirurgische verwijdering met een 1 of 2 cm marge, afhankelijk van 
dikte. Aanvullende prognostische informatie kan door een additionele 
schildwachtklier procedure verschaft worden. Bij een naevus volstaat het 
verwijderen van de afwijking ter voorkoming van een mogelijk recidief. Hierbij speelt 
mee dat het histologisch beeld van een recidief zeer verontrustend kan zijn 
waardoor de indruk van een melanoom ontstaat (een zogenaamd 
pseudomelanoom). Een dergelijke situatie illustreert de beperkingen van de 
gebruikelijke histologische beoordeling. Veel wordt verwacht van het aantonen van 
genetische afwijkingen aangeien er belangrijke klinische toepassingen, aangezien er 
belangrijke verschillen tussen goedaardige en kwaadaardige gezwellen zijn 
gevonden. Het voornaamste doel van dit proefschrift is om meer inzicht te krijgen in 
de verschillende genetische afwijkingen in goedaardige en kwaadaardige 
melanocytaire laesies en na te gaan hoe deze genetische afwijkingen kunnen 
worden gebruikt voor diagnostische toepassingen. 
 
In de meerderheid van de gevallen komt de patholoog met behulp van een juiste 
klinische differentiaal diagnose, gecombineerd met adequaat histologisch onderzoek 
van de melanocytaire afwijking tot een zekere diagnose. In een belangrijke 
minderheid van de verwijderde afwijkingen kan echter geen zekere diagnose 
worden gesteld. In Hoofdstuk 1 worden de soorten afwijkingen die vaak 
diagnostische problemen opleveren beschreven en worden aanbevelingen gedaan 
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die kunnen helpen bij het stellen van de juiste diagnose. In dit verband is van belang 
om nog eens op te merken dat voor een goede histologische diagnose van 
melanomen en naevi paraffine coupes van voldoende kwaliteit vereist zijn. De 
histologische preparaten worden eerst beoordeeld bij overzichtsvergroting om de 
mate van symmetrie van de afwijking vast te stellen. Bij hogere vergroting worden 
kenmerken zoals kernatypie en de aan- of afwezigheid van al dan niet atypische 
mitosefiguren beoordeeld. Afwijkingen die deel uitmaken van een 
ontwikkelingsreeks (bijvoorbeeld dysplastische naevi, melanoom in situ en 
microinvasief melanoom), kunnen bij uitstek diagnostische problemen opleveren als 
gevolg van overlappende histologische kenmerken. De diagnose van melanoom in 
situ is gebaseerd op zogenaamde pagetoide proliferatie (intra-epidermale 
groeiwijze) en sterke atypie van de epidermale melanocyten. Aanvullende 
immunohistochemische technieken kunnen worden toegepast om een mogelijke 
invasieve component uit te sluiten en hiermee overdiagnostiek te voorkomen. 
Enkele kwaadaardige afwijkingen, zoals het naevoid melanoom, kunnen 
symmetrisch zijn en de indruk wekken van uitrijping. Aan de andere kant kunnen 
naevi soms ook kenmerken tonen die passen bij melanomen. Zo is voor de 
diagnose deep penetrating naevus kan het voorkomen van geringe cytonucleaire 
atypie en eventueel enkele verspreid gelegen atypische cellen nog acceptabel. Ook 
in Spitz naevi kan men pleomorfe kernen, duidelijk zichtbare nucleoli en enkele 
mitosefiguren aantreffen. In het bijzonder bij spitzoide afwijkingen komen veel 
diagnostische problemen voor waarbij het moeilijk is om het klinisch-biologisch 
gedrag te voorspellen. Het aantal afwijkingen dat gediagnosticeerd wordt als 
'spitzoide tumor met onzeker maligne potentieel', neemt de laatste jaren duidelijk 
toe, enerzijds omdat afwijkingen eerder (in een vroeg ontwikkelingsstadium) worden 
verwijderd en anderzijds door de dreiging van schadeclaims bij een achteraf gezien 
onjuiste diagnose (waardoor een patholoog minder goed een harde uitspraak durft 
te doen). Een patholoog moet daarom over voldoende kennis en ervaring 
beschikken om melanocytaire afwijkingen te kunnen diagnosticeren en om te 
kunnen beoordelen wanneer een afwijking naar een expert of een panel van experts 
opgestuurd moet worden ter bevestiging van de diagnose. Om tot consistente 
diagnoses te komen is het aan te bevelen dat dergelijke panels gebruik maken van 
goed gedefinieerde histopathologische diagnosen en hierbij gestandaardiseerde 
formuleringen toepassen. Deze diagnosen moeten worden vastgelegd evenals de 
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follow-up van de patiënten. Zo kan materiaal worden verzameld voor 
wetenschappelijk onderzoek dat uiteindelijk nieuwe gegevens oplevert voor de 
ondersteuning van de diagnose bij moeilijk te classificeren gevallen. Omdat 
spitzoide afwijkingen het moeilijkst te classificeren zijn is in dit proefschrift hier de 
nadruk op gelegd. 
 
Voor een mogelijke toepassing van aanvullende diagnostische markers te vinden 
zijn we steeds uitgegaan van in formaline gefixeerd in paraffine ingebed weefsel, 
aangezien dit de dagelijkse praktijk weerspiegelt. Reeds lang wordt er onderzoek 
gedaan om immunohistochemische kleuringen te ontwikkelen die het onderscheid 
tussen goedaardige en kwaadaardige melanocytaire afwijkingen kunnen maken, tot 
op heden echter zonder succes. Ter bepaling van aanvullende diagnostische 
markers in formaline gefixeerd materiaal zijn veranderingen in het DNA het meest 
veelbelovend, omdat dit gemakkelijk en betrouwbaar kan worden geïsoleerd uit het 
routinematig verwerkt weefsel, in tegenstelling tot RNA dat hierbij vaak beschadigd 
wordt. In Hoofdstuk 2 evalueren we de verschillende moleculaire technieken die 
gebruikt zouden kunnen worden om DNA-veranderingen op te sporen in formaline 
gefixeerde tumoren en geven we een overzicht van gepubliceerde resultaten met 
deze technieken. Uit onderzoek door middel van karyotypering, ploidie analyse en in 
situ hybridisatie zijn al veel verschillen tussen benigne en maligne melanocytaire 
afwijkingen naar voren gekomen, echter door het ontbreken van voldoende 
onderscheidend vermogen en het voorkomen van technische problemen blijken 
deze methoden niet goed toepasbaar in de dagelijkse praktijk. Aan het eind van het 
vorig decennium zijn kenmerkende patronen beschreven bestaande uit een 
wisselende toename en verlies van chromosomen of delen van chromosomen; 
veelal gebruikt men hierbij de comparative genomic hybridisation (CGH) techniek. 
Alhoewel CGH van grote waarde is voor wetenschappelijk onderzoek om 
chromosomale imbalans te detecteren, is deze techniek te bewerkelijk voor 
toepassing in de dagelijkse diagnostische praktijk. Allelic Imbalance analyse (AI), 
ook wel verlies van heterozygotie (LOH) genaamd, kan gebruikt worden om 
veranderingen in chromosoom locaties te detecteren met behulp van polymorfe 
markers. Nadeel is dat er slechts enkele chromosomale locaties kunnen worden 
geanalyseerd tijdens een enkel experiment en bovendien kan het onderscheid 
tussen en toe- en afname van de chromosoomlokalisaties niet met zekerheid kan 
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worden gemaakt. Onlangs is multiplex ligation-dependent probe amplification 
(MLPA), op de markt gebracht, een nieuwe techniek, die deze twee nadelen niet 
heeft. Verder is recent ontdekt dat mutatie analyse van het BRAF gen frequent 
voorkomt in melanomen, hetgeen diagnostisch van belang kan zijn. Zowel AI, MLPA 
als mutatie analyse lijken toepasbare methoden om genetische veranderingen op 
DNA niveau te detecteren en ze zouden derhalve, in aanvulling op histologisch 
onderzoek, in de diagnostiek kunnen worden ingezet. Om deze reden zijn deze 
methoden in dit proefschrift uitgebreid onderzocht. 
Voor alle technieken die hierboven beschreven zijn is het nodig voldoende tumor-
DNA te isoleren uit de achtergrondpopulatie van normale cellen, om zo een 
concentratie van tumorcellen van 70 - 80% te verkrijgen. Hiervoor hebben we 
gebruik gemaakt van laser microdissectie (LMD) om tumorcellen van normale cellen 
te scheiden. Bij deze methode wordt geen afdekglas gebruikt zodat er geen 
correctie is van het verschil van brekingsindex tussen lucht en weefsel. Ter 
verbetering van deze situatie werd door ons een methode ontwikkeld om het 
morfologisch beeld te optimaliseren zonder dat dit de laserdissectie of de DNA 
isolatie belemmerde (beschreven in het supplement). 
 
Zoals aangegeven in Hoofdstuk 2, zijn inmiddels van verscheidene subtypes van 
melanomen de meest duidelijke chromosomale afwijkingen beschreven. Er was 
echter nog weinig bekend over mucosale slijmvlies melanomen. Deze afwijkingen 
hebben andere klinische en pathologische kenmerken dan melanomen van de huid 
en zouden zich ook in genetisch opzicht kunnen onderscheiden. Met behulp van 
CGH ontdekten we dat sinonasale melanomen een kenmerkend patroon van 
chromosomale afwijkingen vertonen vergeleken met uveale en cutane melanomen 
(beschreven in Hoofdstuk 3). De CGH-resultaten van sinonasale melanomen laten 
twee opvallende afwijkingen zien. Ten eerste werd in alle onderzochte tumoren een 
toename van chromosoomarm 1q gevonden, ten tweede bevatten alle tumoren óf 
een toename van 6p, óf een verlies van 6q óf beide afwijkingen. Door middel van 
ploidie-analyse bleek dat ook in diploide tumoren toe- en afname van 
chromosoomarmen werden gevonden. Clear-copy toenames en high-copy 
toenames werden alleen gezien in triploide en tetraploide tumoren. Dit maakt 
aannemelijk dat  veranderingen van chromosomen 1 en 6 voorafgaan aan 
polyploidisatie en vorming van "clear-copy gains" en "high-copy gains". Het 
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duidelijke verschil in patronen van chromosomale afwijkingen tussen sinonasale 
melanomen en nasopharyngeale carcinomen zou kunnen suggereren dat 
chromosomale veranderingen worden bepaald door het celtype en minder door 
lokalisatie en blootstelling aan carcinogenen. Daarenboven laat het CGH-patroon 
van sinonasale melanomen in vergelijking met dat van uveale melanomen een 
duidelijk verschillend patroon, hoewel beide tumoren ontstaan uit niet-dermale 
melanocyten die niet blootgesteld zijn aan UV-straling. Voor wat chromosomale 
afwijkingen betreft lijken sinonasale melanomen nog het meest op acrale 
melanomen, een subtype van melanomen die gelokaliseerd zijn op de niet behaarde 
huid van de acra (de uiteinden van hoofd en ledematen). 
 
 Om de gevonden verschillen in genetische afwijkingen zoals beschreven in 
Hoofdstuk 2 en 3 te kunnen toepassen als ondersteuning van de diagnose, hebben 
we verschillende moleculaire technieken onderzocht. In Hoofdstuk 4 hebben we AI 
analyse getest bij de diagnostiek van spitzoide afwijkingen. Hiermee kon inderdaad 
het verschil tussen Spitz naevi en spitzoide melanomen worden bevestigd. Echter, 
in de tussenliggende diagnostische groepen, te weten atypische Spitz naevi en 
laesies die verdacht zijn voor spitzoid melanoom, was het beeld minder 
uitgesproken. Bovendien was de DNA opbrengst van het aangrenzend normale 
weefsel, nodig als referentiepunt om de afwijkingen betrouwbaar op AI te 
analyseren, in veel laesies ontoereikend waardoor slechts een beperkt aantal van 
de afwijkingen met AI geanalyseerd konden worden. Hieruit kan men opmaken dat 
AI analyse niet geschikt is als aanvullende diagnostische test, zodat er alsnog naar 
een beter methode gezocht moet worden. Daarnaast is aanvullend onderzoek nodig 
om aan te tonen of er wel een biologisch spectrum bestaat tussen Spitz nevi en 
spitzoide melanomen. Er werd daarom gezocht naar andere manieren om toe- en 
afname van (delen van) chromosomen te detecteren in formaline gefixeerd 
materiaal dat om diagnostische redenen was geëxcideerd. 
 
 In Hoofdstuk 5 hebben we de toepasbaarheid van multiplex ligation-dependent 
probe amplification (MLPA) als diagnostische methode kritisch geevalueerd. In 
tegenstelling tot de AI analyse kunnen met deze methode wel toe- en afname van 
delen van chromosomen van elkaar worden onderscheiden. Belangrijker is nog dat 
geen normaal DNA van de patiënt nodig is, omdat normaal referentie DNA kan 
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worden geïsoleerd van weefsel verkregen van gezonde personen. Een derde 
voordeel is dat, in vergelijking met ISH en AI analyse, tot 45 loci per experiment 
tegelijk kunnen worden geanalyseerd. Om deze methode te testen hebben we de 
resultaten vergeleken met CGH van deze zelfde tumoren. Uit deze vergelijking bleek 
dat de sensitiviteit van de MLPA goed is. Voor toepassing in de diagnostiek zouden 
ter voorkoming van vals positieve uitslagen wel meerdere probes per chromosomale 
regio van interesse moeten worden onderzocht. We menen te kunnen concluderen 
dat MLPA, mits de samenstelling van de probes goed wordt gekozen, een 
betrouwbare en snelle methode is om grote aantallen van in formaline gefixeerde 
afwijkingen te onderzoeken voor toe- en afname van DNA fragmenten, zowel ten 
behoeve van wetenschappelijk onderzoek als voor de diagnostiek. De techniek is nu 
verder verfijnd, er worden kits samengesteld die op maat zijn gemaakt voor 
specifieke (groepen van) afwijkingen en er is nieuwe software ontwikkeld om de 
analyse te vergemakkelijken.  
 
 Tot op heden is DNA mutatie-analyse een van de meest betrouwbare en 
makkelijk toepasbare methoden gebleken om genetische afwijkingen te detecteren. 
Het NRAS gen was lange tijd het meest frequent gemuteerde gen bij melanomen, 
ook al was dit gen slechts in 30% van de gevallen gemuteerd. Vervolgens bleek 
echter dat het BRAF gen in de meerderheid van de cutane melanomen een mutatie 
bleek te bevatten. In verkennende experimenten konden we bevestigen dat BRAF 
genmutaties inderdaad aanwezig waren in veel cutane melanomen, echter ook in de 
meeste goedaardige melanocytaire afwijkingen. Deze mutaties waren echter niet 
aantoonbaar in het mucosaal melanoom, noch in blue naevi (blauw gekleurde 
moedervlekken), noch in de voor ons onderzoek belangrijke Spitz naevi. Deze 
resultaten werden ook door anderen bevestigd. Omdat spitzoide melanomen nog 
niet als afzonderlijke groep zijn onderzocht zijn we her voorkomen van BRAF, NRAS 
en HRAS genmutaties in (atypische) Spitz naevi, voor melanoom verdachte 
spitzoide afwijkingen en uitgesproken spitzoide melanomen nagegaan bij patiënten 
van 10 jaar en ouder. De resultaten van dit onderzoek zijn beschreven in Hoofdstuk 
6. In spitzoide melanomen bleek in 88% van de tumoren BRAF of NRAS 
genmutaties aantoonbaar terwijl er in (atypische) Spitz naevi geen mutaties in deze 
genen werden gevonden. In Spitz naevi werd echter in 30% van de onderzochte 
afwijkingen wel een HRAS mutatie aangetroffen, in tegenstelling tot de spitzoide 
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melanomen. In de afwijkingen die als 'beschouwen als melanoom' werden 
geclassificeerd werd een lager percentage BRAF en NRAS gen mutaties gevonden. 
In afwijking tot de bevindingen in Hoofdstuk 4 (op basis van AI analyse) lijken deze 
data meer te suggeren dat Spitz naevi en spitzoide melanomen twee verschillende 
subtypes zijn die geen deel uitmaken van een biologisch spectrum. 
 
Toekomstperspectieven 
 
 Algemeen wordt aangenomen dat tumoren zoals melanomen ontstaan door 
veranderingen in een of meer genen. Dit resulteert in toe- en afname van de 
productie van mRNA en als gevolg hiervan verschillen in eiwitexpressie. In de nabije 
toekomst lijkt het detecteren van DNA-veranderingen het meest veelbelovend als 
aanvullend diagnostisch middel, zoals ook af te leiden valt uit de resultaten van dit 
proefschrift. Tumordiagnostiek is echter meer dan een eendimensionale kijk op 
genen; RNA analyse en proteomics kunnen ook specifieke profielen onthullen. 
Omdat histologisch onderzoek vooralsnog de meest belangrijke diagnostische 
methode blijft, is adequate weefselfixatie in formaline nodig om coupes van een 
goede kwaliteit te verkrijgen. Helaas is deze fixatie nadelig voor het resultaat van 
technieken die RNA en eiwit analyse. Daarom kan het voor toekomstig onderzoek 
nuttig zijn om te experimenteren met ander fixatiemethoden, die enerzijds een 
optimale morfologie waarborgen, maar anderzijds geen destructie van RNA of 
cross-linking van eiwitten veroorzaken. Dit is efficiënter dan wellicht te trachten 
methoden te ontwikkelen die de nadelige effecten van formaline op het RNA en de 
eiwitten kunnen beperken. 
 Zoals eerder aangegeven zijn met behulp van diverse moleculair-genetische 
methoden al duidelijke verschillen aangetoond in de genetische samenstelling van 
verschillende melanocytaire afwijkingen. Ook vergelijking van RNA-profielen tussen 
bijvoorbeeld tumorcellijnen met hoge en lage neiging tot metastaseren heeft 
belangrijke verschillen opgeleverd. Mutatie-analyse lijkt op dit moment echter de 
beste methode om als additionele techniek in de diagnostiek toe te passen bij de 
differentiaal diagnose van spitzoide afwijkingen. In reeds gepubliceerde studies 
hebben anderen en wij laten zien dat BRAF en NRAS genmutaties wel frequent 
voorkomen in spitzoide melanomen, maar niet in Spitz naevi. In Spitz naevi 
daarentegen werden echter in 20-30% HRAS genmutaties gevonden, die op hun 
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beurt slechts zeer sporadisch werden aangetroffen in spitzoide melanomen. 
Mutatiedetectie in BRAF, NRAS en HRAS genen kan daarom een bijdrage leveren 
aan de diagnostiek van spitzoide afwijkingen. Op dit moment worden tumoren van 
patiënten jonger dan 15 jaar geanalyseerd en lopende gevallen getest op BRAF, 
NRAS en HRAS genmutaties. Daar multi-center studies en longterm follow-up nodig 
zijn om de diagnostische waarde van de mutatie analyse te bevestigen wordt een 
studie voorbereid waarbij leden van het melanoompanel van de Nederlandse 
melanoomwerkgroep zijn betrokken.  
 Aangezien verschillende (niet spitzoide) naevi reeds BRAF gen mutaties 
bezitten moeten er additionele veranderingen nodig voor het optreden van maligne 
transformatie. In dit licht kan verdere genetische karakterisering van subtypes van 
benige en maligne melanocytaire laesies belangrijke informatie opleveren. Over de 
vroege genetische veranderingen bij het ontstaan van een melanoom is tot nu toe 
nog weinig bekend. Tot nu toe heeft om verschillende redenen de nadruk gelegen 
op de stap van primair melanoom naar melanoom metastase. Primaire melanomen 
en de hieruit ontstane metastasen bevatten echter vaak vrijwel dezelfde genetische 
veranderingen. Dit kan betekenen dat de afwijkingen al bestaan in de vroege fase 
van de ontwikkeling van een melanoom of dat de metastaserende subpopulatie de 
overige eerder aanwezige tumorcellen heeft overwoekerd. Welk scenario zich ook 
afspeelt, de verklaring ervan zal waarschijnlijk niet veel bijdragen aan onze kennis 
over het ontstaan van de maligniteit. Het lijkt wellicht interessanter de moleculair-
genetische veranderingen bij de progressie van een dysplastische naevus naar een 
superficieel spreidend melanoom te onderzoeken. Ook zou onderzocht kunnen 
worden welke van dergelijke veranderingen in melanocytaire cellen een rol spelen 
bij de immunologische regressie van de afwijkingen, aangezien deze een goed 
doelwit zouden kunnen vormen voor behandeling. 
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ABSTRACT 
 
 Laser microbeam microdissection has greatly facilitated the procurement of 
specific cell populations from tissue sections. However, due to the fact that a 
coverslip is not used the morphology of the tissue sections is often poor. To facilitate 
identification of target cells we have developed a mounting method that greatly 
improves the morphological appearance of tissue sections for laser microbeam 
microdissection purposes. Fresh frozen tissue and formalin-fixed paraffin-embedded 
tissue specimens were used to test the quality of the morphological of mounted and 
unmounted tissue. The mounting solution consisted of an adhesive gum and blue 
ink diluted in water. Interference of the mounting solution with DNA quality was 
analysed by polymerase chain reaction of 10-2000 cells isolated by microdissection 
from mounted and unmounted tissue. The mounting solution greatly improved the 
morphology of tissue sections for laser microdissection purposes and had no 
detrimental effects on the isolation and efficiency of the ultraviolet laser. To minimise 
this effect, the mounting solution should be diluted as much as possible. 
Furthermore, the addition of blue ink to the mounting medium restores the cutting 
efficiency of the laser. The mounting solution is easy to prepare and apply and can 
be combined with various staining methods without compromising the quality of DNA 
extracted. 
 
INTRODUCTION 
 
 Isolated nucleic acids and proteins are the basic materials used for most current 
molecular techniques. To obtain reliable results, it is of great importance that this 
starting material is derived from a pure cell population. Two laser assisted 
microdissection methods are used to separate the specific cells of interest from 
infiltrating and surrounding other cells. In laser capture microdissection (LCM), a 
thermoplastic membrane is placed above the tissue and is attached to the cells of 
interest after melting the foil by a low energy near infrared laser pulse. The cells 
remain embedded in the film and are collected by removal of the foil from the 
section.160 The second method is called laser microbeam microdissection (LMM) 
and uses a pulsed ultraviolet (UV) laser as an optical knife to cut out target cells. 
Separated cells are transferred to a reaction tube by needle, by laser pressure 
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catapulting, or by gravity.161 The advantage of LMM is that unwanted adjacent cells 
can be easily photoablated by the UV laser beam. The availability of laser assisted 
microdissection devices has greatly facilitated the isolation of pure cell populations 
and even made it possible to identify mutations in single cells.162,163 However, all 
microdissection methods use tissue sections without coverslip. Most of the light 
passing through the tissue is scattered, resulting in obscured cellular detail thus 
resulting in a poor light microscopic appearance. This limited morphological quality 
hampers recognition of specific cells at the histological level.164,165 To overcome this 
limitation several approaches have been tried so far. The use of microdissection of 
membrane mounted native tissue (MOMeNT) has been suggested as a solution by 
Bohm et al.166 Using this technique, tissue is mounted on a membrane and 
subsequently attached upside down on a glass slide. This approach does result in 
improved morphology, although it is quite laborious, and the morphological quality 
decreases during microdissection. Alternatively, immunohistochemical detection or 
in situ hybridisation of specific cells can be of help.167,168 In many cases, however, 
antibodies or in situ probes that discriminate between cells of interest and other cells 
may not be available. For example, the capability to distinguish between pre-
malignant cells and malignant cells relies on morphological characteristics, thus 
warranting optimal resolution. Therefore, we developed a mounting method that 
solves the refraction problem resulting in excellent morphology of tissue sections for 
LMM purposes. 
 
MATERIAL AND METHODS 
 
 Fresh frozen tissue (FFT) and paraffin-embedded tissue (PET) specimen from 
the files of the department of Pathology of the Radboud University Medical Centre 
Nijmegen, were used in these studies. From these tissue specimen, 4 to 20 µm thick 
tissue sections were cut and mounted directly on glass slides for isolation by laser 
microdissection of areas larger than 1 mm2, or mounted on crosslinked polyethylene 
(PEN) foil attached to a glass slide or to a carrying frame (Leica Microsystems 
GmbH, Wetzlar, Germany, http://www.leica-microsystems.com/website/lms.nsf) for 
laser microdissection of small groups of cells or single cells. The PET tissue 
sections were dewaxed and both FFT and PET sections were washed twice with 
distilled water and stained with haematoxylin or by immunohistochemistry. 
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 The mounting solution was prepared by diluting PinPoint solution (Pinpoint Slide 
DNA Isolation System Zymo Research, Orange, USA; www.zymor.com), an 
adhesive gum, in distilled water and addition of dark blue ink (Quink solv-X, Parker). 
The optimal ratio of the different components of the mounting solution is dependent 
on the structure of the target tissue and was tested at ratios of 16:4:1 to 20:2:1 for 
water, pinpoint, and blue ink, respectively. For tissue with a relatively high cell 
density and little intercellular spaces, such as kidney tissue, a high dilution factor of 
the mounting solution of 1:20 should be used. In contrast, tissue with a relatively low 
cell density with large intercellular spaces and loose connective tissue, such as 
dermis, requires a higher concentration (1:5) of the mounting solution. Dark blue ink 
was added to the mounting solution in a ratio of 1:20. Finally, the mounting solution 
was added to and distributed over the tissue section with a clean disposable pipette 
tip and air dried for 30 minutes. 
 A Leica AS LMD microdissection system with a UV laser (Leica Microsystems 
GmbH) was used to separate a group of target cells from the surrounding tissue. 
Samples microdissected from tissue mounted on glass slides were procured by 
needle and transferred to a reaction tube (frosted flat top tube 0.2 ml, Biozyme, 
Landgraaf, The Netherlands) and samples microdissected from tissue mounted on 
PEN foil were procured by the force of gravity into a reaction tube. 
 To test the DNA isolation efficacy 10-20 cells from FFT and 50-2000 cells from 
PET were microdissected. DNA isolated from PET sections were pretreated by 
incubation in 100 µl P buffer (50 mM Tris-HCl pH 8.2, 100 mM NaCl, 1 mM EDTA, 
0.5% Tween-20, 0.5% NP40, 20 mM DTT) at 90°C for 15 minutes to partially 
reverse the effect of the formalin fixation. DNA was isolated from FFT and PET after 
protein digestion with 0,5 mg/ml proteinase K (Roche Diagnostics GmbH, 
Mannheim, Germany) at 37°C for three days and fresh Proteinase K (0,5 mg/ml) 
was added every 24 hour. Subsequently, genomic DNA from PET and FFT was 
isolated using the DNeasy Tissue kit (Qiagen, GmbH, Hilden, Germany). DNA was 
eluted with 50 µl TE buffer (10 mM Tris pH 8.2, 1mM EDTA pH 8.0). Primers specific 
for the follicle stimulating hormone (FSH) receptor gene (forward primer sequence: 
CTA CCC TGC ACA AAG ACA GTG and reverse primer sequence: GTG TAC GTC 
ATG TCA AAT CCT CTG C) were used resulting in a 210 bp polymerase chain 
reaction (PCR) product. PCR reactions were performed in a total volume of 15 µl 
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and contained 2,5 µl diluted template DNA, buffer IV (Integro, Dieren, The 
Netherlands), 200 µm of each deoxynucleotide triphosphate, 1.5 mM MgCl2, 1 pmol 
of each primer and 30 µg bovine serum albumin (Sigma-Aldrich Chemie B.V, 
Zwijndrecht, The Netherlands). DNA amplification was performed in a PTC 200 (MJ 
Research, Inc, Waltham, Massachusetts, USA). An initial denaturation at 92°C for 3 
min was followed by 35 cycles denaturation at 92°C for 30 s, annealing at 57°C for 
45 s, and extension at 72°C for 45 s.  
(Part of this protocol is also published in the addendum of Molecular Cloning, Cold 
Spring Harbor, "Laser Pressure Catapulting", Chapter 5, Part 2, CHSL Press, New 
York, 2002). 
 
 
RESULTS 
 
 Standard mounting of tissue on a glass slide or a PEN foil covered glass slide or 
frame, as used for laser microdissection purposes, results in poor tissue 
morphology. To overcome this problem we used a mounting solution that does result 
in excellent morphology of tissue specimens for laser microdissection. Figure S-1 
demonstrates the benefit of the use of the mounting solution. It shows a primary 
cutaneous melanoma lesion with benign naevocellular nevus cells and stromal cells 
juxtaposed to melanoma cells before and after use of the mounting solution and 
before and after microdissection of a group of melanoma cells. In the tissue section 
without mounting solution, the melanoma cells could hardly be distinguished from 
the nevus cells or stromal cells, while this was easy in the case where the tissue 
section was covered with mounting solution. 
 To test the DNA isolation efficacy of samples at low cell numbers from tissue 
sections covered with our mounting solution we microdissected 10 and 20 from FFT 
and 50, 100, and 2000 cells from PET sections. Genomic DNA was isolated as 
described in the material and methods section. A PCR amplification of the FSH 
receptor gene was used to compare the DNA quality and quantity of mounted and 
unmounted tissue. As shown in Figure S-2, the mounting solution did not interfere 
with DNA isolation and PCR efficiency of PET. The quantity of product amplified was 
comparable between mounted and unmounted tissue. We also performed similar  
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Figure S-1. A: An unmounted 10 µm paraffin tissue section showing melanoma cells 
juxtaposed to benign naevocellular nevus cells. B: The same area as A after addition of the 
mounting solution. Note the same cell nest (*) in A and B. The arrowheads indicate the 
melanoma cells selected for microdissection. C: The same area as in A and B after laser 
microdissection of the melanoma cells. D: Target cells have been removed (inset) and the 
residual tissue remains intact. (A-D: haematoxylin staining, x 250) 
 
 
 
 
Figure S-2. Aliquots (10 ul) of the PCR products were run on an agarose gel stained with 
ethidiumbromide. At the left lane a 100 bp DNA marker (Invitrogen BV, Breda, The 
Netherlands), A-E: PCR analysis of DNA isolations from 5 different paraffin embedded tissue 
sections, M: PCR with mounting solution but without tissue, +: isolated from tissue sections 
with mounting solution, -: isolated without mounting solution. The mounting solution did not 
affect the PCR results. 
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Figure S-3. Aliquots (10 ul) of the PCR products were run on an 
agarose gel stained with ethidiumbromide. The left hand lane contains 
a 100 bp DNA marker (Invitrogen BV), A-B: PCR analysis of DNA 
isolations from 2 different fresh frozen tissue sections containing 10 
and 200 cells for each PCR respectively, +: DNA isolated from sections 
with mounting solution, -: isolated without mounting solution. No 
influence of the mounting solution on the PCR results is found, even at 
critical DNA concentrations. 
 
 
analyses on small numbers of cells from FFT. No negative influence of the mounting 
solution was detected for FFT as well as PET at DNA concentrations where PCR is 
critical. Results are shown in Figure S-3. 
The mounting solution as described in this supplement can be used in 
combination with various histochemical staining methods and with 
immunohistochemistry. However, it is not compatible with fluorescent methods 
because of the autofluorescence of the pinpoint solution. 
 
DISCUSSION 
 
 Laser microdissection has greatly facilitated the procurement of specific cell 
populations from complex tissue. However, because tissue sections are used 
without a coverslip, the resulting morphology is often poor, with obscured cellular 
detail. Here, we describe a mounting solution, consisting of adhesive gum and blue 
ink diluted in water, which greatly improves the morphology of tissue sections for 
laser microdissection purposes. The mounting solution coats the tissue section in a 
varnish-like manner and therefore obviates the need to use a coverslip for optimal 
morphology. The refractory index of the dried adhesive gum is similar to that of the 
tissue. This results in optimal morphological detail to select the target cells. In tissue 
with a low cell density, intercellular material, and interstitial fluid is lost during the 
fixation process resulting in gaps in the tissue. Larger gaps require less dilution of 
the pinpoint solution, resulting in a higher viscosity of the mounting solution.  
 One disadvantage was that the mounting solution, however, reduced the cutting 
efficiency of the UV laser, as a result of poorer absorption of the laser energy. 
Consequently, microdissection of tissue sections covered with mounting solution 
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required a higher setting of the laser energy, with a resulting larger laser diameter 
and thus a lower cutting specificity. To minimize this effect, the mounting solution 
should be used as diluted as possible. However, the benefit of an increased 
morphology using diluted mounting solution is dependent on the tissue structure of 
the tissue specimen used. Searching for ways to counteract the reduced laser 
cutting efficiency caused by the mounting solution, we found that addition of dark 
blue ink (Quink solv-X, Parker) to the diluted mounting solution in a ratio of 1:20 
facilitated absorption of the UV-laser light resulting in restoration of the laser cutting 
efficiency. The blue ink stained the tissue slightly blue, but it did not interfere with the 
recognition of different cell types.  
 The optimal composition of the mounting solution depends on the structure of 
the tissue. For the tissue types that we have tested either a 16:4:1 or a 20:2:1 ratio 
of water, adhesive gum, and blue ink respectively was required. It is possible that in 
specific cases a slightly different ratio of the components may yield better results. In 
general, a high as possible dilution of the adhesive gum that gives an optimal 
compromise between morphology and laser cutting efficiency should be used. 
Occasionally, some loss of laser energy and thus fine specificity may occur, 
however, for most purposes a sufficient laser cutting efficiency is still obtained. 
When a higher cutting specificity is required than is obtained with a given 
composition of the mounting solution, the addition of more blue ink will increase the 
laser cutting efficiency. We tested the effect of our mounting solution on the DNA 
isolation and amplification efficiency and found no detrimental effect. The adhesive 
gum used in our mounting solution has originally been marketed for use in a 
micropipetting dissection method for isolation of DNA and RNA from tissue section 
areas and therefore should thus indeed not interfere with DNA isolation and 
amplification efficiency.  
 Because PCR artefacts are dependent on the number of target molecules in the 
first round of DNA amplification, it is important to start with a high as possible 
number of target cells.169 Because to the improved morphology, similar cell groups 
can be easily recognized in serial sections and can be pooled for DNA isolation. We 
have now successfully used this approach for the DNA isolation of normal and 
tumour tissue from serial sections from melanocytic tumours for allelic imbalance 
analysis and to dissect morphological different tumour parts to investigate tumour 
heterogeneity.19
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